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Abbreviations and units 
 
Abbreviations and units 
 
[α]ܶܦ specific optical rotation, sodium D line (589 nm);   T: temperature  
δ NMR chemical shift [ppm] 
λ wavelength [nm] 
µ micro (10-6) 
µ specific growth rate (in connection with growth 
determination of bacteria) 
°C degrees Celsius 
Ǻ Ångström 
A (-domain) adenylation (-domain) 
AA/aa amino acid 
ACP acyl carrier protein 
ADP adenosine diphosphate 
AMP adenosine monophosphate 
ATCC American Type Culture Collection 
ATP adenosine triphosphate 
ATR attenuated total reflection 
BALB/3T3 mouse embryonic fibroblast cell line 
bp base pair(s) 
Bq Becquerel, 1 Bq equals 1 cpm 
BV (MO) Baeyer – Villiger (monooxygenase) 
c concentration [g/100ml] (in connection with optical 
rotation) 
C (-domain) condensation (-domain) 
calc. calculated 
CAT regular NRPS module composed of a C- an A- and a T-
domain 
CAZy Carbohydrate-Active Enzymes database 
CD circular dichroism 
CDA calcium-dependent antibiotic 
CDCl3 deuterated chloroform 
(CD3)2CO deuterated acetone 
CD3OD deuterated methanol 
CFU colony forming unit 
Ci Curie, 1 Ci = 3.7 x 1010 Bq 
Cl (-domain) halogenase (-domain) 
CLDP cyclic lipodepsipeptide 
CLP cyclic lipopeptide 
CoA/HS-CoA coenzyme A 
conc. concentrated 
Abbreviations and units  
 
COSY correlated spectroscopy 
cpm counts per minute 
cSSSI complicated skin and skin structure infection 
CV cyclic voltammetry 
Cy (-domain) cyclisation (-domain) 
d doublet (in connection with NMR data)  
DA Dalton 
DAD diode array detector 
DCM dichloromethane 
DEPT distortionless enhancement by polarisation transfer 
DFG ´Deutsche Forschungsgemeinschaft´; German Research 
Foundation 
DH dehydratase 
DMB/DMBgly Davis minimal broth without dextrose / Davis minimal 
broth without dextrose, supplemented with glycerol 
DMEM Dulbecco‘s modified eagle medium 
DMSO dimethyl sulfoxide 
DMSO-d6 deuterated dimethyl sulfoxide 
DNA deoxyribonucleic acid 
E (-domain) epimerisation (-domain) 
EC endcapped 
e.g. Latin ´exempli gratia´; for example 
ER enoyl reductase 
ERYR erythromycin-resistant 
ES efflux system 
ESI electro spray ionisation 
EtOAc ethyl acetate 
FA fatty acid 
FAD flavin adenine dinucleotide 
FAS fatty acid synthase 
FOR ´Forschergruppe´; research unit 
FP flavoprotein 
FPMO flavoprotein monooxygenases 
FT-IR Fourier transformation infrared 
g gram 
GT glycosyltransferase 
h hour 
3-HAD 3-hydroxydecanoic acid 
HMBC heteronuclear multiple-bond correlation spectroscopy 
H2O water 
3-HOA 3-hydroxyoctanoic acid 
hPhg 4-OH-phenylglycine 
HPLC high performance liquid chromatography 
Abbreviations and units 
 
HR high resolution 
HSQC heteronuclear single quantum correlation 
HSV-1 herpes simplex virus type 1 
Hz hertz 
IC50 half maximal inhibitory concentration 
i.e. Latin ´id est´; that is 
IMMIP Institute of Medical Microbiology, Immunology and 
Parasitology 
IR infrared 
J spin-spin coupling constant [Hz] 
KB King’s broth 
KR ketoreductase 
KS ketosynthase 
L/l litre 
LB lysogeny broth 
LC liquid chromatography 
LDL low-density lipoprotein 
LpPLA2 lipoprotein associated phospholipase A2 
LTA lipoteichoic acid 
m multiplet (in connection with NMR data) 
M molar [mol/l] 
MALDI-TOF matrix-assisted laser desorption/ionisation-time of 
flight  
MAT malonyl-acetyl transferase 
Mb mega base pairs = 1,000,000 bp 
MDR multidrug resistance (transporter) 
MeOH methanol 
MFP membrane fusion protein 
MH Mueller-Hinton 
MHz Megahertz 
MIC minimal inhibitory concentration 
925 MM 925 minimal medium broth  
MO monooxygenase 
MoA mode of action 
MR methicillin-resistant 
MRSA methicillin-resistant Staphylococcus aureus 
MS methicillin-susceptible (in context with bioassays) 
MS mass spectrometry (in context with analytics) 
MT methyltransferase 
MWCO molecular weight cut off 
m/z mass-to-charge ratio 
NADH nicotinamide adenine dinucleotide 
NADPH nicotinamide adenine dinucleotide phosphate 
Abbreviations and units  
 
N-AHL N-acylhomoserine lactone 
nanoDESI nanospray desorption electro spray ionisation 
technique 
NB Nutrient broth 
NCBI National Center of Biotechnology Information 
n.d. not determined 
NH4OAc ammonium acetate 
nm nanometer 
NMR nuclear magnetic resonance 
no. number 
NOE nuclear Overhauser effect 
NOESY nuclear Overhauser effect spectroscopy 
nov. latin ´novum´; new 
NRPS nonribosomal peptide synthetase 
n.t. not tested 
OAA oxaloacetate 
OD/OD0/OD600 optical density / at t0 / at λ= 600 nm 
OMF outer membrane factor 
ORF open reading frame 
OSMAC one strain many compounds 
PCP peptidyl carrier protein 
pH potential hydrogenii 
PKS polyketides synthase 
4´-PP 4´-phosphopantetheinyl 
ppm part per million 
pv. pathovar 
QCM quartz crystal microbalance 
R (-domain) reductase (-domain) 
R residue (in combination with chemical structures) 
R2 coefficient of determination 
RFU relative fluorescence unit 
RNA ribonucleic acid 
RND resistance nodulation division 
RP reversed phase 
rpm rounds per minute 
RPMI  Roswell Park Memorial Institute medium 
RT room temperature 
s singlet (in connection with NMR data) 
SFV Semliki Forest virus (togaviridae, a model virus for 
the hepatitis G virus) 
SHV-1 suid herpes virus type 1 (herpesviridae, a model virus 
for human herpes viruses) 
sp. species 
Abbreviations and units 
 
SPE solid phase extraction 
spp. species (plural) 
SRM HG syringomycin minimal medium modified according to 
Prof. Dr. H. Gross 
t triplet (in connection with NMR data) 
T (-domain) thiolation (-domain) 
TCA trichloroacetic acid 
td doubling time 
TDP thymidine diphosphate 
TE (-domain)/ 
TE-I/TE-II 
thioesterase (-domain) / type I TE / type II TE 
TFA trifluoroacetic acid 
THP1 human acute monocytic leukemia cell line 
TOCSY total correlation spectroscopy 
tR retention time 
TSB tryptic soy broth 
U unit 
UV ultraviolet 
VIS visible 
VLC vacuum - liquid chromatography 
VSV (= VSIV) vesicular stomatitis Indiana virus (often abbreviated 
with VSV), rhabdoviridae 
v/v volume/volume 
WHO World Health Organisation 
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Abbreviations for amino acids 
 
amino acid one letter code three letter code 
alanine A Ala 
arginine R Arg 
asparagine N Asn 
aspartic acid D Asp 
cysteine C Cys 
glutamic acid E Glu 
glutamine Q Gln 
glycine G Gly 
histidine H His 
isoleucine I Ile 
leucine L Leu 
lysine K Lys 
methionine M Met 
phenylalanine F Phe 
proline P Pro 
serine S Ser 
threonine T Thr 
tryptophan W Trp 
tyrosine Y Tyr 
valine V Val 
 
Abbreviations for unusual amino acids 
 
Dab 2,4-diaminobutyric acid 
Dhb 2,3-dihydro-2-aminobutyric acid 
hAsn 3-OH asparagine 
hAsp 3-OH aspartic acid 
Hse homoserine 
Kyn kynurenine 
3mGlu 3-methyl glutamic acid 
mOAsp methoxyaspartic acid 
Sar sarcosine 
Thr[4-Cl] 4-chlorothreonine 
ΔTRP Z-2,3-dehydrotryptophan 
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Antibiotics are one of the most powerful therapeutic tools in 
medicine. They inhibit the growth of bacteria, thereby helping 
the body to fight serious bacterial infections. Antibacterial 
drugs have been successfully applied for the treatment of 
various bacterial infections in human beings since the 1940s. 
However, already in the early 60s the first resistant bacterial 
strains occurred and the era of the ´golden age´ of antibiotics 
between the 1940s and the 1970s (see figure 1.1) has drawn to a 
close (Fernebro, 2011). The upraising resistance was 
additionally triggered by misapplication of antimicrobial 
agents, often combined with an over-usage in many parts of the 
world or the misuse due to lack of access to appropriate 
treatment (WHO, 2001). Furthermore, resistance spread out by the 
increasing availability of generic drugs related to the 
advancing global travel, global healthcare and medical tourism 
(Grundmann et al., 2011). The awareness about the importance of 
resistance took time to get established. Instead of the 
necessary intensified search for new antibiotics, industry 
stopped their research programs. 
As a consequence of this development, the pipeline of new drugs 
by now is running dry (WHO, 2001), while the development of 
antibiotic resistance of almost all clinically important 
pathogens increased (Fernebro, 2011). These facts give rise to 
an urgent need of alternatives to conventional antibiotics 
(Fernebro, 2011). 
 
 
 
 
 
 
 
Figure 1.1: antibiotic discovery timeline (adopted from Lewis, 2012) 
Looking into the recent developments, it becomes apparent that 
most of the few approved antibiotics – most likely due to the 
reduced industrial drug discovery programs - simply represent 
Tetracyclines Quinolones 
Streptogramins 
Lipopeptides 
Ansamycins 
Glycopeptides Chloramphenicols 
Aminoglycosides ß-Lactams 
Oxazolidinones Macrolides 
1920 1930 1940 1950 1960 1970 1980 1990 
Sulfadrugs 
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derivatives of known compound classes. Only occasionally a new 
compound class, acting at new targets came to the market, e.g. 
the gyrase inhibitors or the cyclic lipopeptide daptomycin.  
A recent comparative analysis of systemic antibacterial agents 
revealed that only fifteen candidates out of 90 agents actually 
act by new modes of action or act on new targets (Freire-Moran 
et al., 2011). Among these 15 innovative candidates, seven 
active substances belong to the group with new modes of action 
and two thereof – WAP 8294A2 and friulimicin B – belong to the 
group of cyclic lipodepsipeptides (Freire-Moran et al., 2011). 
Based on these facts, cyclic lipopeptides (CLPs) of bacterial 
origin apparently represent a promising class of antibiotics 
with presumably new mode of actions. 
 
 Cyclic lipopeptides  1.1
 
Cyclic lipopeptides are a structurally diverse class of 
compounds which are composed of a fatty acid chain in the length 
of 5-20 carbon atoms and an oligopeptide ranging from 7-25 amino 
acids, whereby 4-14 residues thereof form a ring system (Gross & 
Loper, 2009; Hashizume & Nishimura, 2008). This general 
structure causes the amphiphilic properties of cyclic 
lipopeptides which account for most of the functions CLPs 
possess in nature.  
The peptide antibiotics often contain non-proteinogenic amino 
acids, such as D-configurated, O-methylated, N-methylated, 
halogenated and β-amino acids (see figure 1.1.1). The 
incorporation of these unusual amino acids is attributable to 
the fact that CLPs are biosynthesised by non-ribosomal peptide 
synthetases (NRPSs, see chapter 1.1.1). It has been hypothesised 
that these features protect the compound class towards regular 
ubiquitary peptidases (Hashizume & Nishimura, 2008). Variations 
of the amino acid residues including their sequence as well as 
variations of the side chain regarding length, branching and 
oxidation status and different cyclization schemes generate an 
enormous structural diversity, occupying a huge three-
dimensional chemical space. 
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Since most of the CLPs lose their activity upon cleavage of the 
cyclic structure, the biological activity is dependent on the 
three-dimensional structure (Hashizume & Nishimura, 2008). 
Further factors that influence the potency of CLPs are the 
applied pH value and the presence of bivalent cations. 
homoserine
Hse
dihydro-2-aminobutyric acid
Dhb
2,4-diaminobutyric acid
Dab
4-chlorothreonine
Thr[4-Cl]
sarcosine
Sar
OH
COOHH2N
CH3
COOHH2N COOHH2N
NH2
HO
Cl
COOHH2N
HN
CH3
COOH
 
kynurenine
Kyn
3-Me-glutamic acid
3mGlu
R=H: 3-OH aspartic acid (hAsp )
R=CH3: methoxyaspartic acid (mOAsp )
R=H: 3-OH asparagine (hAsn )
R=PO3H2: phosphorylated hAsn
4-OH-phenylglycine
hPhg
Z-2,3,-dehydrotryptophan
(DTrp )
O
COOHH2N
NH2
OH
COOHH2N
H
N
H2N
COOH
ORHOOC
COOHH2N
ORH2NOC
COOHH2N
CH3
COOHH2N
COOH
 
Figure 1.1.1: non-proteinogenic amino acids occurring in lipopeptides 
Cyclic lipopeptides are produced by a variety of species e.g. 
Pseudomonads (see chapter 1.2.1), Bacillus spp., Actinomyces 
spp. (e.g. friulimicin), Streptomyces spp., Actinoplanes spp. 
(ramoplanin), Burkholderiae and by some members of 
Xantomonadaceae and Flavobacteriaceae (e.g. empedopeptin). 
Furthermore, structurally divers CLPs have been isolated from 
marine organisms e.g. from cyanobacteria of the genus 
Microcystis or Nostoc or from marine sponges (Hashizume & 
Nishimura, 2008). 
CLPs display activity against a variety of species, including 
multi-resistant human-pathogenic bacteria like MRSA and viruses 
(Vollenbroich et al., 1997a). Furthermore, they possess 
antitumor (Wang et al., 2007), cytotoxic (de Lucca et al., 
4 Introduction 
 
1999), immunosuppressant (Cameotra & Makkar, 2004) and 
surfactant properties. The latter property seems to be 
accountable for the potential of CLPs to increase the 
bioavailability of water-insoluble substrates, to lower surface 
tension and to interact with cellular membranes (Raaijmakers et 
al., 2006).  
Beside these properties and functions, cyclic lipopeptides play 
an essential role in the protection of their producer for 
instance against predators as toxic compounds or by reduction of 
the susceptibility to antibiotic treatment by development and 
formation of biofilms (Raaijmakers et al., 2010; Mazzola et al., 
2009). 
In addition, CLPs are important for the infection process in 
plant pathogenic Pseudomonas species, while in non-pathogenic 
strains of the genera Pseudomonas and Bacillus CLPs were 
observed to stimulate the plant immune system (Raaijmakers et 
al., 2010). 
Other natural functions of cyclic lipopeptides are their ability 
to chelate and degrade xenobiotic compounds (reviewed by 
Raaijmakers et al., 2010), their role in motility and attachment 
to surfaces (Raaijmakers et al., 2006) and their function as 
signalling molecules for coordinated growth and differentiation 
(Mahariel et al., 1997). 
 
 Biosynthesis of cyclic lipopeptides 1.1.1
 
Cyclic lipopeptides are produced on multi – enzyme complexes 
called nonribosomal peptide synthetases (NRPS) that are 
organised in a modular fashion. In contrast to the ribosomal 
synthesis of peptides which are restricted to a very confined 
substrate pool consisting of the 21 proteinogenic amino acids, 
NRPSs are capable to incorporate also non-proteinogenic amino 
acids, like for example hydroxy and N-methylated amino acid 
residues (see figure 1.1.1; Mahariel et al., 1997; Mootz et al., 
2002; Schwarzer et al., 2003). 
Nonribosomal peptide synthetases typically contain the same 
number and order of modules as the resulting number and sequence 
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of amino acids in the corresponding peptide product. This so-
called ´colinearity rule´ results from the construction of the 
multi-enzyme complex. Each module contains at least three core 
domains for one complete elongation cycle of the peptide moiety: 
the adenylation domain (A-domain), the peptidyl-carrier protein 
(PCP-domain, syn. = thiolation domain / T-domain) and the 
condensation domain (C-domain). The A-domain selects a specific 
amino acid monomer from the available substrate pool, activates 
it by formation of an amino acyl adenylate under consumption of 
ATP. 
Subsequently, the activated amino acid is transferred to the 
PCP-domain forming an aminoacyl thioester, which is covalently 
linked to the cysteamine group of an enzyme-bound 4´- 
phosphopantetheinyl (4´-PP) cofactor. This covalent tether 
allows the transport to the adjacent catalytic centres of the 
multienzyme. In the next step, the C-domain located between 
every successive pair of A- and PCP-domains catalyses the 
formation of a peptide bond which finalises one elongation cycle 
(Fischbach & Walsh, 2006; Challis & Naismith, 2004; Challis et 
al., 2000). 
Aside the three mentioned core domains, additional domains can 
be integrated affording modifications of incorporated residues: 
epimerisation (E) domains enable the conversion of L-configured 
amino acids into the corresponding D-form, methyltransferase 
(MT) domains are responsible for N-methylation, while 
cyclisation (Cy) domains catalyse the formation of heterocyclic 
ring systems and reductase (R) domains change the oxidation 
status of atoms.   
When the specific length of the peptide chain is reached, a 
terminal thioesterase (TE) domain finalises the assembly line. 
The TE-domain catalyses the release of the product by hydrolysis 
and optionally performs a cyclisation. TE-domains can be 
subdivided into two types: type I TE-domains (TE-I), usually 
representing the last domain in the multienzyme responsible for 
cleavage of the assembled product and type II TE-domains (TE-
II).  
TE-II are associated with NRPSs and involved in the regeneration 
of misprimed PCPs by removing short acyl chains from the 4´-PP 
cofactors. Otherwise, e.g. tethered acetyl-CoA would inactivate 
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the NRPS, because substrates without an amino-group cannot be 
elongated (Linne et al., 2004; Schwarzer et al., 2002). 
Moreover, Walsh and co-workers could demonstrate that the TE-II 
domains possess the ability to cleave amino acids from NRPS 
modules at moderate rates and to discriminate ´correct´ from 
´incorrect´ amino acids based on the half-life of unprocessed 
intermediates displaced from the normal binding sites (Yeh et 
al., 2004). Furthermore, TE-domains of type II also interact 
with TE-I-domains and possess a strong impact on the efficacy of 
the biosynthetic machinery. This fact derives from the 
observation that the knockout of TE-II in arthrofactin 
biosynthesis lead to a decrease of arthrofactin production by 
95% (Roongsawang et al., 2007).  
Nonribosomal peptide synthetases can be subdivided into three 
types (A-C), differing in the organisation of their modules 
(Mootz et al., 2002): 
Type A: linear NRPSs  
In type A NRPSs the core domains are arranged in the order CAT, 
adding one amino acid per elongation cycle. In the first module, 
the C-domain is missing and the terminal module usually contains 
a TE-domain (in fungi often replaced by special C-domains). Type 
A NRPSs usually act in accordance with the ´colinearity rule´ 
(see above). 
Type B: iterative NRPSs 
In iterative NRPSs the modules are used more than once in the 
biosynthesis and correspond to only one set of a repeated 
sequence of the multimeric product. The final PCP or TE domain 
is responsible for the number of iterative cycles and the 
chemical nature of the bonds between the monomers (Mootz et al., 
2002). An iterative use of modules was described in the 
coelichelin biosynthesis in Streptomyces coelicolor (Lautru et 
al., 2005) and in the biosynthesis of congocidine, produced by 
Streptomyces ambofaciens (Juguet et al., 2009). 
Type C: nonlinear NRPSs 
Nonlinear NRPSs deviate in at least one module from the usual 
arrangement of the core domains (e.g. NRPS of syringomycin; 
Guenzi et al., 1998). 
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This deviation is often accompanied by unusual internal 
cyclisations (e.g. bleomycin) or branch-point synthesis (e.g. 
vibriobactin) and results in nonlinear peptide products. In 
contrast to linear NRPSs, type C NRPSs are able to incorporate 
small soluble molecules lacking a carboxyl-group such as amines. 
An extension to the described deviations of the usual NRPS 
machinery can be observed in the ´module skipping´ (e.g. in the 
myxochromide S biosynthesis) in modular NRPSs (see figure 
1.1.2). In this case not the skipping of modules as an aberrant 
process resulting in truncated minor metabolites is meant, but 
skipping as programmed event (Wenzel & Müller, 2005). 
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 Cyclic lipopeptide antibiotics 1.1.2
 
Corresponding to the structural diversity, cyclic lipopeptides 
exhibit bioactivity against a broad spectrum of other 
microorganisms.  
In this study the antibacterial aspects of CLPs were 
highlighted, this is why in the following an in-depth overview 
about this part of the antibiotic spectrum of CLPs will be 
given.  
In general, cyclic lipopeptides are rather active against Gram-
positive than Gram-negative bacteria. This might be caused by 
the Gram-negative outer membrane or peptidoglycan-layer, which 
probably hinders CLPs to access the plasma membrane (Nybroe & 
Sørensen, 2004). An exception represents the polymyxins, which 
are selectively toxic for Gram-negative bacteria. 
The medicinal significance of this compound class shall be 
illustrated by examples of the following cyclic lipopeptides 
that are already in clinical use or that are currently 
investigated in clinical trials. 
Daptomycin (see figure 1.1.3), which was introduced in the 
market as Cubicin® in 2003, impressively demonstrates the 
potential of this substance class featuring activity against a 
variety of Gram-positive bacteria including multi-resistant 
human pathogenic species causing serious infections.  
The approved indications of Cubicin® are complicated skin and 
skin structure infections (cSSSI) for example caused by MRSA and 
bacteraemia including those with right-sided infective 
endocarditis (Steenbergen et al., 2005). Daptomycin is produced 
by Streptomyces roseosporus and exhibits bactericidal activity 
in vitro thereby showing MICs of ≤ 1µg/ml for most of the tested 
strains (Baltz et al., 2005). 
Daptomycin belongs to the group of acidic lipopeptide 
antibiotics which are predominately produced by Actinomycetales 
and share a straight or branched-chain fatty acid moiety with 6-
16 carbons, differing in the degree of saturation and the 
oxidation state (Strieker & Mahariel, 2009), which is invariably 
attached to the macrocyclic peptide core. 
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Together with CDA (calcium-dependent antibiotic), isolated from 
Streptomyces coelicolor A3 (2) (Lakey et al., 1983), CDA-derived 
CLPs and CLPs of the A21978C-complex, daptomycin belongs to the 
subgroup of acidic cyclic lipodepsipeptides (CLDPs), i.e. that 
at least one amide bond of the macrocycle is exchanged by an 
ester bond. The acidity is attributable to the presence of two 
aspartic acid residues in the conserved motif Asp-X-Asp-Gly of 
the ring structure and further acidic amino acids in the peptide 
moiety like 3-methoxy-aspartic acid or additional Asp-residues 
(Strieker & Mahariel, 2009).  
Other important representatives of this group are WAP-8294A2 and 
friulimicin B (see figure 1.1.4), which both are in Phase I of 
clinical development (Freire-Moran et al., 2011). 
WAP-8294A2 is produced by Lysobacter sp. and exhibits activity 
against MRSA as well as against various strains of 
Propionibacterium acnes including clinical isolates and multi-
drug resistant strains. Therefore, it is under investigation for 
systemic use against MRSA and formulated as a cream against acne 
(Pirri et al., 2009).  
 
Figure 1.1.3: daptomycin (Cubicin®) 
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Figure 1.1.4: friulimicin B 
Friulimicin B, produced by Actinoplanes friuliensis DSM 7358 
(Aretz et al., 2000), shows an antagonistic spectrum similar to 
that of daptomycin, both featuring higher antibiotic potency 
than teicoplanin (Bemer et al., 2003). Friulimicin B possesses a 
unique mode of action and affects the cell envelope of Gram-
positive bacteria by interruption of the cell wall precursor 
cycle through the formation of a Ca2+-dependent complex with the 
bactoprenol phosphate carrier C55-P (Schneider et al., 2009). 
However, despite the structural similarity and potency, 
daptomycin does not interact with this target. Its mode of 
action is still lacking complete elucidation and is the subject 
of intense debate since a long time. Aside the obvious 
dependency of the activity on the presence of calcium, earliest 
assumptions pointed towards the energised cytoplasmic membrane 
as target leading to an interference of the peptidoglycan 
biosynthesis (Alborn et al., 1991). 
Later, other authors proposed, that an enzyme of the 
lipoteichoic acid (LTA) biosynthesis represents the decisive 
target (Canepari et al., 1990). However, Laganas and co-workers 
refuted this hypothesis by pointing out the lack of the 
essential kinetic specifity (Laganas et al., 2003), which would 
be required for this theory. Meanwhile, it is resolved, that the 
mode of action of daptomycin involves the calcium-dependent 
insertion of the compound into the bacterial cytoplasmic 
membrane (Jung et al., 2004), while the mechanism of bacterial 
killing still remains even more controversial and may involve 
multiple activities. Among these, effects on membrane integrity, 
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rapid inhibition of protein, DNA and RNA synthesis and 
inhibition of lipoteichoic acid synthesis are currently being 
discussed (Hancock, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.5: colistin (polymyxin E)  
Another group of CLPs which already reached the market are the 
polymyxins which were primarily isolated in the late 1940s from 
Bacillus polymyxa and consist of five chemically different 
compounds (polymyxins A-E; Storm et al., 1977). The polymyxins 
are active against selected Gram-negative bacteria, including P. 
aeruginosa, Klebsiella, Actinobacter and Enterobacter species. 
The two candidates being in clinical use since the 1950s 
(polymyxins B and E (= colistin, see figure 1.1.5)) were 
restricted to local use except for treatment of cystic fibrosis 
in the 1980s due to their high nephro- and neurotoxicity. 
Meanwhile, a revival has taken place and the intravenous 
treatment of serious P. aeruginosa and A. baumannii infections 
with polymyxins is reconsidered as a valuable option due to the 
increase of resistances and a lack of alternatives (Falagas & 
Kasiakou, 2005). Colistin targets the bacterial cell membrane 
through electrostatic interaction between the cationic 
polypeptide and the anionic lipopolysaccharide molecules in the 
outer membrane of the Gram-negative bacteria. Subsequently, it 
displaces magnesium and calcium ions from the membrane, leading 
to an increase of the permeability of the cell envelope, leakage 
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of cell contents and finally cell death (Falagas & Kasiakou, 
2005).  
Ramoplanins, first isolated in 1984 from Actinoplanes sp. ATCC 
33076 (Cavalleri et al., 1984), are a family of the macrocyclic 
lipopeptides which represent also promising clinical candidates 
for the treatment of infectious diseases caused by Gram-positive 
bacteria. Ramoplanin inhibits the bacterial translocase during a 
late step of peptidoglycan biosynthesis by binding as a dimer to 
lipid II, the substrate for these enzymes (Hashizume & 
Nishimura, 2008).  
Another significant example for the activity of CLPs is 
empedopeptin, which was isolated from the Gram-negative soil 
bacterium Empedobacter sp. (Konishi et al., 1984). The 
antibacterial spectrum resembles that of amphomycin and 
vancomycin, inhibiting predominately Gram-positive and anaerobic 
bacteria. Empedopeptin belongs to the group of guanidine-
containing CLPs, which are characterised by the presence of 
arginine and two hydroxy aspartic acids. Furthermore, they share 
proline, hydroxy-proline and serine as common amino acids in 
their peptide nucleus. The activity includes resistant strains 
and shows therapeutic effects in models of staphylococcal 
septicaemia in mice (Hashizume & Nishimura, 2008). 
 
 Pseudomonads as an underexplored source for new 1.2
cyclic lipopeptide antibiotics  
 
Pseudomonas is a genus of Gram-negative Gammaproteobacteria 
which is spread ubiquitous in nature colonising a wide variety 
of niches like soil, water, plant surfaces or animals due to 
their ability to use diverse organic compounds as energy sources 
(Gross & Loper, 2009). Pseudomonas are prominent for their 
plant- and human-pathogenic species like Pseudomonas syringae 
and Pseudomonas aeruginosa, respectively, but the genus includes 
also species that degrade xenobiotic compounds, promote plant 
growth, antagonise plant pathogenic fungi and induce resistance 
in plants (Raaijmakers et al., 2006). 
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The facility to culture Pseudomonas strains in vitro and the 
growing availability of genome sequences makes the genus an 
excellent focus for scientific research. Starting with the 
publication of the whole genome sequence of Pseudomonas 
aeruginosa PAO1 in 2000 (Stover et al., 2000), up to date more 
than thirty complete genome sequences are available (NCBI 
search, May 2012) and a strong increase in numbers can be 
predicted due to modern sequencing technologies (Gross & Loper, 
2009). The genome size ranges between 4.5 Mb and 7.2 Mb having a 
GC content of 57.5-66.6 %. Up to 7 % of the genomic information 
can be devoted to secondary metabolism which demonstrates the 
huge biosynthetic capacity of this genus. 
Pseudomonads are hereby capable to produce an enormous spectrum 
of bioactive and structural diverse secondary metabolites 
ranging from polyketides, alkaloids to quinones and many small 
sophisticated highly bioactive compounds (Gross & Loper, 2009). 
Pseudomonads are also an excellent source for cyclic lipopeptide 
antibiotics as nearly every Pseudomonas species produces a CLP 
for physiological or defence purposes. 
Pseudomonas lipopeptides were so far mostly investigated only in 
their agricultural, phytochemical and biofilm-controlling 
context, but rarely systematically as antibiotics. Thus, this 
genus represents a huge reservoir for new promising antibiotic 
active CLPs, which are currently underexplored. In the 
following, an overview about the current classification system 
of Pseudomonas lipopeptides will be given. 
 
 Cyclic lipopeptides produced by Pseudomonas spp. 1.2.1
 
Cyclic lipopeptides produced by Pseudomonas spp. cyclise between 
two amino acids in the peptide moiety to form a lactone ring and 
can be subdivided into several classes according to the number, 
type and configuration of the incorporated amino acids and the 
length and composition of the fatty acid tail (Raaijmakers et 
al., 2006). Based on an initial classification by Nybroe and 
Sørensen in 2004, who distributed Pseudomonas-derived CLPs into 
four major groups, the viscosin-, amphisin-, tolaasin- and 
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syringomycin-group (Nybroe & Sørensen, 2004), several increments 
of the classification have been published including further 
isolated CLPs (e.g. Raaijmakers et al., 2006; Gross & Loper, 
2009). Hence, a division in at least nine groups (see table 
1.2.1) can be conducted as described in the following. 
Cyclic lipopeptides of the plusbacin group belong to the 
guanidine-containing cyclic lipopeptides and share arginine, 
proline, serine, hydroxyroline and two hydroxyaspartic acid 
residues as the common amino acids in their peptide nucleus 
(Hashizume & Nishimura, 2008). The plusbacin group contains 
plusbacins A1-A4 and B1-B4 (Shoji et al., 1992a), differing in the 
second hydroxyproline residue between A and B and in the fatty 
acid residue between A1 to A4. Plusbacins as well as arthrofactin 
(see below) cyclise via lactone ring formation between the fatty 
acid chain and the terminal amino acid (Shoji et al., 1992b). 
Thus, these two Pseudomonas CLPs represent the only members of 
this compound class that deviate from the usual ring formation 
pattern in which the lactonisation takes place between two amino 
acids of the peptide portion.  
CLPs of the viscosin and amphisin group are composed of nine 
respectively 11 amino acids building the peptide moiety. For 
both groups the fatty acid chain is in most cases 3-
hydroxydecanoic acid (3-HDA). The lactone is formed between the 
C-terminal amino acid and the Thr-residue found at amino acid 
position three (Nybroe & Sørensen, 2004). The only exception is 
the aforementioned arthrofactin, belonging to the amphisin 
group, which is described to cyclise into the fatty acid chain 
(Morikawa et al., 1993).  
Along with the isolation of orfamide from P. fluorescens Pf-5 in 
2007 an additional class of CLPs was founded, the orfamide group 
(Gross et al., 2007). The orfamide group is characterised by a 
3-hydroxy dodecanoic or tetradecanoic (myristic) acid connected 
to the N-terminus of a ten amino acid containing cyclic peptide. 
The syringomycin group is regarding the number of amino acids 
structurally related to the viscosin group, both containing nine 
AA in the peptide chain. However, in contrast to the viscosin 
group, the syringomycin group contains unusual amino acids such 
as 2,4-diaminobutyric acid (Dab), 2,3-dihydro-2-aminobutyric 
acid (Dhb) and a C-terminal chlorinated threonine residue (4-Cl-
 Introduction 15 
 
L-Thr) which is responsible for the antifungal activity of 
syringomycin (Grgurina et al., 1994).  
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The cyclisation takes place between the N-terminal serine and 
the C-terminal 4-Cl-L-Thr. Furthermore, the fatty acid chains 
can consist of a 3-hydroxy or a 3,4-dihydroxy fatty acid chain 
in the length of 10-14 carbon atoms (Raaijmakers et al., 2006). 
Cyclic lipopeptides of the tolaasin group are distinguished by 
the so far mentioned CLP groups by shorter side chains and 
larger peptide moieties. Their lipid tail is either 3-hydroxy-
pentanoic acid, 3-HDA or 3-hydroxyoctanoic acid (3-HOA) and the 
peptide moiety can be composed of 19-25 amino acids, containing 
unusual amino acids like homoserine (Hse), Dab and Dhb. The 
lactone ring is formed between the allo-Thr residue and the C-
terminal amino acid and contains 5-8 amino acids (Bassarello et 
al., 2004; Nutkins et al., 1991). CLPs belonging to this group 
are often produced by plant-pathogenic Pseudomonads and 
constitute important virulence factors (Raaijmakers et al., 
2006). 
The isolation of entolysins A and B from P. entomophila L 48 in 
2010 led to a new group of CLPs, harbouring a peptide moiety 
which contains 14 amino acids as a specific feature. The 
formation of the lactone ring takes place between the C-terminal 
Figure 1.2.1: orfamide A, a cyclic lipopeptide isolated from P. fluorescens
Pf-5 
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carboxyl-group (Ile) and the 10th amino acid (Ser) (Vallet-Gely 
et al., 2010; Bode et al., 2012).  
Table 1.2.1: primary structures of representatives of the eight classes of 
CLPs produced by Pseudomonas spp. 
 
Deviations of a considered CLP from the name-giving CLP of a class are 
denoted in light grey, consensus amino acids are denoted in dark grey. 
Abbreviations: Dab: 2,4-diaminobutyric acid, Dhb: 2,3-dehydroaminobutyric 
acid, Hse: homoserine α-Thr: allo-threonine, D-α-Ile: D-allo-isoleucine. All 
other amino acids are identified by standard three-letter biochemical 
notation. (Table adopted from Gross et al., 2009); i = iso - fatty acid  
The putisolvin group includes putisolvin A and B, isolated from 
P. putida PCL1445, both characterised by a hexanoic lipid tail, 
a peptide moiety of 12 AA and a cyclisation which occurs between 
the C-terminal carboxyl group and the ninth amino acid residue 
(Kuiper et al., 2004). 
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Finally, the syringopeptin group contains CLPs composed of 22-25 
amino acids, connected to 3-hydroxy-decanoic acid, forming a 
lactone ring including the terminal 8 AAs. 
 
  Antibacterial Pseudomonas CLPs 1.2.2
 
Antibiotically active highlights of Pseudomonas CLPs represent 
the massetolides (massetolide A see figure 1.2.2) and 
syringomycin E, both exhibiting strong activity e.g. against 
Mycobacterium species (see table 1.2.2; Gerard et al., 1997). 
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Mycobacteria constitute a group within the Gram-positives who 
are eminently sensitive to Pseudomonas CLPs which could be 
traceable to the hydrophobic, waxy cell surface of mycobacteria 
whereby the passage of hydrophobic CLPs through the plasma 
membrane might be facilitated (Nybroe & Sørensen, 2004). 
Further CLPs isolated from Pseudomonas spp. display activities 
towards Bacillus megaterium and B. cereus such as the 
corpeptins, the syringopeptins and tolaasin (Lavermicocca et 
al., 1997; Emanuele et al., 1998). Low micro molar minimal 
inhibitory concentrations against B. megaterium like 3.75 µM and 
4.20 µM for corpeptin A and B, respectively demonstrate again 
the potency of this substance class. 
  
massetolide A: R = CH3 
viscosin: R = H 
Figure 1.2.2: massetolide A and viscosin, two antimycobacterial cyclic 
lipopeptides 
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Table 1.2.2: antimycobacterial activities of selected Pseudomonas CLPs 
Mycobacterium CLP producer MIC 
[µg/ ml] 
M. avium- 
intracellularea 
massetolide A P. fluorescens SS101 2.5-5 
viscosin P. sp. MF-30 5-10 
M. tuberculosisa massetolide A P. fluorescens SS101 5-10 
viscosin P. sp. MF-30 10-20 
M. smegmatisb syringopeptin 22A 
syringomycin E 
P. syringae pv. syringae 
B359 
2-3 
1.5 
a Sayed et al., 2000; Gerard et al., 1997 
b Buber et al., 2002 
Another example for the antibiotic activity of Pseudomonas CLPs 
are the plusbacins (see figure 1.2.3), which belong to 
guanidine-containing CLPs like empedopeptin (see chapter 1.1.2), 
exhibiting a similar antibiotic spectrum including MRSA. The 
mode of action of plusbacin A3 involves blocking of the 
transglycosylation process and its forgoing steps of cell wall 
peptidoglycan synthesis, which is distinct from that of 
vancomycin (Hashizume & Nishimura, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.3: plusbacins 
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 Genome mining for CLPs 1.3
 
In recent years the availability of genomes and the 
affordability of the corresponding analytics strongly increased 
(Gross & Loper, 2009) and revised the view of the metabolic 
capabilities of microorganisms (Gross, 2007). As a result of 
more than 500 microbial genome sequences that are currently 
available in publicly-accessible databases, it could be observed 
that the majority of biosynthesis pathways encoding secondary 
metabolites are hidden in the genome. Empirically, this 
phenomenon is true for microorganisms possessing a genome size 
of 4 Mb or higher. This offers a huge potential to find a 
plethora of new bioactive molecules. Furthermore, in this 
context a deeper understanding of the biosynthesis of e.g. 
cyclic lipopeptides and the appearance of the involved genes in 
the genomes could be gained (Corre & Challis, 2009).  
Traditional culture-based, bioassay-guided concepts to discover 
natural products only lead to a small section of the 
biosynthetic capacity encoded in the genomes (Gross, 2009). 
Therefore, new concepts were required to find the new bioactive 
structures, hidden in the genomes. These perceptions lead to new 
technologies to screen for specific substance classes with 
genome mining tools (Zerikly & Challis, 2009; Challis, 2008; 
Gross et al., 2007). 
Several of these tools have been already proposed in this 
research field (Gross, 2007). To date, four methodologies have 
been successfully applied (see figure 1.3.1). The ´prediction 
and screening´ approach predicts at first the substrate 
specificity of the discovered orphan biosynthetic system as 
accurately as possible. This bioinformatics analysis allows to 
propose the resulting secondary metabolite and in addition its 
corresponding physico-chemical or even bioactive properties. 
Subsequently, the compound can be discovered by the deduced 
characteristics, e.g. mass-range or UV-profile. 
For orphan gene clusters where only few predictions about the 
substrate specificity of the encoded enzymes can be made, other 
approaches such as the ´gene knockout and comparative profiling´ 
method are more suitable. Hereby, disruption of the gene cluster 
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of interest by insertion mutagenesis and subsequent comparison 
of the secondary metabolite spectrum of the resulting mutant 
with its wild type identifies the corresponding natural product. 
The metabolite profiling is preferably performed with LC/MS or 
DAD-HPLC instrumentation. 
Another tool applicable to this research field is heterologous 
expression, i.e. the transfer of the orphan natural product 
pathway from the original producer into a different optimised 
bacterial host system.  
 
Figure 1.3.1 established genome mining strategies to unveil the products of 
orphan gene clusters  
In 2005, a fourth approach to the genome mining toolbox was 
added. Hereby, a bioinformatics analysis of the concerned orphan 
gene cluster allows proposing the resultant secondary metabolite 
or at least a partial structure. After confirmation of 
expression, a precursor that will be specifically incorporated 
into the final product is selected and fed to the microorganism 
in an isotopically labelled form (e.g. 15N, 13C-amino acids). 
Natural products utilizing this precursor can then be tracked 
through the isolation process by 1H-15N, or 15N-13C selective NMR 
experiments.  
Genome mining for new natural product discovery is a method 
exploiting the evolved availability of DNA sequence data to 
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locate genes which encode enzymes likely to be involved in 
natural product synthesis. Hereby, the enzymes can easily be 
located in sequenced genomes by use of computational sequence 
comparison tools (Zerikly & Challis, 2009). 
In this way, genomes can be ´mined´ for e.g. typical patterns of 
NRPS, indicating the presence of putative CLP biosynthesis 
genes. Specific features of NRPS genes involved in CLP synthesis 
can be the condensation domain of the first NRPS module or the 
appearance of two TE-domains in the last module of the cluster 
(de Bruijn et al., 2007).    
In comparison to traditional isolation strategies, the genome 
mining approaches offers the following advantages: from the 
bioinformatics prediction of the resulting compound, the novelty 
of a compound can be already deduced with a high probability. 
Thus, isolation efforts will be only undertaken in worthwhile 
cases. Knowledge about the expected chemical structure including 
its polarity and stability allows the optimisation of the 
extraction and isolation strategies to actually obtain the 
compound. Moreover, genome mining overcomes the difficulty of 
bioassay-guided technologies to unveil the products of silent 
pathways by directly screening the genome (Gross, 2009). 
Considering the potential of CLPs, their frequent occurrence and 
structural diversity in the genus Pseudomonas, the application 
of genome mining tools for the search of NRPS-derived CLPs in 
Pseudomonads represents a promising approach to find new 
antimicrobial agents, which might cover the urgent need of new 
antibiotics.  
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 Scope of the present study 2
  
The study was performed within the frame of the DFG research 
group (FOR 854) “Post-genomic strategies for new antibiotic 
drugs and targets”. Motivated by the globally spreading 
antibacterial resistance, which represents a serious health 
threat, the objective of this consortium is to investigate 
promising new antibiotic compounds, mechanisms and targets, 
using genomic and reverse genomic approaches. Partial project 8 
“Genomic mining for antimicrobial lipopeptides” wanted to 
contribute to this overall goal by the isolation and testing of 
antibacterial natural products of the cyclic lipopeptide class. 
However, instead of employing classical bioassay-guided 
strategies, a genome driven-approach was applied.  
Putative candidate structures should be identified by an in 
silico screening for cyclic lipopeptides in genomes of the 
promising and underexplored genus Pseudomonas. Subsequently, the 
targeted CLPs will be isolated using chromatographic methods and 
their structures elucidated by spectroscopic methods e.g. NMR 
and MS. Upon structure elucidation, the bioactivity of the 
cyclic lipopeptides should be investigated and first insights 
into the mode of action shall be gained.  
In case of discovery of intriguing biosynthetic backgrounds, the 
study can be extended by corresponding feeding- and knock-out 
studies.  
 
In a side-project of this study, the antimicrobial cyclic 
lipodepsipeptide empedopeptin should be isolated from the strain 
Empedobacter haloabium nov. sp. for the purpose of structural 
confirmation and collaborative mode of action studies. 
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 Material and methods 3
 Microbiological methods 3.1
 
 Media composition 3.1.1
 
Media Ingredient amount 
[g/l] 
reference 
DMBgly DifcoTM Minimal Broth Davis 
without Dextrose 
10.6  
glycerol 1.84  
King´s broth (KB) 
pH 7.2 
Proteose Peptone No.3 
(Becton Dickinson) 
20 King et al., 1954 
Bacto agar 15  
glycerol 10  
K2HPO4 (anhydrous) 1.5  
MgSO4 x 7 H2O 1.5  
For liquid cultivation the media was composed without Bacto agar. 
Linseed medium 
pH 7.0 
sucrose (= D(+)saccharose) 30 Konishi et al., 1984 
linseed meal 20 
(NH4)2SO4  3 
CaCO3 5 
Lysogeny broth 
(LB) 
pH 7.0 
Bacto Tryptone 10 Bertani, 1951 
yeast extract 5  
NaCl 10  
glucose   1  
925 Minimal 
medium broth (925 
MM) 
K2HPO4 3  
NaH2PO4 1  
NH4Cl 1  
MgSO4 x 7 H2O 0.39  
saccharose 100  
Saccharose was dissolved in 100 ml water and filtered sterile into the 
autoclaved media. 
  
24 Material and methods 
 
Nutrient broth 
(NB)  
pH 7.0 
Bacto Peptone 5  
meat extract 3  
glycerol 10 ml  
Potato medium potatoes 300  
 Bacto Peptone 5  
 glucose monohydrate 5  
 NaH2PO4 x 12 H2O 3  
 KH2PO4 x 6 H2O 0.5  
 NaCl 3  
Potatoes were sliced and cooked for 30 min in 500 ml of water. The water was 
filtered using a round filter, supplemented with the above-mentioned 
ingredients and refilled with distilled water to one litre.  
Seed medium  
pH 7.0 
soluble starch 20 Konishi et al., 1984 
glucose 10 
meat extract 2 
yeast extract 2 
NZ Case 5 
CaCO3 2 
After suspension of the media ingredients in one litre of water, the medium 
was left alone till sedimentation took place. Subsequently, the resultant 
supernatant was decanted and sterilised. 
SRM HG* histidine 4 Mo & Gross, 1991 
MgSO4 x 7 H2O 0.1971  
K2HPO4 0.8  
KH2PO4 0.8  
FeCl3 0.0016  
glucose 10  
fructose 1  
arbutin 0.027  
FeCl3, glucose, fructose and arbutin where dissolved in water, proceeded as 
described in chapter 3.1.4 (heat labile solutions) and added to the 
autoclaved media. 
*syringomycin minimal medium modified according to Prof. Dr. H. Gross 
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Cultivations containing Amberlite 
In case of a subsequent absorber resin-based extraction, the 
media was supplemented with 2% of Amberlite XAD-16. In order to 
avoid impurities and to obtain a neutral pH value, the resin was 
washed in a fritted funnel with 10 litre of water before use.  
 
 Bacterial strains 3.1.2
 
Table 3.1.1: bacterial strains used during this study 
bacterial strain relevant characteristics or purpose reference(s) or 
source 
E. haloabium nov. 
sp. 
wild-type strain, contains the full 
functional empedopeptin gene cluster 
ATCC 31962 
P. syringae pv. 
syringae B728a 
Rifampin-resistant mutant of a wild-type 
strain originally collected from bean leaves; 
strain for in silico screening 
Loper & Lindow, 
1987  
P. syringae pv. 
tomato DC3000 
Rifampin derivative of DC52 (wild-type 
P. syringae pv. tomato race 0 strain), 
pathogen of tomato and Arabidopsis spp., 
strain for in silico screening 
Cuppels, 1986 
P. entomophila strain for in silico screening, 
containing three putative lipopeptide 
gene clusters 
Vodovar et al., 
2006 
P. sp. SH-C52 wild-type, isolated in the province of 
Noord-Brabant, The Netherlands, within 
the frame of a project investigating 
disease suppressive soils 
J. M. 
Raaijmakers*   
C52Δ26a          
(P. sp. SH-C52) 
knockout mutant, lacking the 
glycosyltransferase and containing a 
gentamycin resistance cassette 
M. van der Voort, 
Raaijmakers group 
C52Δ26IFa        
(P. sp. SH-C52) 
in frame knockout mutant missing the 
glycosyltransferase 
M. van der Voort, 
Raaijmakers group 
C52Δ27a          
(P. sp. SH-C52) 
knockout of the structural NRPS gene M. van der Voort, 
Raaijmakers group 
C52Δ28a          
(P. sp. SH-C52) 
knockout of the corresponding 
monooxygenase comprising a gentamycin 
resistance cassette 
M. van der Voort, 
Raaijmakers group 
C52Δ33b          
(P. sp. SH-C52) 
knockout of the structural NRPS gene M. van der Voort, 
Raaijmakers group 
* Associate Professor, Laboratory of Phytopathology, University of 
Wageningen, the Netherlands 
a knockout mutants with mutations in the gene cluster predicted to be 
responsible for the production of a lipodipeptide 
b knockout mutants with mutations in the genes hypothetically belonging to a 
chlorinated syringomycin-like lipopeptide 
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 Cultivation of bacteria 3.1.3
 
Precultures of Pseudomonas strains 
Precultures were grown 24-48 h at room temperature on a Gerhardt 
LS30 horizontal shaker at 100 rpm in 50 ml Falcon tubes 
containing 12 ml DMBgly, inoculated with 80-100 µl cryo culture.  
 
Cultivations for screening of Pseudomonas strains using an OSMAC 
approach 
Liquid cultures were inoculated with 250 µl of the corresponding 
preculture and grown on a small scale (each 250 ml) in KB, LB, 
NB, DMBgly, 925 MM, SRM HG and potato medium (see chapter 3.1.2) 
over a period of three days, incubated at different temperatures 
(RT, 18°C and 28°C) and 140 rpm using an INFORS HT Multitron 
incubator shaker. For each experiment, the corresponding medium 
without inoculum served as a control.  
 
Cultivation of main cultures 
Main cultures were cultivated in DMBgly in 5 l Erlenmeyer 
flasks, containing 1.5 l medium, inoculated with 1.5 ml of the 
preculture and incubated for 3 d at RT and 140 rpm using an 
INFORS HT Multitron incubator shaker. 
Cultivations were done either on a 4.5 l (labelling experiments) 
or 9 l scale. 
 
Solid cultures 
Agar plates were inoculated with a sufficient amount of 
preculture by streaking and incubated at RT over a period of 
three days.  
 
Cultivation of Empedobacter haloabium nov. sp. (ATCC 31962) 
The cultivation of Empedobacter haloabium nov. sp. (ATCC31962) 
was handled using Biosafety Level 2 practices and containment, 
and performed as described previously (Konishi et al., 1984). 
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Precultures were cultivated in 10 ml seed 
media inoculated with 100 µl cryo culture 
in 50 ml Falcon tubes for 48 h at RT on a 
Gerhardt LS30 horizontal shaker at 100 rpm. 
3 l of the main culture were grown in 
linseed medium (see fig. no. 3.1.1) in 5 l 
Erlenmeyer flasks, each containing 1 l of 
the culture broth and inoculated with 5 ml 
of preculture. Cultures were fermented for 
four days at 27°C on an INFORS HT Multitron 
incubator shaker shaking at 140 rpm. 
 
 Sterilisation 3.1.4
 
Heat-stable media, buffers and solutions and glassware were 
sterilised in a steam autoclave (Varioklav) at 121°C and 1.2 bar 
for 20 min. In case culture media contained, or autoclavable 
equipment had contact with bacteria belonging to biosafety class 
two, the exhaust filter system was additionally activated. 
Filters with cellulose acetate membranes (Millipore, Renner, 
Darmstadt, Germany) with a pore diameter of 0.22 µm were used to 
filter sterilise heat sensitive solutions.  
 
 Bacterial growth curve determination and quantitative 3.1.5
analysis of brabantamide A production over a 72 h period 
 
For the determination of doubling time and growth rate nine 
cultures were prepared. These were grown in 5 l Erlenmeyer 
flasks filled with 1.5 l DMBgly medium. To prevent cultivation 
differences and achieve a uniform growth it was decided to work 
with nine 1.5 l cultures instead of growing many small cultures. 
All flasks were inoculated with 1.5 ml preculture. The time of 
inoculation was set as the starting point. 
Samples were taken every 1.5 hours over a period of four days 
and processed to the following experimental steps: 
Figure 3.1.1: linseed 
medium, cultivation of 
E. haloabium nov. sp. 
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Three of nine cultures were rotationately harvested at all 
defined harvesting times to assure similar culture volumes and 
growth conditions. 100 ml of each of the cultures were withdrawn 
under sterile conditions after shaking the flasks to guarantee a 
uniform distribution of cells and secreted substances. 1 ml of 
every sample was transferred into a cuvette to measure the 
optical density on a Shimadzu UV mini 1240 UV-VIS 
spectrophotometer at 600 nm. 
After determination of the UV absorption, the remaining culture 
was acidified with HClconc. to a pH value of 2 and extracted three 
times with EtOAC (1:1). The combined organic supernatants were 
evaporated to dryness and analysed by LC-MS.  
 
For product quantification, five standard solutions were 
prepared: 
Stock solution: 0.5 mg/ml of brabantamide A in MeOH 
Solution 1: 250 µl stock solution + 750 µl MeOH = standard 5 
[0.125 mg/ml] 
Solution 2: 50 µl stock solution + 4950 µl MeOH = standard 4 
[0.005 mg/ml] 
Solution 3: 250 µl of solution 2 + 250 µl MeOH = standard 3 
[0.0025 mg/ml] 
Solution 4: 100 µl of solution 2 + 900 µl MeOH = standard 2 
[0.0005 mg/ml]  
Solution 5: 400 µl of solution 4 + 400 µl MeOH = standard 1 
[0.00025 mg/ml] 
 
Calculation of the specific growth rate and the doubling time 
 
OD = optical density       
OD0 = optical density at t0   ܱܦ ൌ ܱܦ଴ ൈ ݁ஜ௧ 
t = time [h] 
µ = specific growth rate     
td = doubling time [h]      μ ൌ ୪୬ 	ଶ௧೏   
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 Investigation of suitable carbon sources for Pseudomonas 3.1.6
sp. SH-C52 
 
In order to optimise the cultivation medium for maximum 
secondary metabolite production, it was investigated, which 
carbon sources can be utilised by the strain Pseudomonas sp. SH-
C52. For this purpose an API®50CH standardised test (Biomerieux, 
Marcy l’Etoile France) system was employed. The system 
associates 50 biochemical tests for the study of the 
carbohydrate metabolism of microorganisms. API®50 CH was used in 
conjunction with API®50CHB/E Medium.  
Inoculum cultures with a turbidity equivalent to 2 McFarland 
(0.451 at 600 nm) were prepared according to the manufacturer´s 
protocol and control strips applied. Test strips were read after 
24 and 48 hours of incubation at room temperature. 
With the exception of the esculin test, a positive test result 
is indicated by a change in colour of the medium from red to 
yellow. This reaction is based on acidification of the media by 
a growing culture, i.e. utilisation of the carbon source, which 
is visualized by the pH dependent indicator phenol red. In case, 
the bacterium can hydrolyse the compound esculin as carbon 
source, a change in colour from red to black is observed. 
 
 Detection of antibacterial activity 3.1.7
 
Determinations of the antibacterial activity were performed by 
Michaele Josten (Member of the research group of Prof. Dr. H. - 
G. Sahl, Institute of Medical Microbiology, Immunology and 
Parasitology (IMMIP), Pharmaceutical Microbiology Unit, 
University of Bonn, Bonn, Germany). 
 
Determination of the MIC 
MIC determinations were performed in microtiter plates. Strains 
were grown in half-concentrated Mueller-Hinton (MH) broth 
(Oxoid). The only exception was Arthrobacter crystallopoietes 
DSM 20117 which was grown in tryptic soy broth (Oxoid). 
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MICs with serial twofold dilution steps were performed (1:2). 
Bacteria were added to give an inoculum of 10 CFU/ml in a volume 
of 0.2 ml. Bacteria were incubated for 24 h at 37°C. Afterwards 
the MIC was read as the lowest compound concentration causing 
inhibition of visible growth. Results are mean values of three 
independent determinations. Since some lipopeptides were 
previously reported to possess a calcium dependency for optimum 
activity (Baltz et al., 2005), the effect of calcium substituted 
medium on the MICs was evaluated. Two organisms, S. aureus SG511 
and Bacillus subtilis 168 were used in the test which consisted 
of a broth dilution MIC determination in supplemented (0.2 mg/ml 
CaCl2) and unsupplemented in half-concentrated MH broth. 
	
Agar diffusion assays 
The antibacterial activity was determined by agar diffusion 
assays. Culture plates (5% sheep blood Columbia agar, BD) were 
overlaid with 3 ml tryptic soy soft agar, inoculated with 3 TSB 
(tryptic soy broth, Oxoid) growth suspension of the bacteria to 
be tested. Compounds were diluted with DMSO to a concentration 
of 1 mg/ml and 3 µl of this dilution were placed on the surface 
of the agar. After 24 h incubation at 37°C the diameter of the 
inhibition zone was measured. The indicator strains represent 
clinical isolates from distinct patients as well as standard 
laboratory strains and are listed below. The strains were 
maintained on MH agar or on blood agar. 
 
Gram-positive bacteria: 
Arthrobacter crystallopoietes DSM 20017, Bacillus megaterium, B. 
subtilis 168, Corynebacterium diphteriae, C. pseudodiphteri-
ticum, C. xerosis Va 167198, Enterococcus faecium I-11305b, E. 
faecium I-11054, Listeria welchimeri DSM 20650, Micrococcus 
luteus ATCC 1856, Mycobacterium smegmatis ATCC 70084, 
Staphylococcus aureus SG511, S. aureus 5185 (MS*), S. aureus LT-
1334 (MR*), S. epidermidis LT-1324 (MR*), S. epidermidis ATCC 
12228, S. simulans 22,  
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Gram-negative bacteria: 
Eschericha coli DH5 alpha, Escherichia coli O-19592, Klebsiella 
pneumonia subsp. ozeanae I-10910, Citrobacter freundii I-11090, 
Pseudomonas aeruginosa I-10968, Serratia marcescens, 
Stenotrophomonas maltophila O-16451 and S. maltophila I-10717  
Fungi: 
Candida albicans 
 
*MS = methicillin – susceptible, MR = methicillin - resistant 
 
 Determination of cytotoxicity 3.1.8
 
Cytotoxicity tests were performed by the research group of Prof. 
Dr. H. Brötz–Österhelt (Institute of Pharmaceutical Biology and 
Biotechnology, University of Düsseldorf, Germany).  
Toxicity towards THP1 human leukemic monocyte cells and BALB/3T3 
mouse embryonic fibroblast cells were measured using a 
fluorometric Alamar Blue assay. 
THP1 cells were grown in DMEM medium (PAN Biotech GmbH), 
containing 4.5 g/l glucose and 3.7 g/l NaHCO3, supplemented with 
10% foetal calf serum (v/v), 1% sodium pyruvate and 1% L-
glutamine. BALB/3T3 cells were cultured in RPMI-1640 medium (PAN 
Biotech GmbH) containing 2.0 g/l NaHCO3, supplemented with 10% 
foetal calf serum (v/v), 1% L–glutamine and 1 % penicillin-
streptomycin (10000 U/ml penicillin and 10 mg/ml streptomycin; 
PAN Biotech GmbH). 
Cells were seeded in 96-well plates at 10 000 cells/well in 190 
µl. Pure compounds were dissolved in 20 µl DMSO. For serial 
dilutions, a suspension of 2 mg/ml was generated, using medium 
as diluent, and 11-fold serial dilutions thereof were made; 10 
µl sample of a dilution was added per well, resulting in a final 
assay concentration of 0.031 – 64 µg test compound per ml. The 
plates were incubated for 72 h in a humidified atmosphere of 5% 
CO2 and at 37 oC. Negative controls consisted of the indicated 
medium, while cycloheximide served as a positive control.  
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After 48 h, 10 µl Alamar Blue/well were added and the incubation 
continued for another 24 h. After 72 h of total incubation time, 
the fluorescence was read using a 96-well fluorometer (Tecan) 
with excitation at 560 nm and emission at 600 nm. Results are 
expressed in relative fluorescence units (RFU), i.e. the ratio 
of fluorescence emitted by treated cells vs. fluorescence 
emitted by the control (medium only). RFU were plotted against 
sample concentrations and the corresponding IC50 values computed.  
 
 Luciferase reporter gene assay 3.1.9
 
Luciferase reporter gene assays were performed by the research 
group of Prof. Dr. H. Brötz–Österhelt (Institute of 
Pharmaceutical Biology and Biotechnology, University of 
Düsseldorf, Germany).  
Table 3.1.2: applied Bacillus subtilis reporter strains 
reporter strains constructs of the promoters 
B. subtilis 1S34pS63MH124 *yvgS promoter fused to firefly luciferase gene, 
transcription reporter gene assay, EryR 
B. subtilis 1S34pS72  *yheI promoter fused to firefly luciferase gene, 
translation reporter gene assay, EryR 
B. subtilis 1S34pS77 *yorB promoter fused to firefly luciferase gene, 
replication reporter gene assay, EryR 
B. subtilis 1S34pS107 
 
*ypuA promoter fused to firefly luciferase gene, 
cell wall synthesis and cell envelope stress 
reporter gene assay, EryR                                           
B. subtilis 1S34pS130 yvqI promoter fused to firefly luciferase gene, 
cell wall synthesis and cell envelope reporter gene 
assay, EryR 
* Urban et al., 2007; EryR = erythromycin-resistant 
Reporter strains were grown on LB agar and then cultured 
overnight in 10 ml LB medium, both supplemented with 5 µg/ml 
erythromycin at 37°C and 200 rpm. Cultures were diluted to an 
OD600 of 0.05 in 20 ml LB medium or Belitzky minimal medium 
(Stülke et al., 1993) with 5 µg/ml erythromycin, grown to an 
OD600 of 0.9 or 0.4 (yheI strain) under the conditions described 
above and diluted to an OD600 of 0.02. 
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A serial twofold dilution of each test compound (0.031 µg/ml to 
64 µg/ml) in 60 µl LB broth in a white 96-well flat bottom 
polystyrol microtiter plate (Greiner) was inoculated with 60 µl 
of the adjusted bacterial suspension. Each microtiter plate 
contained negative controls (full assay mixture without compound 
addition) and positive controls (reference antibiotics known to 
cause maximal signal induction).  
Table 3.1.3: antibiotics used as reference compounds 
antibiotic source concentration strain 
chloramphenicol Sigma-Aldrich 0.049- 100 µg/ml yheI 
ciprofloxacin Fluka 0.003- 6.25 µg/ml yorB 
rifampicin AppliChem 3x 10-5 – 0.0625 µg/ml yvgS 
vancomycin AppliChem 0.049- 100 µg/ml yvgI and ypuA 
Microtiter plates were incubated at 37°C for a period depending 
on the induction kinetics of the reporter strain: 1 h for the 
yvqI and ypuA strains, 1.5 h for the yvgS strain, 3.5 h for the 
yorB strain and 4 h for the yheI strain. After this incubation 
step 60 µl citrate buffer (0.1 M, pH 5) containing 2 mM 
luciferin (Serva) was added and flash luminescence was measured 
using a microtiter plate reader (Mithras, Berthold or Infinite 
200, Tecan). 
 
 Incorporation of radioactive metabolites 3.1.10
 
Tests regarding the incorporation of radioactive metabolites 
were performed by Michaele Josten (IMMIP, Pharmaceutical 
Microbiology Unit, University of Bonn, Bonn, Germany). 
A culture of Pseudomonas sp. SH-C52 was grown in half-
concentrated MH broth (Oxoid). The culture was incubated 
overnight at 37°C and subsequently diluted to an optical density 
(OD) of ~ 0.04. The culture was divided into two 10 ml aliquots 
in Erlenmeyer flasks. The first aliquot was grown up to an OD of 
0.5 and the second sample up to an OD of 0.95. After 10 min each 
culture was supplemented with 25 µl 14C-proline (0.5 nmol/ml). 
Samples were drawn on schedule. 500 µl of the culture were 
pipetted into 2 ml ice cold trichloroacetic acid (10% TCA + 1 M 
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NaCl + 1 ml cool metabolite). Precipitations rested at least 30 
min on ice before filtering with Whatman glass fibre filters and 
washing with 5 ml of a solution containing 2.5% TCA, 1 M NaCl 
and 50 mM cold metabolite. Filters were dried and transferred to 
counting vials filled with scintillation fluid (Quickszint 100; 
Zinsser, Frankfurt, Germany). The radioactivity was measured in 
a beta-counter (1900CA; Packard, Downers Grove, IL, USA). 
 
 Biosynthetic investigations of brabantamides 3.2
 
Biosynthetic studies were carried out by provision of putative 
isotopically labelled precursors of brabantamide to the 
bacterium P. sp. SH-C52. The cultivation of the bacterium for 
the labelling experiments was performed according to established 
procedures (chapter 3.1.1) and done on a 4.5 litres scale. The 
addition of precursors occurred 4 h after inoculation.  
Precursors were dissolved in a small amount of purest water to 
avoid a significant increase of the culture volume. The solution 
was sterile filtered, divided into equal parts and pipetted into 
three 5 l Erlenmeyer flasks, each containing the 1.5 l of 
bacterial broth.  
Thus were added:  
1.0 g 1-13C – sodium acetate (222.2 mg/l)      
1.0 g 1,2-13C - sodium acetate (222.2 mg/l)     
1.0 g 1-13C - L–glycine (222.2 mg/l) 
250 mg 1-13C – L–proline (55.6 mg/l) 
1.0 g 1-13C - hydrogen carbonate (222.2 mg/l)    
500 mg 1-13C – L–serine  (111.1 mg/l)      
250 mg U-13C – L-serine  (55.6 mg/l)   
The isotopically labelled compounds were obtained from Cambridge 
Isotope Laboratories or from Aldrich, respectively. 
After addition of the dissolved stable isotope precursors, the 
cultivation was continued as described above. 
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 Chemical methods 3.3
 
 Extraction of bacteria  3.3.1
 
Extraction of Pseudomonas cultures 
Liquid cultivation:  
The culture broth was adjusted with HClconc. to a pH value of 2. 
The acidified cultures were extracted three times with ethyl 
acetate (1:1) and the resulting organic supernatant was 
evaporated to dryness with a vacuum rotary evaporator at 30°C. 
The water phase was discarded. 
 
Liquid cultivation containing Amberlite XAD-16: 
Cells and XAD absorber resin was harvested from the culture 
broth employing a fritted funnel. Subsequently, the residue was 
washed with water to remove adherent cells from the harvested 
resin. The washed adsorber resin was extracted by rinsing 3 x 1 
l of EtOAc through the fritted funnel. The crude extract was 
dried by evaporation in vacuum at 30 degree.  
 
Solid cultivation: 
The complete agar material was chopped into 
pieces and transferred into Erlenmeyer flasks 
(see figure 3.3.1). Extraction was performed 
by addition of an equal amount of acidified 
ethyl acetate (250 ml per plate) and stirring 
over a period of 30 min. This procedure was 
repeated twice and the resulting organic 
supernatant was evaporated to dryness using a 
vacuum evaporator at 30°C.  
 
Figure 3.3.1: 
extraction of 
solid cultivations
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Extraction of Empedobacter haloabium nov. spec. 
The culture broth was acidified with HClconc. to a pH-value of 3. 
After addition of an equal volume of n-butanol, the two-phase 
system was stirred under the laminar air flow over a period of 
one day. The organic supernatant was decanted and evaporated to 
dryness with a vacuum rotary evaporator at 40°C. The aqueous 
layer was discarded. 
 
 Vacuum liquid chromatography 3.3.2
 
VLC was carried out using column with a diameter of 65 mm filled 
with Polygoprep 60 C18 material (0.05 mm, Macherey-Nagel 
711500.1000; reversed phase). For this purpose the columns were 
wet-packed with an adequate amount of Polygoprep dissolved in 
methanol and condensed with vacuum. Afterwards, the columns were 
equilibrated with the starting composition of the eluents 
(methanol - water – mixtures).  
The crude extract was dissolved in a small amount of the first 
eluent and applied to the top of the column with a spoon to 
avoid destruction of the column bed. Elution was started by 
pouring mobile phase on the top of the column and if necessary 
vacuum was applied.  
In general, the following stepwise gradient was applied: 
Fraction 1: MeOH/H2O 50:50 
Fraction 2: MeOH/H2O 70:30 
Fraction 3: MeOH/H2O 90:10 
Fraction 4: MeOH/H2O 100:0 
Fraction 5: DCM  100% 
The volume of solvents was adjusted to the column size. 
Typically 400 ml of the first eluent was used for equilibration 
and 400 ml of the mixtures for fractions 1-3 were applied. 
Fractions 4 and 5 were performed employing 600 ml solvent to 
achieve complete recovery of the extracts. Fractions were 
 Material and methods 37 
 
collected in round-bottom flasks and evaporated to dryness at 
30°C under reduced pressure using a rotary evaporator. 
 
 High performance liquid chromatography  3.3.3
 
HPLC was carried out using one of the following HPLC systems: 
System 1: a Merck-Hitachi system consisting of a D-6000A 
interface with D-7000 HSM software version 4.0, a L-6200A pump, 
a Rheodyne 7725i injector and a L-4500 diode array detector. 
System 2: an Agilent system (1100 series) containing a G1379A 
degasser, a G1312A binary pump, a G1312A auto sampler and a 
G1315C diode array detector; software: ChemStation. 
System 3: a Waters system equipped with a 600 controller pump, a 
717 plus auto sampler with inline degasser Waters AF and a 996 
photodiode array detector; software: Millenium32. 
System 4: a Merck-Hitachi system consisting of a Knauer 
interface box, a L-6200A pump, a Rheodyne 7125 injector and an 
UV-VIS L-7420 detector; software: Knauer EuroChrom® 2000 version 
1.65. 
 
Applied columns: 
Column 1: Macherey-Nagel Nucleosil 120-5 C18 (5 µm, 250 x 4 mm) 
Column 2: Nucleodur C18 Isis (5 µm, 250 x 4.6 mm, EC) 
Column 3: Nuleodur 100-5 HILIC (250 x 4.6 mm, EC) 
Column 4: XTerraTM RP18 (5 µm, 250 x 4.6 mm) 
Column 5: Waters Symmetry Shield RP 18 (5 µm, 250 x 4.6 mm) 
Column 6: Knauer Eurospher-100 C18 (5 µm, 250 x 8 mm) 
Column 7: Macherey-Nagel Nucleodur 100-5 C18 (5 µm, 250 x 8 mm) 
Typical flow rates were 0.8 ml/min and 1.5-1.8 ml/min for 4.6 mm 
columns and 8 mm HPLC columns, respectively. All solvents except 
H2O were either distilled prior to use or of HPLC-grade quality. 
Buffer solutions like ammonium acetate buffer were sterile 
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filtered to avoid injection of insoluble parts which otherwise 
would cause an elevated backpressure. 
 
 NMR spectrometry 3.3.4
 
NMR spectra of the isolated compounds were recorded on a Bruker 
Avance 300 DPX operating at 300 MHz (1H) and 75 MHz (13C), a 
Bruker Avance 500 DPX spectrometer operating at 500 MHz (1H) and 
125 MHz (13C), a Varian INOVA 600 spectrometer operating at 600 
MHz (1H) and 150 MHz (13C) or a Varian INOVA 900 spectrometer, 
operating at 900 MHz (1H) and 225 MHz (13C). NMR spectra were 
processed using Bruker XWIN-NMR Version 2.6, 3.1 and 3.5 
software or MNova. Spectra were referenced to residual solvent 
signals with resonances at δH/C 2.04/29.8 ((CD3)2CO), δH/C 3.35/49.0 
(CD3OD) and δH/C 2.50/39.5 (DMSO). To deduce the multiplicity of 
carbons, DEPT experiments were performed. In order to elucidate 
the complete structures the following NMR experiments were 
carried out:  
1H, 13C, DEPT135, 1H-1H COSY, HSQC (1H-13C direct correlation) and 
HMBC (1H-13C long-range correlation), NOESY (Nuclear Overhauser 
Effect Spectroscopy) employing different mixing times (300 ms, 
400 ms, 500 ms and 1500 ms) 
 
Calculation of the incorporation ratio of 13C labelled compounds 
 
Experiments with single labelled substances:  
To evaluate the enrichment of the labelled carbon atoms, the 
integral of carbon 6´ of brabantamide A was set to 1.000 in 
every spectrum and the integrals of the other carbons were 
compared in the spectra of the labelled and the non-labelled 
compound.  
 
Enrichment = enhancement of the signal x 1.1% - 1.1% 
 
 Material and methods 39 
 
Enhancement of the signal = quotient of the integrals (enriched 
value / natural abundance) 
1.1% = natural abundance of 13C atoms  
 
Labelling experiment with 1,2-13C-acetate: 
To evaluate the relative enrichments first the total integral of 
the 13C-NMR signal for each resonance of brabantamide A was 
measured. The integration value of the 13C signal appearing in 
the centre of each cluster, representing those 13C atoms not 
coupled to adjacent 13C atoms for each resonance of brabantamide 
A was quantified and the quotient was determined (Chang et al., 
2004).  
 
Relative enrichment [%] = ௧௢௧௔௟	௜௡௧௘௚௥௔௟	௢௙	௘௡௥௜௖௛௘ௗ	௖௔௥௕௢௡	௔௧௢௠௜௡௧௘௚௥௔௟	௢௙	௨௡௖௢௨௣௟௘ௗ	௦௜௚௡௔௟ ൈ 100 
 
 Mass spectrometry 3.3.5
 
HPLC-ESI-MS measurements were conducted by E. Eguereva 
(Institute for Pharmaceutical Biology, University of Bonn) using 
an Agilent 1100 series HPLC including diode array detector, 
coupled with an API 2000 Triple Quadrupole LC/MS/MS. Prior to 
the measurement, the samples were dissolved in LC/MS-grade 
methanol, setting up to a final concentration of 5 mg/ml and 
transferred to IVA TPX vials 32 x 11.6 mm with an integrated 
glass micro insert (0.2 ml). HPLC was carried out employing a 
Macherey-Nagel Nucleodur 100 C-18 column (5 µm, 125 mm x 2 mm) 
and a buffered (2 mmol NH4OAc) gradient system (MeOH/H2O). At a 
flow of 0.25 ml/min the percentage of MeOH was increased from  
10 % to 100% over 20 min followed by 10 min isocratic elution at 
100 % MeOH. Experiments were recorded in positive (+Q1) as well 
as negative (-Q1) mode using a declustering potential of either 
30 V or 70 V. Spectra were processed via Applied Biosystems/MDS 
Sciex Analyst Software. 
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HR-ESI-MS measurements were performed by Ms. Peters-Pflaumbaum, 
Department of Chemistry, University of Bonn using a Bruker 
Daltonics micrOTOF-Q instrument. 
 
 Optical rotation 3.3.6
 
The optical rotation was measured on a Jasco model DIP-140 
polarimeter. The standard measurement was carried out in 
methanol at λ = 589 nm corresponding to the sodium D line. The 
temperature was monitored by an external thermometer. The sample 
cell length was 1 dm.  
ሾαሿୈ୘ ൌ
α
c ൈ d ൈ 10
ସ 
 
ሾαሿୈ୘ ൌ specific optical rotation [°] 
D = sodium D line (λ = 589 nm) 
T = Temperature [°C] 
α = rotation angle [°] 
c = concentration [g/100 ml] 
d = cell length [mm]  
The values for the rotation angle α were determined by an 
average value based on at least 12 measurements.  
 
 IR spectroscopy 3.3.7
 
IR spectra were obtained employing a Perkin-Elmer FT-IR Spectrum 
BX spectrometer interfaced with a Specac Golden Gate Diamond ATR 
system. Data processing was conducted with Spectrum v3.01 
software. 
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 UV spectroscopy 3.3.8
 
UV spectra were recorded on a Perkin-Elmer Lambda 40 with UV 
WinLab Version 2.80.03 software, using 1.0 cm quartz cells. The 
molar absorption coefficient ε was determined in accordance with 
the Lambert-Beer-Law. Spectra were measured in methanol. 
 
ܣ ൌ ε ൈ c ൈ d	 
A = Absorption 
ε = molar absorption coefficient [ ୪୫୭୪ൈୡ୫] 
c = concentration [୫୭୪୪ ] 
d = cell length [cm] 
 
 CD spectroscopy 3.3.9
 
CD spectra were recorded using a J-810 spectropolarimeter at the 
Kekulé Institute of Organic and Biochemistry, University of 
Bonn. The sample was dissolved in methanol to a concentration of 
0.5 mg/ml and measured at a wavelength range of 190 to 400 nm. 
The average value of 5 measurements was taken with a sensitivity 
of 100 mdeg and a scanning speed of 50 nm/min at 20 degree. The 
obtained raw-spectrum was further processed with the smoothing 
function integrated in the measurement software. 
 
 Solid phase extraction (SPE) 3.3.10
 
Solid phase extraction was carried out using Bakerbond prepacked 
columns RP with 2000 mg capacity. The column was equilibrated 
with the initial mobile phase (methanol-water – mixture).  
The crude extract was dissolved in a small amount of the first 
eluent mixture and applied to the top of the column with a 
pipette. Elution was started by pouring mobile phase on the top 
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of the column and vacuum was applied using a JT Baker SPE-24G 
glass vacuum chamber 7423-00. 
30 ml of the following eluents were used: 
Fraction 1: MeOH/H2O 50:50 
Fraction 2: MeOH/H2O 70:30 
Fraction 3: MeOH/H2O 90:10 
Fraction 4: MeOH/H2O 100:0 
Fraction 5: DCM  100% 
Fractions were collected in round-bottom flasks and evaporated 
to dryness at 30°C under reduced pressure using a rotary 
evaporator. 
 
 Bioinformatics tools 3.4
 
Genes and operons for in silico analysis were found by BLAST 
homology and by searching the corresponding genomes in GenBank 
(NCBI database). 
Open reading frames (ORFs) were identified using ORF Finder from 
the NCBI database, translated with the ExPASy translate tool 
(http://web.expasy.org/translate/) and analysed with Blastp in 
the NCBI database.  
The NRPS/PKS predictor software (Bachmann & Ravel, 2009) was 
used to predict the backbone of cyclic lipopeptides, to identify 
different domains and to extract the corresponding sequences. 
For further investigations on the composition of gene clusters, 
antiSMASH: rapid identification, annotation and analysis of 
secondary metabolite biosynthesis gene clusters (Medema et al., 
2011) was used. For phylogenetic analyses of different domains, 
alignments were performed with ClustalW2 (Larkin et al., 2007). 
Phylogenetic trees were generated using Genious v5.5, created by 
Biomatters, available from http://www.geneious.com.  
For classifications of C-domains, the web-based software NaPDos 
(Natural Product Domain Seeker; Ziemert et al., 2012) was 
applied. 
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 Results and discussion 4
 In silico screening for cyclic lipopeptides 4.1
 
At the beginning of the study and continually during the study 
genome sequences of the genus Pseudomonas or of related genera, 
which were either publicly available or available in 
collaboration with other research labs, were subjected to an in 
silico screening for cyclic lipopeptides.  
Initially, eight gene clusters were found and analysed. A 
bioinformatical analysis of the corresponding genes led to first 
insights into the expected size and structure of the products of 
the orphan gene clusters. 
 
P. entomophila L48 
Already in the publication about the genome sequence of P. 
entomophila L48 three putative NRPS-based biosynthetic gene 
clusters were reported (Vodovar et al., 2006).  
The first of the three lipopeptide biosynthesis gene clusters in 
P. entomophila L48, located on the genes pseen2716-pseen2718 is 
predicted to encode a hexa-lipopeptide (see figure 4.1.1). 
 
 
 
 
 
 
Figure 4.1.1: putative hexa-lipopeptide in P. entomophila L48 (also present 
in P. syringae pv. syringae B728a and phaseolica 1448A) 
Analysis of the deduced amino acid sequences revealed that the 
proteins PSEEN2716, PSEEN2717 and PSEEN2718 comprise in total six 
NRPS-modules. With the exception of the first and third module, 
each module is composed of a condensation domain, an adenylation 
domain and a thiolation domain, whereby PSEEN2718 is furthermore 
Gln 
44 Results and discussion 
 
extended by polyketidic domains and represents therefore a hybrid 
NRPS-PKS.  
In case of PSEEN2716 and PSEEN2718, the first module is lacking 
the condensation domain and PSEEN2716 comprises a cyclisation 
domain instead of the C-domain in module three. TE-domains were 
located terminally in PSEEN2717 and PSEEN2718. Using NRPS/PKS web 
based software (see chapter 3.4) the primary structures of the 
six A-domains were analysed, leading to the following proposed 
composition of the peptide moiety: Arg-Pro-Cys-Gln-Ile-Pro. 
The second lipopeptide biosynthesis gene cluster in the genome of 
P. entomophila L48, located on pseen0132, pseen3044-pseen3045 and 
pseen3332 is suggested to encode, depending on the role of 
pseen0132 and pseen3332 either a dodeca-, tetradeca- or a 
pentadeca-lipopeptide (see figure 4.1.2). In case of a 14-AA or 
15-AA containing peptide, the cluster appears to be split and 
with the exception of the tandem thioesterase and the missing C 
domain in PSEEN0132 canonical. 
 
 
 
 
 
 
 
 
 
Figure 4.1.2: putative dodeca-, tetradeca- or pentadeca-lipopeptide (possibly 
putisolvin-like) present in P. entomophila L48 (entolysin) 
During the course of this study the tetradeca-lipopeptide 
entolysin could be isolated and correlated to the aforementioned 
gene cluster by Lemaitre and co-workers (Vallet-Gely et al., 
2010). The corresponding genes pseen3332 and pseen3044-pseen3045 
were renamed as etlA, etlC and etlB, respectively, whereas it was 
shown, that pseen0132 was not essential for the production of the 
resulting entolysins.  
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The third lipopeptide predicted to be produced by P. entomophila 
L48 (pseen2139-pseen2156) was a putative penta-lipopeptide (see 
figure 4.1.3). Analysis of the corresponding amino acid sequences 
showed one typical module (CAT) each one encoded by pseen2149 and 
pseen2150 and three by pseen2155, respectively. Furthermore, a 
TE-domain in PSEEN2139, a ketosynthase and a T-domain in 
PSEEN2153 could be assigned to the biosynthesis gene cluster.  
 
 
 
 
 
 
 
 
Using NRPS/PKS web based software (see chapter 3.4) the primary 
structures of the five A-domains were analysed, leading to the 
following proposed composition of the peptide moiety: Ile-Thr-
Gly-Ser-Glu. 
 
Pseudomonas syringae pv. syringae B728a and pv. tomato DC3000 
By homology blast further NRPS-clusters coding for lipopeptides 
could be observed in both Pseudomonas syringae strains (Feil et 
al., 2005; Buell et al., 2003).  
In the genome sequence of P. syringae pv. syringae B728a (Feil et 
al., 2005) three orphan lipopeptides were identified. The first 
one, psyr_2576-psyr_2577, was predicted to produce an unusual 
octa-lipopeptide (figure 4.1.4). A homolog of this cluster was 
also found in the strain of the pathovar tomato DC3000 (Buell et 
al., 2003). For P. syringae pv. tomato DC3000 the corresponding 
lipopeptide (named syringafactin) was isolated and the structure 
was determined (Berti et al., 2007). 
Syringafactins were suggested to be linear lipopeptides, making 
this class of CLPs a solitary exception to the usual cyclic 
lipopeptides generated by Pseudomonads.  
Figure 4.1.3: putative pentalipopeptide (also present in P. syringae pv.
syringae, psyr_1792-1794)	
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Figure 4.1.4: putative octa-lipopeptide (also present in P. syringae pv. 
tomato DC3000, pspto_2829 and pspto_2830)  
Regarding the second gene cluster, encoding a putative hexa-
lipopeptide (see figure 4.1.5), located on psyr_3722, it was 
indicated, that the ortholog appearing in P. syringae pv. tomato 
DC3000 is truncated and therefore likely to be non-functional or 
to produce a different peptide (Feil et al., 2005). 
 
 
 
 
 
 
 
Analysis of the biosynthesis gene cluster psyr_3722 revealed six 
regular NRPS-modules (CAT), with the last one additionally 
comprising a TE-domain. The prediction of the specificity of the 
corresponding A-domains using standard bioinformatics tools 
delivered only low identity scores for known amino acids 
(resulting aa´s depicted in figure 4.1.5). Hence, the analysis 
was complemented with a phylogenetic analysis (see figure 
4.1.7). This approach revealed that all six A-domains 
surprisingly cluster together and form a new yet uncharacterized 
clade.   
The third CLP cluster represents a homolog of a CLP cluster 
present in P. entomophila L48 (figure 4.1.2) and might be 
responsible for the production of the abovementioned 
pentalipopeptide. 
A sequence alignment comparing pseen2716 with psyr_1792, 
pseen2717 with psyr_1793 and pseen2718 with psyr_1794 showed 72%, 
74% and 67% identity, respectively (data not shown). 
Figure 4.1.5: putative hexa-lipopeptide present in P. syringae pv. syringae 
B728a 
TeA TC A TCA TC A TC A TC A TC
Leu      Ser          Glu         Val    Ala      Ser 
Psyr_3722 
Psyr_2576 Psyr_2577 
 Leu      Leu            Gln             Leu  Thr     Val            Leu  Leu  
Te TeA TCA TC A TC A TC A TCA TC A TC A TC
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Pseudomonas sp. SH-C52 
In the draft genome of Pseudomonas sp. SH-C52, two gene clusters 
could be identified. The first was predicted to encode a di-
lipopeptide and the second to code for a new chlorinated nona-
lipopeptide with a syringomycin-like structure (see chapter 
4.3.1). 
 
Ralstonia solanacaerum GMI 1000 
Since the genus Ralstonia was formerly classified as Pseudomonas 
with similarity in most aspects, except that it does not produce 
the typical Pseudomonas fluorescent pigments, also genome 
sequenced strains of this genus were included in the study. In 
strain R. solanacaerum GMI1000 a biosynthesis pathway encoding a 
putative pentapeptide could be found by homology blast search 
against the amino acid sequences of the double TE-domain of the 
orfamide gene cluster. Analysis of the resulting aa-sequence with 
the NRPS/PKS-predictor showed a non-ribosomal peptide synthetase 
comprising five modules with canonical architecture and 
additional two TE-domains (see figure 4.1.6).  
 
 
 
 
 
 
 
Regarding the A-domain specificity, only the A-domain of the 
first module could be unambiguously predicted to be specific for 
valine. However, similar to gene cluster psyr_3722, inspection 
of the specificity of the remaining A-domains was challenging.  
 
  
Val Ser Gly ß-Ala Gly 
Figure 4.1.6: putative pentapeptide in Ralstonia solanacaerum GMI 1000 
Te TeA TC A TC A TC A TC A TC
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Leu 
Ala 
Ile 
Thr/Dhb 
Val 
Ser 
Glu/ 
Asp 
Figure 4.1.7: 
Phylogenetic analysis 
(selected section) of 
amino acid sequences 
of 97 adenylation 
domains extracted from 
the modules of the CLP 
gene clusters encoding 
synthetases involved 
in syringomycin, 
syringopeptin, 
massetolide A, 
arthrofactin, 
entolysin and orfamide 
synthesis, and from 
the putative CLP 
clusters of R. 
solanacaerum GMI 1000 
(ralA) and P. syringae 
pv. syringae B728a 
(psyr). Questionmarks 
indicate A domains in 
newly identified CLP 
genes.  
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Application of standard bioinformatics tools resulted in low 
probability values for known AA´s (see figure 4.1.6) whereas 
phylogenetic analyses grouped them into one single clade 
adjacent to A-domain proteins specific for alanine and those for 
the yet undetermined clade generated by the A-domains of the 
psyr_3722 cluster (see figure 4.1.7).   
Subsequent chemical and biosynthetic studies were focussed on 
the orphan gene clusters of the strain P. sp. SH-C52. The 
decision for this focus was based on several aspects: 
Strain Pseudomonas entomophila L48 was not available at the 
beginning of the study and already under investigation regarding 
the predicted lipopeptides by a research group in France, which 
reported consequently in 2010 entolysins A and B as products of 
one of the considered CLP gene (Vallet-Gely et al., 2010) as 
mentioned above. 
The strains of Pseudomonas syringae pv. syringae B728a and pv. 
tomato DC3000 were subjected to a broad screening for the 
described lipopeptides (see chapter 4.2). These lipopeptide gene 
clusters were targeted despite the products of one thereof, the 
syringafactins, were already published (Berti et al., 2007), 
because only a tentative linear structure was proposed by the 
authors. Furthermore, other lipopeptides were predicted for the 
strains as well which were not isolated yet.  
R. solanacaerum GMI1000 was already under investigation of a 
research group in Jena, which yielded the known siderophore 
micacocidin (Kreutzer et al., 2011).  
For the strain Pseudomonas sp. SH-C52, an exclusive access was 
given by collaboration with the University of Wageningen which 
granted investigations without competition. 
 
 Screening for the predicted CLPs using an OSMAC 4.2
approach 
 
As described in the previous chapter, the strains of P. syringae 
pv. syringae B728a and pv. tomato DC3000 were subjected to a 
broad screening for secondary metabolites employing the OSMAC 
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approach  (Bode et al., 2002). In brief, the OSMAC (one strain 
many compounds) method describes the ability of one strain to 
produce a variety of secondary metabolites depending on the 
cultivation conditions. 
In the context of this study, the application of the OSMAC 
approach was used to overcome the low expression of the observed 
gene clusters encoding for putative CLPs. The cultivation and 
extraction of the cultures were performed according to the 
established procedures described in chapter 3.1.3 and 3.3.1.  
For each crude extract and the corresponding negative control, 
an LC-MS analysis was performed and a 1H-NMR spectrum was 
recorded (data not shown). The 1H-NMR spectra and the DAD-
chromatograms were reviewed for characteristic resonances and 
UV-profiles of lipopeptides, respectively. However, none of the 
predicted structures could be observed and no CLPs were obtained 
despite the application of several diverse induction trials. 
 
 Investigations on Pseudomonas sp. SH-C52 4.3
 
 Genome mining for CLPs 4.3.1
 
In the draft genome sequence of Pseudomonas sp. SH-C52 two NRPS 
gene cluster encoding putative CLPs could be identified. One 
cluster was predicted to code for a di-lipopeptide, while the 
second cluster most likely encodes a new chlorinated nona-
lipopeptide with a syringomycin-like structure (see figures 
4.3.1 and 4.3.3). 
Putative di-lipopeptide 
The first gene cluster, located on a generated fosmid (I. de 
Bruijn, research group of J.M. Raaijmakers, University of 
Wageningen, The Netherlands), is composed of a 
glycosyltransferase (GT), a nonribosomal peptide synthetase, a 
FAD-dependent monooxygenase (MO), a LuxR-type transcriptional 
regulator (R) and a RND-type efflux system (ES) (see figure 
4.3.1).  
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Analysis of the deduced amino acid sequences revealed that the 
NRPS comprises two modules, each composed of a condensation 
domain, an adenylation domain and a thiolation domain, and a 
terminal TE-domain. Using web-based bioinformatics software tools 
(see chapter 3.4), the specificity of the active centres of the 
two A-domains were analysed in silico, and predicted to activate 
serine and proline. To verify the specificities of the A-domains, 
a phylogenetic analysis was performed, including various A-
domains of already chemically established CLPs which are 
correlated with their respective biosynthesis clusters (see 
figure 4.3.2; Rees et al., 2007; Roongsawang et al., 2003; 
Scholz-Schroeder et al., 2003; Gross et al., 2007; Miao et al., 
2005; Feil et al., 2005; Guenzi et al., 1998; de Bruijn et al., 
2008; Vallet-Gely et al., 2010). 
In agreement with the initial predicted substrate specificity, 
the two A-domains of the dilipopeptide, brbA_1_Ser? and 
brbA_2_Pro? cluster into the clade of serine and proline, 
respectively, which corroborates the first analysis. In detail, 
the first A-domain sequence, predicted to incorporate a serine 
residue is in the same clade of serine-specific A-domains of 
massetolide, orfamide, arthrofactin, syringomycin, syringopeptin 
and entolysin. 
The second amino acid sequence clusters with proline- and 4-Cl-
threonine- specific A-domains of the syringopeptin and 
syringomycin biosynthesis gene cluster, respectively. Thus, the 
phylogenetic analysis provides some ambiguity, however taking 
into consideration, that only one proline-specific A domain is 
currently available, the phylogenetic analysis suggests also a 
proline-specificity of the A-domain brbA_2_Pro?. 
  
GT NRPS MO 
ProSer
ES LR 
Figure 4.3.1: gene cluster in P. sp. SH-C52 encoding a di-lipopeptide  
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Ala 
Figure 4.3.2: Phylogenetic 
analysis of amino acid 
sequences of 97 A-domains 
extracted from the modules 
of the CLP gene clusters 
encoding synthetases 
involved in arthrofactin, 
entolysin, orfamide, 
massetolide, syringomycin, 
syringopeptin, fusarin C, 
pyoverdine synthesis and 
from the two predicted 
CLPs (indicated by 
question marks). 
Clustering was performed 
in clustalW2 (see chapter 
3.4) program using the 
neighbour-joining 
algorithm. Blue boxes mark 
modules of brabantamide, 
pink boxes mark modules of 
the encoded nona-
lipopeptide. 
Val 
Thr/Dhb 
Ser 
Dab
Asp
Glu 
Gln 
Leu 
Ile 
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In order to gain further insight into the brabantamide gene 
cluster, also the C-domains were subjected to a phylogenetic 
analysis (see figure 4.3.4). The analysis revealed that the 
first condensation domain C1 of the first module represents a 
typical ´starter C domain´ which acylates the first amino acid 
with a β-hydroxy fatty acid. The second C-domain of the NRPS 
cluster was expected to be responsible for the fusion of serine 
and proline, belonging either to the LCL, DCL or the dual E/C 
(epimerization/ condensation) functional subtype of C-domains 
(Balibar et al., 2005; von Döhren et al., 1999; Clugston et al., 
2003; Rausch et al., 2007). 
Table 4.3.1: result of the NapDOS analysis of the C-domains of brabantamide 
and the predicted nona-lipopeptide  
Query ID Database match 
ID 
% 
identity 
Align 
length 
e-value Pathway 
product 
Domain 
class 
brbA_C1 syrin1_C1_start 36 366 5e-65 syringomycin start 
brbA_C2 micro1_C1_modAA 32 414 6e-60 microcystin modAA 
thaA_C1 syrin1_C1_start 69 369 4e-153 syringomycin start 
thaA_C2 syrin1_C7_LCL 57 434 5e-125 syringomycin LCL 
thaA_C3 syrin1_C3_dual 61 423 2e-136 syringomycin dual 
thaA_C4 syrin1_C7_LCL 58 434 1e-141 syringomycin dual 
thaA_C5 syrin1_C4_dual 69 416 5e-164 syringomycin dual 
thaB_C1 syrin1_C7_LCL 57 425 9e-125 syringomycin LCL 
thaB_C2 cdaps1_C7_LCL 34 445 3e-46 CDA LCL 
thaB_C3 syrin1_C7_LCL 82 434 0.0 syringomycin LCL 
thaB_C4 syrin1_C8_dual 81 416 0.0 syringomycin dual 
thaB_C5 syrin1_C9_LCL 78 433 0.0 syringomycin LCL 
Within the frame of the phylogenetic investigations, the second 
C-domain clustered between conventional DCL/LCL domains and dual 
condensation/ epimerisation domains (see figure 4.3.4). The 
missing second elongated His-motif (HH(I/L)xxxxGD), described to 
indicate C-domains with dual functions (Balibar et al., 2005), 
suggests the assumption, that the second C domain belongs to the 
conventional C domains. Additional analysis of the C-domains 
using NapDOS (see table 4.3.1) assigned the first C-domain to 
the starter C-domains and the second to the modAA domains 
(modified amino acid domains), whereby a modification of the 
second amino acid seems to be likely.  
In summary, the NRPS gene codes for a lipo-dipeptide, whereby 
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the peptidic portion consists of Ser and Pro, while the lipid 
moiety comprises most likely a β-hydroxy fatty acid of unknown 
chain length. The latter is provided by primary metabolism and 
its biosynthesis genes are not clustered with the identified di-
lipopeptide gene cluster. The alignment of the GT suggests that 
it utilises rhamnose as substrate. Thus, the resultant glycosyl-
residue in the predicted lipopeptide is possibly rhamnose. It 
showed 51% amini acid identity to a rhamnosyltransferase 
deriving from Burkholderia thailandensis E264. 
Further investigations regarding the structural genes of the 
cluster were made by comparative alignments of the putative 
glycosyltransferase and the putative MO (for data see tables 
8.1.1 and 8.1.2, appendix). The alignment of the GT suggests that 
that it utilizes rhamnose as substrate. It showed 51% amini acid 
identity to a rhamnosyltransferase deriving from Burkholderia 
thailandensis E264. 
The results of the homology-search for the involved monooxygenase 
showed a maximum identity of 42% to the aligned sequences. The 
best hit was a putative FAD-dependent monooxygenase from 
Xenorhabdus bovienii SS-2004. These results suggest that the MO 
belongs to a new class of enzymes, which is not further 
investigated up to date. 
 
Putative chlorinated nona-lipopeptide 
 
 
 
                       
   
 
 
 
 
 
 
A T Cl
A TC A TC A TC A TC A TC C A TC A TC A TC TC Te
m9 
Thr 
thaC 
m9 m7 m6m1 m4 
Z-Dhb  Asp (3-OH) Thr ? Ser Asp (3-OH) 
 
? ? 
m2 
thaA thaB 
m3 m5 m8 
Figure 4.3.3: predicted chlorinated nona-lipopeptide in P. sp. SH-C52; m 
= module 
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The second lipopeptide gene cluster in P. sp. SH-C52 is composed 
of three NRPS genes (see figure 4.3.3). The first NRPS gene 
(thaA) comprises five modules which show the typical CAT domain 
pattern. The second NRPS gene (thaB) is composed of four modules. 
Thereby, the typical CAT pattern can only be observed in the 
first three modules while the fourth module is lacking the A-
domain and thus remains incomplete.  
Additionally, ThaB codes for a further C-domain upstream of 
module six and the usual TE-domain which is terminating the NRPS 
machinery. The third nonribosomal synthetase, ThaC, encodes an A-
domain, a T-domain and a halogenase domain (Cl) which is 
evocative of SyrB and SyrC, comprising an AT-pattern and a Cl-
domain, respectively. Thus, it seems likely, that module nine 
(see figure 4.3.3) is composed of the two incomplete modules 
belonging to ThaB and ThaC, respectively, thus showing a similar 
arrangement as SyrE, SyrB and SyrC of the syringomycin 
biosynthesis gene cluster (Guenzi et al., 1998). Furthermore, it 
can be hypothesised, that the A-domain of ThaC activates 
chlorinated threonine in combination with the Cl-domain in the 
same manner than observed in the syringomycin biosynthesis. 
Whether the additional C-domain upstream of module six which is 
encoded by thaB and seems to be a conventional C-domain (see 
below) is non-functional or skipped or it is used in combination 
with another A-domain which is not directly adjacent currently 
remains unclear.  
Using multiple NRPS/PKS web-based software (see chapter 3.4) the 
primary structures of the A-domains were analysed. The predicted 
specificities of the resulting A-domains led to the assumption, 
that the majority of the residues in the binding pockets are 
either rare or even unknown (see table 4.3.2). To get more 
information about the incorporated amino acids, the sequences 
were included in the aforementioned phylogenetic analysis (see 
figure 4.3.2). 
The results of the investigation confirmed the predictions for 
ThaA-1 and ThaB-6 activating Ser and Thr, respectively. ThaB-7 is 
in the same cluster as ThaB-6, but seems to be closer related to 
Z-Dhb from SyrE-7. The predicted residues of ThaA-3 and ThaB-8 
could also be confirmed, clustering directly adjacent to the 3-
OH-L-Asp-residue from SyrE-8. The results for the other A-domains 
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remain inconclusive either by clustering in areas with diverse 
specificities (ThaA-5 and ThaC-9) or clustering with each other 
in new yet uncorrelated clades (ThaA-2 and ThaA-4). 
Table 4.3.2: prediction of A-domain specificities with different programs 
 ThaA-1 ThaA-2 ThaA-3 ThaA-4 ThaA-5 ThaB-6 ThaB-7 ThaB-8 ThaC-9 
Predicted 
Subst.(1) 
Ser - Asp - - Thr Thr Asp Thr 
NRPSPred. 
code (1) 
Ser Orn Asp Lys His Thr Thr Asp Thr 
NRPSPred. 
SVM (1) 
Ser Asp/Asn 
Glu/Gln 
Aad 
Asp Asp/Asn 
Glu/Gln 
Aad 
Val/Leu 
Ile/Abu 
Iva 
Thr Thr Asp Thr 
Minowa HMM 
(1) 
Ser Arg Arg Ala Ala Thr Thr Gln Thr- 
4-Cl 
NRPS/ 
PKS (2) 
Ser 5h-Orn Leu - - Thr Thr Leu 
 
Thr 
NRPS/ 
PKS (3) 
D-Ser Asp Asp 
(3OH) 
Orn His? Thr Thr Asp 
(3OH) 
Thr-4-
Cl 
(1) antismash 
(2) Bachmann & Ravel, 2009 
(3) http://www.nii.res.in/nrps-pks.html 
Regarding the C-domains, the cluster shows a starter C-domain in 
the first module, which is able to attach a fatty acid (figure 
4.3.4). Furthermore, it can be observed, that the C-domains of 
module no. three and four encoded by thaA and the C-domain of 
module no. eight which is encoded by thaB seem to display dual 
activity (condensation and epimerisation). The residual C-domains 
cluster with conventional C-domains. These results are congruent 
with the results of the NapDOS-analysis (see table 4.3.1).  
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Figure 4.3.4: Phylogenetic analysis of C Domains from arthrofactin,
syringomycin, syringopeptin and the two predicted cyclic lipopeptides.
C-domains predicted to be conventional are above the blue line, and
those predicted to be dual C/E domains are below. Arrows indicate known
deviations from the phylogentic predictions. Clustering was performed
in clustalW2 (see chapter 3.4) program using the neighbour-joining
algorithm. Blue boxes mark C-domains of brabantamide, pink boxes those
of the encoded nona-lipopeptide, respectively 
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 Proof of the gene clusters encoding the predicted 4.3.2
lipopeptides  
 
For both gene clusters of interest deletion mutants, targeting 
the structural NRPS genes were generated. Subsequently, the 
obtained mutant strains C52Δ27 and C52Δ33 and the corresponding 
wild-type strain of Pseudomonas sp. SH-C52 (see chapter 3.1.1) 
were cultivated and extracted according to established 
procedures (see chapters 3.1.3 and 3.3.1). The obtained crude 
extracts were then subjected to LC-MS analysis (see chapter 
3.3.5) and a comparison of the secondary metabolite spectrum was 
performed.  
In case of the knockout mutant strain C52Δ27, the LC-MS analysis 
clearly demonstrated the absence of a peak at tR = 22.5 min in 
the chromatogram with a corresponding mass of 555 m/z and UV-
maxima at 224 nm and 252 nm. To demonstrate unambiguously the 
affiliation of the expected lipo-dipeptide metabolite to the 
cluster, the mass traces of the wild-type strain as well as of 
the knockout strain were extracted for the identified mass and 
overlaid (see figure 4.3.5).   
 
 
Figure 4.3.5: LC/MS analysis of P. sp. SH-C52 knockout (pink) vs. wild-type 
(blue) strain. The extracted chromatogram (mass range = 554 – 556 m/z) is 
shown.    
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In the case of knockout-strain C52Δ33 no differences in the 
metabolite profile to the wild-type strain could be observed. In 
order to activate the expression of the thaABC gene cluster, 
encoding a lipo-nonapeptide, the OSMAC strategy was applied (see 
chapter 4.2). However, in none of the tested culture media the 
comparison of the metabolite profiles showed any differences. 
 
 Isolation and structure elucidation of the predicted di-4.3.3
lipopeptide 
 
In order to isolate the identified di-lipopeptide, Pseudomonas 
sp. SH-C52 was cultivated on a nine litre scale (see chapter 
3.1.3). Subsequently, the culture was extracted, separated by 
vacuum liquid chromatography and VLC-fraction 3 was further 
purified by HPLC (system 4, column 6, UV-monitoring at 224 nm 
and 252 nm) according to chapters 3.3.1 - 3.3.3. The runs were 
performed isocratically, using 85% methanol and 15% H2O 
supplemented with 0.05% TFA, over a duration of 45 minutes. 
Three peaks showed the characteristic UV-spectrum (UV-maxima at 
224 nm and 252 nm) of the CLP of interest (see chapter 4.3.2) 
and were isolated for further investigation with yields of 12.6 
mg (SH-C52-3B = compound 1), 3.6 mg (SH-C52-3C = compound 2) and 
2.0 mg (SH-C52-3D = compound 3). 
Structure elucidation 
The structure elucidation of the purified compounds was mainly 
based on NMR experiments (see chapter 3.3.4). 
Interpretation of the 1H-13C HSQC spectrum allowed the 
correlation of all proton resonances to the 13C NMR resonances of 
directly bonded carbon atoms. The number and resonances of 
primary, secondary and tertiary carbon atoms was identified via 
a DEPT135 NMR spectrum (Distortionless Enhancement by 
Polarisation Transfer, 135° angle) and 1H-1H spin systems were 
recognized using 1H-1H COSY data. The resulting partial 
structures were connected using cross correlations of the 1H-13C 
HMBC spectrum.  
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Further measurements like UV-spectra, IR, CD and HR ESI-MS were 
conducted to investigate the physico-chemical properties of the 
structures (see table 4.3.3).  
Table 4.3.3: physico-chemical properties of the isolated compounds 
 Compound 1 Compound 2 Compound 3 
Molecular Formula C28H46N2O9 C30H48N2O9 C30H50N2O9 
HR-ESI-MS [M+Na]+ 577.3096 603.3253 605.3409 
Calc. mass [M] 554.3203 580.3360 582.3516 
UV λmax nm (ε MeOH) 224 (945) 252 (1393)
224 (926) 
252 (1333) 
221 (1025) 
252 (1311)
IR νmax cm-1 
3396, 2923, 2853, 2359, 2340, 
1790, 1732, 1681, 1646, 1505, 
1464, 1374 
n.d. n.d. 
CDmax [nm]a 288, 255, 215 n.d. n.d. 
ሾࢻሿࡰ૛૝ [°] + 39.7 + 68.8 + 11.2 
n.d. = not determined 
a see figure 8.1.1, appendix  
Structure elucidation of compound 1 
HR ESI-MS analysis revealed an adduct-ion [M+Na]+ at m/z 
577.3096, consistent with the molecular formula of C28H46N2O9Na.  
 
 
Figure 4.3.6: 1H-NMR spectrum of compound 1 (SB-253514/ brabantamide A)
measured in d4-methanol (300 MHz) 
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From this molecular formula seven double bond equivalents were 
deduced. Since the 13C-NMR spectrum of 1 (figure 8.1.2, table 
4.3.4) contained three carbonyl groups (δC 158.3, 166.4 and 
173.7), one double bond (δC 166.4 and 98.0), compound 1 had to be 
tricyclic.  
Four isolated spin systems could be distinguished via a 1H-1H 
COSY spectrum (see figure 8.1.5, appendix). 
Spin system A (see figure 4.3.7 – A) comprised the protons of a 
glycosidic moiety (H11’- H36’).  
Table 4.3.4: NMR Spectroscopic data (300 MHz, d4-methanol) for compound 1 
(brabantamide A, (δ in ppm)) 
Atom δC mult δH [J in Hz]  COSY HMBC NOE 
2 158.3 qC - - 5, 8a - 
4 168.8 qC - - 5, 6a, 9 - 
5 66.3 CH 5.03, ddd [7.8, 
      6.6, 9.0]
9*,6a/b 6b,7, 9 6b 
6a 31.2 CH2 1.66, m 5,6b,7  5, 7, 8a, 9# 5*, 6b 
6b   2.68, dd, [6.5, 
      3.8]
5, 6a 5, 7, 8a, 9# 5, 6a, 7 
7 27.3 CH2 2.14, m 6a/b,8a 6b*, 8a/b 5, 6b, 8a/b 
8a 47.0 CH2 3.35, m 7, 8b 6b, 7 7, 8b 
8b   3.65, m 7, 8a 6b, 7 7, 8a 
9 98.0 CH 6.29, d, [2.3] 5* 5* - 
10 166.4 qC - - - - 
12 173.7 qC - - 13, 14 - 
13 44.2 CH2 2.74, m 14 14, 15* 14 
14 74.9 CH 4.20, m 13, 15 13 13, 15, 16, 1’ 
15 34.5 CH2 1.61, m 14, 16 13 1’, 14 
16 25.9 CH2 1.38, m 15 14* 25 
17-22 ~30.8 CH2 1.34, m - - - 
23 33.0 CH2 1.33, m - 25 - 
24 23.8 CH2 1.34, m 25 23, 25 - 
25 14.5 CH3 0.94, t, [6.6] 24 23 16* 
1’ 99.9 CH 4.83, s 2’ 14 9#, 14, 15, 2’ 
2’ 72.7 CH 3.78, dd, [3.1, 
      1.6]
1’ - 1’, 3’, 5’ 
3’ 72.4 CH 3.62, m 2’*, (4’) 1’ 2’, 9# 
4’ 73.8 CH 3.39, m 5’/ 3’ 2’, 6’ 6’, 24 
5’ 70.5 CH 3.61, m 6’, (4’) 4’, 6’ 2’, 6’ 
6´ 18.0 CH3 1.26, d, [6.2} 5’ 4’ 4’, 5’, 24 
* weak signal, # very weak signal 
The presence of a sugar moiety could be verified by 13C-NMR 
chemical shifts of methine carbons C2’ to C5’, resonating 
between 70.5 and 73.8 ppm, which is characteristic for carbon 
atoms attached to oxygen. The 13C-NMR resonance signal of C6’ was 
shifted highfield to 18.0 ppm, indicating the presence of a 
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desoxy sugar while C1’ showed a downfield shift to 99.9 ppm as 
estimated for a doubly oxygenated acetale carbon (Pretsch et 
al., 2001). 
The second partial structure (spin systems B-1 and B-2, figure 
4.3.7), which could be observed was a fatty acid moiety, 
demonstrated by the characteristic triplet resonance signal at 
0.94 ppm in the 1H-NMR spectrum for the terminal methyl group 
H325 and the large number of magnetically equivalent methylene 
signals at 1.3 – 1.4 ppm (H216 to H224). The downfield shift of 
the α–methylene group of myristic acid (δC/H 44.2/ 2.74) and the 
γ–CH2 group (δC/H 34.5/ 1.61) indicated the expected amide bond of 
the lipopeptide and an oxygen atom linked to the carbon atom in 
ß-position, respectively. A 1H-13C HMBC correlation observed 
between H14 and C1’ confirmed the assumption that the 
rhamnopyranose is linked to the fatty acid chain.  
Finally, a third spin system (figure 4.3.7 – C) could be 
delineated from the COSY spectrum, which defined a proline 
moiety. The obtained partial structures were subsequently 
connected with HMBC correlations. 
 
 
 
 
 
 
 
 
Figure 4.3.7: key correlations of compound 1 (SB-253514/ brabantamide A) with 
spin systems A, B and C 
These efforts resulted in three partial structures, which were 
used for a de-replication crosscheck with the natural product 
database ´AntiMarin´. Hereby, compound 1 could be identified as 
SB-253514, which was first published in 2000 (Thirkettle, 
2000a).  
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Stereochemistry 
Due to the small amount of substance, the absolute 
stereochemistry of the molecule was not determined. Based on the 
x-ray structure published in 2000 (Busby et al., 2000) the 
configuration of both stereo centres (C5 and C14) was adopted as 
R and the double bond between C4 and C9 as trans configured, 
respectively (Busby et al., 2000).   
 
Relative configuration of the rhamnose moiety 
In order to confirm the stereochemistry of the published α-L-
rhamnopyranose, a NOESY spectrum (nuclear Overhauser effect 
spectroscopy) was measured, which allows analysing through-space 
interactions of proton atoms (distances smaller than 5 Å).  
The obtained 1H-1H-NOESY spectrum confirmed the presence of α–
rhamnose revealing correlations between H1’ and H2’ which are 
both expected to be equatorial protons. Furthermore, the absence 
of correlations between H1’ and H3’ as well as H1’ and H5’ which 
should be obtained in case of an axial position of the proton at 
C1’ support the α-form (see figure 4.3.8). 
In contrast to the most naturally occurring sugars which are D-
configured, rhamnose occurs in nature usually in its L-form 
(Dewick, 2001) why the attachment of L-rhamnose seems likely. 
 
 
 
 
 
 
 
 
Figure 4.3.8: selected NOESY correlations which support the presence of the 
α-anomer 
 
Structure elucidation of compound 2 
In an HR MS analysis, compound 2 (brabantamide B) displayed an 
adduct-ion [M+Na]+ at m/z 603.3253, consistent with the molecular 
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formula of C30H48N2O9Na. Comparison of the 1H- and 13C-NMR spectra 
of compound 1 with those of compound 2 proved 2 to be closely 
related with 1 (see table 4.3.5).  
Table 4.3.5: NMR Spectroscopic data (300 MHz, d4-methanol) for compound 2 
(brabantamide B), (δ in ppm))  
Atom  δC          mult δH, [J in Hz] COSY HMBC 
2 158.3 qC - - 8a/b 
4 168.8 qC - - - 
5 66.3 CH 5.03 6a/b, 9* - 
6a 31.2 CH2 1.66 5, 6b, 7 - 
6b  2.68 7 5, 9, 8a 
7 27.3 CH2 2.14 6a/b, 8a/b - 
8a 47.0 CH2 3.35 7 - 
8b  3.65 7 - 
9 98.0  CH 6.29 5 - 
10 166.4 qC - - - 
12 173.7 qC - -  
13 44.0  CH2 2.74 14 - 
14 74.9  CH 4.21 13 - 
15 34.5  CH2 1.61 16 - 
16 25.9  CH2 1.39 15 - 
17/18 ~30.8 CH2 1.35 - - 
19 28.2  CH2 2.08 20, 21 20, 21 
20 130.7  CH2 5.40, dd, 5.5, 4.0 19 - 
21 131.0 CH2 5.40, dd, 5.5, 4.0 - 19 
22 28.2  CH2 2.08 20, 21 20, 21 
23/24 ~30.8 CH2 1.35 - - 
25 33.3  CH2 1.33 - 27 
26 23.8  CH2 1.34 27 - 
27 14.5 CH3 0.94 26 - 
1’ 100.1 CH 4.83 2’ - 
2’ 72.7  CH 3.79 1’, 3’ 1’ 
3’ 72.4 CH 3.62 2’ - 
4’ 73.8  CH 3.39 - 6’ 
5’ 70.5  CH 3.61 6’ 1’, 6’ 
6´ 18.0  CH3 1.26 5’ - 
*weak signal  
Solely, additional resonances at 2.08 ppm and 5.40 ppm (see 
figure 4.3.9) could be observed. The latter resonance indicated 
a double bond, a fact which was corroborated by additional 
resonances at 130.7 ppm and 131.0 ppm, observed in the 13C-NMR 
spectrum (figure 4.3.10). Since 2 showed in the NMR spectra only 
deviations in the lipid moiety, the mass difference of 26 mass 
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units between compound 1 and compound 2 could be readily 
ascribed to an elongation of the fatty acid side chain of two 
carbons (2 x 14 Da = 28 Da) and the occurrence of a double bond 
in the side chain (-2 Da). A literature and database search 
revealed that metabolite 2 possibly represents compound SB-
253517, which is suggested to possess an unsaturated 
hexadecenoic acid side chain. 
 
Figure 4.3.9: 1H-NMR spectrum of compound 2 (SB-253517/ brabantamide B) in d4-
methanol (300 MHz) 
The cis-oid geometry of the double bond was evidenced by a small 
3JH20,H21 coupling constant of 5.5 Hz. This finding was also 
supported by the chemical shift values of the adjacent carbon 
atoms C19 and C22 (δC 28.2) which were typical for a cis 
configured double bond, since allylic carbon signals of the Z 
and E isomers are specifically observed at δC 26-28 and  δC 31-
32, respectively (Ishii et al., 2006; Stierle & Faulkner, 1980).  
1H-1H COSY couplings (see figure 8.1.7) were suggestive that the 
double bond is localized between C19 and C20 (numeration confers 
to compound 1, figure 4.3.7).  
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Figure 4.3.10: 13C-NMR spectrum of compound 2 (SB-253517/ brabantamide B) in 
d4-methanol (75 MHz) 
However, since protons 16-24 span a massive methylene envelope 
from 1.3 – 1.4 ppm, the proton cannot be unambiguously assigned 
to one of the CH2-groups. One indication for the equivalence of 
compound SB-253517 and compound 2 is the similar peak pattern 
obtained in the purification by HPLC of the main metabolite with 
its congeners (data not shown) and the chromatogram shown in the 
reference publication (Thirkettle, 2000a&b).  
As a further attempt for the localisation of the double bond an 
empirical method was applied. Hereby, the differences of the 
chemical shifts of the considered olefinic carbon atoms can be 
employed to determine the configuration and the localisation of 
a double bond in a fatty acid (Bus et al., 1977; Gunstone, 
1993). The values published for different kinds of unsaturated 
fatty acids and fatty acid methyl esters coincided well with the 
obtained values from congener 2 (see table 4.3.6).  
Application of this method indicated that the double bond 
belongs to the Δ9 class, which corresponds to a localisation 
between C20 and C21 of compound 2. Based on these facts, the 
substance could be identified as SB-253517 (Thirkettle, 2000a; 
Thirkettle et al., 2000). 
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Table 4.3.6: differences in chemical shift (ppm) between the two olefinic 
carbon atoms in monoene acids and methyl esters in comparison to the measured 
values of compound 2 
 compound 2 methyl esters acids 
double bond  cis2 cis1 cis2 
Δ6  1.30 1.50 1.60 
Δ7  0.73 0.90 0.85 
Δ8  0.45 0.50 0.50 
Δ9 0.323 0.24 0.35 0.26 
Δ10  - 0.20 0.17 
Δ11  - 0.10 0.07 
1 values adopted from Bus et al., 1977 
2 values adopted from Gunstone, 1993 
3 values for C20 and C21 rounded to two decimal places are 130.68 
and 131.00, respectively 
 
Structure elucidation of compound 3 
The molecular formula C30H50N2O9 of compound 3 was confirmed by 
HR-ESI-MS measurements (found: 605.3409 g/mol (C30H50N2O9Na), 
calculated: 582.3516 g/mol). Thus, the only difference between 
compound 2 and 3 appeared to be the saturation of the fatty acid 
side chain in metabolite 3.  
This assumption could be confirmed by NMR measurements which 
showed all resonances of the core structure of 1 and 2 (see 
figures 8.1.9 and 8.1.10). In comparison with the 1H-NMR spectrum 
of compound 2, compound 3 did not show signals at 5.40 ppm and 
2.08 ppm (see table 4.3.7). These protons belong to the carbon 
atoms of the Δ20,21 double bond in compound 2 (C20 and C21) and 
the carbon atoms directly related to the double bond (C19 and 
C22), respectively. 
In combination with the NMR data it can be concluded, that 
compound 3 contains a saturated 3-hydroxy hexadecanoic acid (3-
hydroxy palmitic acid) instead of the corresponding unsaturated 
fatty acid in compound 2. Thus, the metabolite could be 
identified as SB-253518, which was also reported in the 
aforementioned publication (Thirkettle, 2000b).  
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Table 4.3.7: NMR Spectroscopic data (300 MHz, d4-methanol) for compound 3 
(brabantamide C), (δ in ppm) 
Atom  δC         mult δH       COSY HMBC
2 158.3 qC - - 8a/b
4 168.8 qC - - -
5 66.3 CH 5.04 6a/b, 9 2, 6a/b, 4*, 9* 
6a 31.3 CH2 1.68 5, 7 5, 8
6b  2.69 7 -
7 27.3 CH2 2.16 6a/b,8a/b -
8a 47.0 CH2 3.35 7 2
8b  3.67 7 -
9 98.2 CH 6.31 5 4, 5
10 166.4 qC - - -
12 173.6 qC - - -
13 44.1  CH2 2.76 14 14
14 75.1  CH 4.21 13, 15 13, 12*,1’ 
15 34.6  CH2 1.63 14 -
16 26.0  CH2 1.39 - -
17-24 ~30.8 CH2 1.35 - -
25 33.1  CH2 1.34 - -
26 24.0  CH2 1.34 - -
27 14.5 CH3 0.95 25, 26 2’, 3’ 
1’ 100.2 CH 4.85 2’ 2’, 3’ 
2’ 72.8  CH 3.80 1’, 5’ 4’
3’ 72.4 CH 3.63 6’ -
4’ 73.9  CH 3.40 3’ 6’
5’ 70.4 CH 3.62 2’ -
6´ 18.3  CH3 1.26 2’ 4’, 5’ 
* weak signal  
 
Since metabolites 1-3 were isolated from Pseudomonas sp. SH-C52, 
a bacterium obtained from the province of Noord-Brabant of The 
Netherlands and due to its chemical structure, we suggest the 
trivial names brabantamides A (1), B (2) and C (3) for these 
natural products instead of the usage of the industrial 
acronyms. 
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 Hypothetical biosynthesis of brabantamide 4.3.4
 
The biosynthesis of brabantamide A is suggested to start with 
the synthesis of the fatty acid in the primary metabolism. 
Fatty acid synthases (FASs) generate FAs from C2 units until the 
required chain length – in this case 14 for brabantamide A or 16 
for brabantamide B and C - is reached (see figure 4.3.12).  
The fatty acid synthesis starts with an acetyl starter unit 
(acetyl-CoA) which is converted into an enzyme-bound thioester 
of a ketosynthase (KS) and a malonyl-CoA unit bound to an acyl 
carrier protein (ACP). After Claisen-condensation, the ß-keto-
ester is reduced to the corresponding ß-hydroxy-ester by a 
ketoreductase (KR), dehydrated by a dehydratase (DH) and finally 
reduced again by an enoyl reductase (ER) (Staunton & Weissman, 
2001; Dewick, 2001). 
After this first reaction cycle the chain is extended by a 
further C2 unit and is repeated until the requested fatty acid 
chain is achieved. The chain gets passed to a thioesterase (TE) 
where it is released as a fatty acyl-CoA.  
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The fatty acid synthesis starts with an acetyl starter unit  
After hydroxylation of the generated fatty acid, the synthesised 
3-hydroxy myristic acid in its activated form is picked up by 
the first C-domain from the non-ribosomal peptide synthetase of 
the brabantamide gene cluster. Subsequently, the fatty acid gets 
attached to serine, which is bound to the corresponding 
thiolation domain. The biosynthesis continues with the described 
mechanism of non-ribosomal synthesis (see chapter 1.1.2), 
elongating the tethered molecule by the condensation of proline. 
The resulting lipodipeptide is subsequently passed on to the TE 
which allegorizes the final enzyme of the NRPS (see figure 
4.3.13 (2)). The cleavage from the TE-domain is accompanied by 
an internal cyclisation (3) resulting in a 1,3-dioxo-
pyrrolizidine (4).  
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Figure 4.3.12: fatty acid synthesis: MAT: malonyl-acetyl transferase; ACP:
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The presence of a FAD-dependent monooxygenase in the gene 
cluster leads to the assumption, that the next step in the 
biosynthesis is a Baeyer-Villiger-like oxidation (Baeyer & 
Villiger, 1899). In this kind of reactions NADPH, FAD and O2 are 
required for the conversion of a ketone to an ester (Dewick, 
2001). The FAD cofactor gets reduced by NADPH and subsequently 
builds a peroxy-enzyme complex (flavinperoxide), a reactive 
intermediate, by the use of molecular oxygen. The nucleophilic 
attack at the carbonyl-group of the pyrrolizidine by the 
peroxide (4) generates the typical Criegee-intermediate (5). 
After rearrangement, the intermediate decomposes under release 
of 4-hydroxy-flavin and formation of a lactone with an extended 
ring system (6). Subsequently, another intramolecular 
rearrangement takes place, initiated through a nucleophilic 
attack of the carbonyl-group of the lactone by the hydroxyl 
group (6) resulting in a further ring extension (7). The 
instable cyclocarbamate decomposes by ring opening to the 2-(2-
Tetradecanoylcarbamoyl-acetyl)-pyrrolidine-1-carboxylic acid 
anion (8). 
The anion attacks the proton of the α-C-atom of the ketone 
resulting in an enolat-anion which similarly affects the 
carboxylic acid (9), finally leading to the formation of 
unglycosylated brabantamide A (10). Hypothetically, the final 
step of the biosynthesis could be the attachment of the rhamnose 
to the unglycosylated molecule by the glycosyltransferase to 
give brabantamide A. Another option would be an earlier 
attachment of the glycosyl-residue while the molecule is still 
bound to the NRPS at one of the aforementioned steps. The exact 
time of the attachment cannot be predicted unambiguously.   
 
 Investigations on the biosynthesis of brabantamides 4.3.5
 
The aforementioned hypothetical biosynthesis of brabantamide 
includes some intriguing steps which so far have been not 
observed in combination with a common ´NRPS-machinery´ 
generating lipopeptides. These massive rearrangements postulated 
in the biosynthesis hypothesis required verification by 
labelling experiments with stable isotopes.  
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Initially, a growth curve was performed to identify the point in 
time of maximum production of brabantamide and to determine the 
ideal feeding time for the chosen precursors. Subsequently, 
feeding experiments with L-serine and L-proline, both amino 
acids predicted to be incorporated by the corresponding specific 
A-domains of the NRPS, were performed. Following the 
hypothetical biosynthesis, the labelled carbon atoms of serine 
should be incorporated at the positions of carbon atoms no. 2, 
10 and 9 of brabantamide and the labelled C1-atom of proline at 
the position of carbon atom no. 4, respectively (see figure 
4.3.14). Due to the failed incorporation of proline (see chapter 
4.3.5.8), an additional experiment with glycine was performed.  
Labelled acetate was used to confirm the biosynthetic origin of 
the fatty acid moiety which should result in the enhancement of 
the signals of carbon atoms no. 12, 14, 16, 18, 20, 22 and 24. 
Universally labelled acetate should additionally approve the 
intact incorporation of the acetate units (Vederas, 1987). 
Furthermore, 1-13C – hydrogen carbonate was used to investigate 
another possible origin of the carbonyl group of the lactone 
moiety in case it is not serine-derived.  
 
         brabantamide A 
      
               acetate-derived atoms 
       serine-derived atoms  
   proline-derived atom          
 
Figure 4.3.14: prediction of the labelling results with different precursors 
for brabantamide A; the numbers in the labelled atoms mark the associated 
carbon atom in the original amino acid  
 
 Carbon sources utilised by Pseudomonas sp. SH-C52  4.3.5.1
 
The investigations on carbon sources that can be utilised by 
Pseudomonas sp. SH-C52 were performed with the API®50 CH 
standardised test system (Biomerieux, Marcy l’Etoile France) as 
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described in chapter 3.1.6. With this test system, the 
degradation of 49 different carbon sources (see table 4.3.8) can 
be tested.  
Table 4.3.8: carbon sources utilised by Pseudomonas sp. SH-C52; + = positive; 
- = negative; ? = ambigous 
carbon source incubation time carbon source incubation time 24 h 48 h 24 h 48 h 
glycerol + + salicin - - 
erythritol ? ? D-cellobiose - - 
D-arabinose ? ? D-maltose - - 
L-arabinose + + D-lactose (bovine origin) - - 
D-ribose ? + D-melibiose - - 
D-xylose + + D-saccharose (sucrose) + + 
L-xylose ? ? D-trehalose + + 
D-adonitol - - inulin - - 
methyl- ß-D-
xylopyranoside - - D-melezitose - - 
D-galactose + + D-raffinose - - 
D-glucose + + amidon (starch) - - 
D-fructose + + glycogen - - 
D-mannose + + xylitol - - 
L-sorbose - - gentiobiose - - 
L-rhamnose - - D-turanose - - 
dulcitol - - D-lyxose - - 
inositol - + D-tagotose - - 
D-mannitol ? + D-fucose + + 
D-sorbitol - ? L-fucose - - 
methyl- α-D-
mannopyranoside - - D-arabitol - + 
methyl- α-D-
glucopyranoside - - L-arabitol - - 
N-acetylglucosamine - - potassium gluconate + + 
amygdalin - - potassium 2-ketogluconate - - 
arbutin - - potassium 5-ketogluconate - - 
esculin ferric citrate ? ?    
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The results show, that Pseudomonas sp. SH-C52 mainly utilises 
monosaccharides as carbon sources, thereby preferring the L-form 
of arabinose and the D-form of xylose.  
The only di-saccharides used by P. sp. SH-C52 were sucrose and 
trehalose whereas no oligo- or polysaccharides were degraded. 
Furthermore, some alditols (glycerol, mannitol, D-arabitol), a 
desoxy sugar (D-fucose) and one carboxylic acid (potassium 
gluconate) could be used as carbon source.  
 
 Growth curve of P. sp. SH-C52 and production rate of 4.3.5.2
brabantamide A  
 
In order to determine the optimal feeding and harvesting time 
for the labelling experiments, a bacterial growth curve of 
Pseudomonas sp. SH-C52 and a quantitative analysis of 
brabantamide production were performed (see chapter 3.1.5).  
The specific growth rate of P. sp. SH-C52 could be determined as 
0.3892, with a resulting doubling time of 2.11 hours (see figure 
4.3.15).  
 
Figure 4.3.15: Determination of the doubling time of P. sp. SH-C52 
The growth curve (see figure 4.3.16) revealed a lag-phase of ~ 5 
h, followed by a starting phase of ~ 3 h and an exponential 
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phase till 15 h. The slow-down phase lasts till ~ 29 h when the 
growth of P. sp. SH-C52 passes over to stationary phase.  
 
Figure 4.3.16: growth curve of Pseudomonas sp. SH-C52 
The calibration line for the determination of the production 
rate of brabantamide A was determined with standards two till 
five (see figure 9.1.12). The chromatogram of standard number 
one exhibited no peak in LC-MS analysis and was therefore not 
evaluable. 
 
Figure 4.3.17: production of brabantamide A by Pseudomonas sp. SH-C52 
The optimal feeding time was determined as the end of the 
starting phase and the following transition to the exponential 
phase. In accordance with the determined production rate of 
brabantamide A (see figure 4.3.18), the feeding time was 
committed to 8 hours. Before this point of time, no significant 
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production of brabantamide A could be observed. The harvesting 
time kept at 60-72 hours due to a decreasing production rate 
after 72 hours. 
 
 Results of the 1-13C - sodium acetate feeding 4.3.5.3
 
The feeding experiment was performed by adding isotopically 
labelled 1-13C - sodium acetate in a concentration of 222.2 mg/l 
and subsequent extraction according to the established procedure 
(see chapters 3.2 and 3.3.1). The crude extract was separated by 
RP-SPE (see chapter 3.3.10) and the resulting fractions were 
analysed by 1H-NMR to target the fraction containing the labelled 
metabolite. In the 1H-NMR spectrum of fraction C, brabantamide 
could be identified by the typical fatty acid resonances at 0.94 
ppm and 1.29 ppm for the terminal methyl group and the methylene 
groups, respectively, its characteristic methine resonance at 
5.03 ppm and the double bond resonance at 6.29 ppm. Hence, this 
fraction was further purified by HPLC, using system 4 and column 
1 (see chapter 3.3.3), employing a linear gradient starting with 
70% methanol and 30% water increasing to 100 % methanol in 30 
min followed by 10 min isocratic elution with pure methanol. 
After purification, fraction C-4 could be identified 
unambiguously as brabantamide A (see 1H-NMR spectrum appendix 
figure 8.1.12). The 13C-NMR spectrum of the purified compound 
showed enhanced signals of the carbon atoms no. 4, 8, 12, 14, 16 
and 24 (see table 4.3.9 and figures 4.3.18 and 8.1.13, 
appendix).  
         brabantamide A 
 
       
              labelled atoms 
 
 
 
Figure 4.3.18: result of the labelling experiment with 1-13C – sodium acetate 
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Table 4.3.9: enrichment of carbon atoms in brabantamide A after labelling 
with 1-13C – sodium acetate  
carbon no. A B C D natural labelled quotient B/A enrichment [%]
2 0.338 0.092 0.24 - 
4 0.644 1.900 2.95 2.1 
5 1.057 0.994 0.94 - 
6 1.160 1.138 0.98 - 
7 1.009 0.900 0.89 - 
8 0.948 8.638 9.11 8.9 
9 1.054 0.672 0.64 - 
10 0.434 0.059 0.14 - 
12 0.587 2.069 3.52 - 
13 1.032 0.551 0.52 - 
14 1.054 6.151 5.84 - 
15 1.161 0.727 0.63 - 
16 0.845 7.294 8.63 8.4 
17-22 6.716 34.641 5.16 3.6 
23 1.139 0.732 0.64 - 
24 1.115 9.221 8.10 7.8 
25 1.032 0.688 0.65 - 
1’ 1.070 0.712 0.91 - 
2’ 1.095 0.944 0.91 - 
3’ 1.170 0.881 0.75 - 
4’ 1.073 0.792 0.74 - 
5’ 1.046 0.686 0.66 - 
6’ 1.000 1.000 1.00 - 
For calculation purposes carbon atom no. 6´ was set to 1.000; A: integrals of 
the non-labelled compound, B: integrals of the labelled compound, C: quotient 
of the integrals (enriched/not enriched), D: enrichment of carbon atoms 
(calculation see chapter 3.3.4) 
Furthermore, the signal intensity of the carbons 17-22 
increased. The overlapping signals around 30 ppm of these atoms 
in the 13C-NMR spectrum precluded a detailed discrimination of 
regular and enhanced carbon atoms. However, considering that 
carbon 12, 14 and 24 represent secured 13C-enriched carbons, 
according to biosynthetic rules, the enhancement of the 
resonances around 30 ppm can be attributed to carbons no. 18, 20 
and 22 which have undergone 13C enrichment. 
 
 Results of the labelling experiment with 1,2-13C – 4.3.5.4
sodium acetate 
 
In order to investigate the incorporation of intact acetate, 
universally labelled sodium acetate (U-13C sodium acetate) was 
added to the culture four hours after inoculation at a 
concentration of 222.2 mg/ml. Subsequently, the established 
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procedure comprising three days of growth, extraction and 
purification by VLC and HPLC was applied (see chapters 3.3.1-
3.3.3).  
The expected peak – pattern of the HPLC-chromatogram could be 
observed in fraction C and subsequent purification yielded 2.4 
mg brabantamide A which was confirmed by 1H-NMR spectroscopy (see 
figure 8.1.14).  
Table 4.3.10: enrichment of carbon atoms in brabantamide A after labelling 
with 1,2-13C – sodium acetate 
carbon no. A B C D natural labelled quotient B/A enrichment [%]
4 0.644 0.35 0.54 - 
6 1.160 -a -a -a 
9 1.054 0.54 0.51 - 
13 1.032 0.97 0.94 - 
16 0.845 0.93 1.10 0.1 
17-22 6.716 18.31 2.72 1.9 
23 1.139 2.17 1.91 1.0 
1’ 1.070 0.43 0.41 - 
2’ 1.095 0.73 0.67 - 
3’ 1.170 0.67 0.57 - 
4’ 1.073 0.75 0.70 - 
5’ 1.046 0.76 0.73 - 
6’ 1.000 1.00 1.00 - 
For calculation purposes carbon atom no. 6´ was set to 1.000; A: integrals of 
the non-labelled compound, B: total integrals of the labelled compound, C: 
quotient of the integrals (enriched/ not enriched), D: enrichment of carbon 
atoms (calculation see chapter 3.3.4). 
a signal could not be integrated due to overlap with the carbons of the 
methylene envelope; carbon atoms C2, C10 and C12 were not apparent in the 13C-
NMR spectrum 
The evaluation of the relative enrichment was performed using 
two different calculations. To determine whether a position of 
the carbon skeleton contains more 13C than that corresponding to 
natural abundance, the spectra of the unlabelled and labelled 
metabolites were compared (see table 4.3.10; Séquin & Scott, 
1974). In case of appearing doublets, indicating acetate units 
which were incorporated as a whole unit, the enrichment was 
determined by comparison of the total integral (integral with 
satellites) to the integration value of the uncoupled signal and 
the coupling constants were determined (see table 4.3.11 and 
figure 4.3.19; Chang et al., 2004). 
Incorporation of complete acetate units were observed for carbon 
atoms C-7 and C-8 (Jcc 32.4-32.5 Hz), C-14 and C-15 (Jcc 36.3-37.8 
Hz) and C-24 and C-25(Jcc 34.7-34.8 Hz). Furthermore, C-5 (Jcc 
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42.7 Hz) showed satellites, but the expected corresponding 
enhancement of C-4 was not observed maybe due to the small 
amount of brabantamide A or its quaternary character.  
Table 4.3.11: calculation of the incorporated acetate units into brabantamide 
A after labelling with U-13C – sodium acetate 
carbon 
no. A B C D 
 JCC [Hz] 
total integral 
of enriched 
brabantamide A 
integration value 
for uncoupled 
signal 
% relative 
enrichment from 
intact 
incorporation 
5 42.7 2.43 1.21 201 
7 32.5 5.90 1.68 351 
8 32.4 4.93 1.68 293 
14 37.8 1.81 1.11 163 
15 36.3 3.61 1.63 221 
24 34.8; 69.2 5.14 1.70 302 
25 34.7 3.53 0.67 527 
Further labelled atoms were obtained at positions C-16, C-17 to 
C-22 and C-23, together building with the above mentioned carbon 
atoms no. 14, 15, 24 and 25 the expected enhancement of the 
fatty acid moiety. Carbon atom no. 6 couldn´t be evaluated due 
to overlap with carbons 17-22.  
 
 
 
 
   
 
  
 Figure 4.3.19: labelling pattern of brabantamide A after labelling with 
U-13C - sodium acetate 
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Figure 4.3.20: 13C NMR spectrum of brabantamide A in d4-methanol after 
labelling with 1,2-13C - sodium acetate (75 MHz, 66000 scans); the enlarged 
insets illustrate carbon atoms with satellites in comparison to the obtained 
singlets 
The determination of the C1 of each acetate unit was based on 
the results from the feeding experiment with single labelled 
acetate. 
Carbon atoms no. 5, 7 and 8 are incorporated by the citrate 
cycle (see chapters 4.3.5.6 and 4.3.5.7). 
 
 Results of feeding experiment with 1-13C - L-serine 4.3.5.5
 
Serine labelling was performed by addition of 500 mg 1-13C – L–
serine (111.1 mg/l), four hours after inoculation, to cultures 
of P. sp. SH-C52 (see chapter 3.1.3). Extraction and workup of 
the crude extract (183.2 mg) by VLC and HPLC using established 
procedures (see chapters 3.3.1 – 3.3.3 and 4.3.5.3) yielded 2.8 
mg of labelled brabantamide A which could be unambiguously 
identified by 1H-NMR (see figure 8.1.15). 
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Figure 4.3.21: 1-13C NMR spectrum of brabantamide A after labelling with 1-13C 
- L-serine in d4-methanol at 75 MHz (ns = 12260) 
In the 13C-NMR spectrum of the purified compound, the resonances 
for carbon atoms no. 2 and 4 showed significant enhancement (see 
figure 4.3.21 and 4.3.22 and table 4.3.12). The enrichment of 
carbon atom no. 4 appears at first unexpected and will be 
discussed in chapter 4.3.5.6. 
 
               brabantamide A 
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            labelled atom  
                     (unexpected) 
 
Figure 4.3.22: result of the labelling experiment with 1-13C - L–serine 
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Table 4.3.12: enrichment of carbon atoms in brabantamide A after labelling 
with 1-13C – L–serine  
carbon no. A B C D 
 natural labelled quotient enrichment [%]
2 0.383 4.018 10.49 8.4 
4 0.644 1.873 2.91 1.5 
5 1.057 0.864 0.82 - 
6 1.160 1.575 1.36 0.1 
7 1.009 0.941 0.93 - 
8 0.948 1.033 1.09 - 
9 1.054 0.637 0.60 - 
10 0.434 0.263 0.61 - 
12 0.587 0.471 0.80 - 
13 1.032 0.813 0.79 - 
14 1.054 0.929 0.88 - 
15 1.161 1.168 1.00 - 
16 0.845 1.173 1.39 0.2 
17-22 6.716 8.997 1.34 0.1 
23 1.139 1.278 1.12 - 
24 1.115 1.213 0.90 - 
25 1.032 1.276 1.24 - 
1’ 1.070 0.658 0.61 - 
2’ 1.095 1.294 1.18 - 
3’ 1.170 1.145 0.99 - 
4’ 1.073 1.199 1.12 - 
5’ 1.046 0.963 0.92 - 
6’ 1.000 1.000 1.00 - 
For calculation purposes carbon atom no. 6´ was set to 1.000; A: integrals of 
the non-labelled compound, B: integrals of the labelled compound, C: quotient 
of the integrals (enriched/ not enriched), D: enrichment of carbon atoms 
(calculation see chapter 3.3.4) 
 
 Labelling experiment with U-13C L-serine 4.3.5.6
 
In order to investigate the incorporation of serine, universally 
labelled serine (U-13C L–serine) was added to the culture four 
hours after inoculation at a concentration of 55.6 mg/ml. 
Subsequently, the established procedure comprising three days of 
growth, extraction and purification by VLC was applied (see 
chapters 3.3.1 and 3.3.2).  Further purification was achieved by 
HPLC employing system 4 and column 1 (see chapter 3.3.3) using a 
gradient starting with a methanol-water mixture (70:30) 
increasing to 100 % methanol in 30 minutes, followed by ten min 
isocratic elution with methanol.  
The expected peak–pattern of the HPLC-chromatogram could be 
observed in fraction C and yielded in 3.2 mg brabantamide A 
which was confirmed by 1H-NMR spectroscopy (see figure 8.1.16). 
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The 13C-spectrum of brabantamide A (see figure 4.3.24) showed 
enhanced signals of C2, C9 and C10 as expected from the proposed 
biosynthesis (see chapter 4.3.4). Additionally, the spectrum 
revealed an incorporation pattern similar to the one observed in 
the labelling experiment with universally labelled acetate. 
Thus, all residual carbon atoms except no. 1’, 2’, 3’, 5’ and 6’ 
belonging to the rhamnopyranose moiety showed enrichments 
towards the natural abundance of 13C. 
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Figure 4.3.24: 13C NMR of brabantamide A after labelling with U-13C - L-serine 
in d4-methanol (75 MHz, 21000 scans); the enlarged inset illustrates the usual 
splitting pattern obtained by incorporation of double labelled precursors  
Figure 4.3.23: labelling pattern resulting from the feeding experiment of 
brabantamide A with U-13C - L-serine  
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Table 4.3.13: enrichment of carbon atoms in brabantamide A after labelling 
with U-13C - L-serine  
carbon no. A B C D natural labelled quotient B/A enrichment [%] 
2 0.383 2.58 6.74 6.3 
4 0.644 3.81 5.92 5.4 
5 1.057 0.87 0.82 - 
6 1.160 -a -a -a 
17-22 6.716 30.27 4.51 3.86 
1’ 1.070 0.92 0.86 - 
2’ 1.095 1.14 1.04 0.04 
3’ 1.170 1.36 1.16 0.18 
5’ 1.046 0.78 0.75 - 
6’ 1.000 1.00 1.00 - 
For calculation purposes carbon atom no. 6´ was set to 1.000; A: integrals of 
the non-labelled compound, B: total integrals of the labelled compound, C: 
quotient of the integrals (enriched/ not enriched), D: enrichment of carbon 
atoms (calculation see chapter 3.3.4) 
a signal could not be integrated due to overlap with resonances of the carbon 
atoms 17-22 
Table 4.3.14: calculation of the incorporated acetate units into brabantamide 
A after labelling with U-13C - L-serine 
carbon 
no. A B C D 
 JCC [Hz] 
total integral 
of enriched 
brabantamide A 
integration value 
for uncoupled 
signal 
% relative 
enrichment from 
intact 
incorporation 
7 32.0 3.58 1.52 236 
8 31.9 3.92 1.78 220 
9 70.5 5.69 1.29 441 
10 70.4 3.24 0.84 386 
12 49.6 2.13 0.76 280 
13 50.6 4.41 1.78 248 
14 38.9 3.61 1.68 215 
15 38.6; 72.9 6.30 2.52 250 
16 35.5; 68.5 5.51 1.84 299 
23 34.4 5.42 2.46 220 
24 34.9; 69.1 5.70 2.02 282 
25 34.9 4.66 1.39 335 
4’ 40.6 3.64 0.84 433 
As described in chapter 4.3.5.4, two calculations were applied 
to enable the incorporation rate of labelled carbon atoms. The 
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values of the enrichments are listed in tables 4.3.13 and 
4.3.14. 
The enhancement of the acetate-derived carbon atoms can be 
attributed to the serine – dehydratase (also called serine – 
deaminase). This enzyme dehydrates serine in a first step, 
subsequently followed by deamination under consumption of water, 
resulting in pyruvate and ammonia (see figure 4.3.25; Kim & 
Gadd, 2008).  
HO
COOH
NH2
COOH
NH2
COOH
OH2O NH3H2O
 
Figure 4.3.25: serine dehydratase (serine deaminase); blue colour indicates 
labelled carbon atoms  
Thus, the received pyruvate can be used for anabolic and 
catabolic purposes like for example being transformed into 
acetyl-CoA by a pyruvate-dehydrogenase and recycled into the 
citrate cycle by citrate-synthase (see figure 4.3.26).  
Hence, the labelled precursor can be integrated in brabantamide 
A as acetate units similar to the labelling experiment with 
universally labelled acetate. (For detailed description of the 
citrate cycle see chapter 4.3.5.7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The labelling of all acetate-derived carbon atoms was already 
reported by a research group working with glycine precursors 
(Cushley et al., 1973). In this work, an additional step, the 
Figure 4.3.26: reactions catalysed by pyruvate dehydratase and by citrate
synthase; the applied colour scheme refers to one used in the labelling
pattern in figure 4.3.23 
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glycine-serine interconversion is mentioned, but the following 
steps leading to the doubly labelled acetate units take place in 
a similar sequence.  
The appearance of the label at C4’ in the rhamnose portion was 
at first unexpected but can be envisioned by degradation of 
serine to hydroxyl-pyruvate and channelling into sugar 
biosynthesis via glycerol-3-phosphate (see appendix, figures 
8.1.17 and 8.1.18). 
 
 Labelling experiment with 1-13C - hydrogen carbonate 4.3.5.7
 
The feeding experiment was performed by adding isotopically 
labelled 1-13C – hydrogen carbonate in a concentration of 222.2 
mg/l as described in chapter 3.2. The further processing 
procedure was adopted from the labelling experiment with 1-13C - 
L-serine (see chapter 4.3.5.5). Analysis of the resulting 
fractions by 1H-NMR discovered the labelled metabolite in 
fraction C. 
After purification by HPLC, fraction C-3 could be identified 
unambiguously as brabantamide A (see figure 8.1.19).  
 
 
 
 
          
 
        
 
Figure 4.3.27: result of the labelling experiment with 1-13C – hydrogen 
carbonate 
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Table 4.3.15: enrichment of carbon atoms in brabantamide A after labelling 
with 1-13C - hydrogen carbonate 
carbon no. A B C D
 natural labelled quotient enrichment [%]
2 0.383 0.151 0.39 - 
4 0.644 1.565 2.43 1.6 
5 1.057 1.026 0.97 - 
6 1.160 0.838 0.72 - 
7 1.009 0.958 0.95 - 
8 0.948 1.520 1.60 0.7 
9 1.054 0.858 0.81 - 
10 0.434 0.158 0.36 - 
12 0.587 0.285 0.49 - 
13 1.032 0.644 0.62 - 
14 1.054 0.836 0.79 - 
15 1.161 0.775 0.67 - 
16 0.845 0.823 0.97 - 
17-22 6.716 6.157 0.92 - 
23 1.139 0.888 0.78 - 
24 1.115 0.439 0.39 - 
25 1.032 0.670 0.65 - 
1’ 1.070 0.843 0.79 - 
2’ 1.095 0.880 0.80 - 
3’ 1.170 0.919 0.79 - 
4’ 1.073 0.953 0.89 - 
5’ 1.046 0.975 0.93 - 
6’ 1.000 1.000 1.00 - 
For calculation purposes carbon atom no. 6´ was set to 1.000, A: integrals 
of the non-labelled compound, B: integrals of the labelled compound, C: 
quotient of the integrals (enriched/ not enriched), D: enrichment of carbon 
atoms (calculation see chapter 3.3.4) 
The 13C-NMR spectrum of the purified compound obtained enhanced 
signals of the carbon atoms no. 4 and 8 (see table 4.3.15, 
figure 4.3.27 and figure 8.1.20, appendix). Therefore, it can be 
excluded, that the biosynthetic origin of carbon no. 2 is based 
on the incorporation of hydrogen carbonate. 
The incorporation of the labelled hydrogen carbonate into C4 and 
C8 can be explained by the citric acid cycle (see figure 
4.3.28). Hydrogen carbonate can be introduced into the citric 
acid cycle by the pyruvate carboxylase which catalyses the 
carboxylation of pyruvate to form oxaloacetate (OAA). Following 
the citric acid cycle OAA gets transformed to isocitrate which 
in turn is finally converted step by step into proline. The 
labelled positions match with the incorporation of proline into 
brabantamide A according to the hypothesised biosynthesis (see 
chapter 4.3.4). 
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 Investigations on proline incorporation  4.3.5.8
 
Attempts to prove intact incorporation of 1-13C isotopically 
labelled proline (55.6 mg/l) failed twice, since brabantamide 
production was apparently abolished under these conditions.  
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These results led to the hypotheses that either proline uptake 
mechanisms in P. sp. SH-C52 are malfunctional or that an 
elevated proline concentration in the medium exert a negative 
feedback on brabantamide production. However, investigations 
regarding its proline tolerance on small scale level did not 
abolish brabantamide production. Neither the addition of D- nor 
of L-proline at different concentrations (83.3 mg/l or 166.7 
mg/l) using the established cultivation methods led to a 
decrease of production. In contrast, a slight increase in 
brabantamide production was observed when the culture medium 
contained L-Pro. Likewise, an enhanced production could be 
observed when cultures were supplemented with serine (333.3 
mg/ml) or the extraction was conducted with Amberlite resin.  
Furthermore, the ability of the strain to take up proline was 
probed with a feeding study using radioactive proline. These 
experiments were performed by Michaele Josten (IMMIP, 
Pharmaceutical Microbiology Unit, University of Bonn, Bonn, 
Germany) according to the method described in chapter 3.1.10. 
The investigations showed, that Pseudomonas sp. SH-C52 is able 
to assimilate proline (see figure 4.3.29 and the corresponding 
values in table 8.1.3, appendix). 
 
 
 
 
 
 
 
Figure 4.3.29: repeat determination of proline-uptake in P. sp. SH-C52; CPM = 
counts per minute; OD = optical density  
A further attempt to verify the proline incorporation was 
conducted, this time using 1-13C isotopically labelled L-glycine 
as a precursor of proline in the citric acid cycle (see figure 
4.3.28). Hence, 222.2 mg L-glycine were fed analogously to the 
other labelling experiments. However, no brabantamide production 
was observed with addition of glycine to the culture media.  
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 Further biosynthetic studies using knockout mutants 4.3.5.9
 
In order to unravel further steps of the biosynthesis of 
brabantamide A, further knockout studies were performed, 
targeting the involved glycosyltransferase and the 
monooxygenase, respectively. The corresponding knockout mutants 
C52Δ26 and C52Δ28 were cultivated on a 4.5 l scale analogously 
to wild-type cultivations (see chapter 3.1.3) and subsequently 
processed according to the established extraction and separation 
procedure (see chapters 3.3.1 and 3.3.2). However, neither the 
expected brabantamide aglycon nor the hypothesised intermediate 
(see step 4, hypothetical biosynthesis in chapter 4.3.4) could 
be detected.   
Further attempts with optimized ´in-frame´-deletion mutants 
targeting the glycosyltransferase (strain C52Δ26IF) failed as 
well as an isotope-guided approach employing 1-13C – L–serine 
(111.1 mg/l) to track down the expected derivative. 
 
 Biological activity of brabantamides 4.3.6
 
The influence of brabantamides on the growth of a panel of Gram-
positive and Gram-negative bacteria and some fungi was 
determined. 
Hereby, brabantamides showed only inhibitory activities against 
Gram-positive bacteria whereas Gram–negative bacteria and fungi 
were not affected (see table 4.3.16 and appendix, table 8.1.4; 
Reder-Christ et al., 2012). 
All brabantamides displayed strong inhibitory activity against 
A. crystallopoietes. Furthermore, brabantamides B and C showed 
good inhibitory effects towards B. subtilis, B. cereus, B. 
megaterium, C. xerosis and M. luteus while brabantamide A only 
showed a small or no bacteria-free areola. In addition, 
brabantamide A influenced the growth of S. aureus and M. 
smegmatis strains, whereas brabantamide B was observed to 
moderately inhibit the growth of diverse S. aureus strains. 
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Table 4.3.16: antimicrobial disk diffusion inhibitory activities of 
brabantamides against chosen Gram-positive bacteria (A = brabantamide A; B = 
brabantamide B; C = brabantamide C) 
Organism Zone of inhibition [mm] 
 A B C 
Arthrobacter crystallopoietes DSM 20117 13 14 14 
Bacillus cereus   n.t. 8d 8b 
Bacillus subtilis 168 4 11a 10a 
Bacillus megaterium 0 11c 10c 
Corynebacterium pseudodiphtheriticum 3 n.t. n.t. 
Corynebacterium diphtheriae 3 n.t. n.t. 
Corynebacterium xerosis Va 167198 3 12b 12b 
Listeria welchimeri DSM 20650 3 0 0 
Micrococcus luteus ATCC 4698 n.t. 10a 10a 
Mycobacterium smegmatis ATCC 70084 3 0 0 
Staphylococcus aureus		SG 511 3 0 0 
Staphylococcus aureus 5185 (MS) 3 4a 0 
Staphylococcus aureus I-11574 (MS)  n.t. 6a 0 
Staphylococcus aureus LT-1334 (MR)  0 6a 0 
a turbid; b very turbid; c clear with resistances; d bright with turbid court 
MS = methicillin-susceptible; MR = methicillin-resistant;	n.t. = not tested	
The determined MICs (table 4.3.17) of brabantamides matched well 
to the corresponding inhibition zones. Brabantamides showed 
significant antibacterial activities against A. crystallopoietes 
DSM 20117, B. subtilis 168, B. megaterium and M. luteus, while 
values for C. xerosis Va167198, M. smegmatis ATCC 70084, L. 
welchimeri DSM 20650 and S. aureus SG 511 must be judged as 
moderate. 
It is noteworthy to mention, that brabantamide C shows 
considerable lower minimal inhibition concentrations towards the 
tested bacteria than brabantamide A and B. This can be seen as 
first hint for a structure – activity relationship (see chapter 
5.2.3.1).     
Since it is known, that the activity of some CLPs is calcium-
dependent (Baltz et al., 2005), brabantamide A was re-tested in 
the presence of Ca2+ ions to avoid false-negative results (data 
not shown). However, no difference in potency was observed which 
implies that a dependency of calcium is not given. For this 
reason as well as due to restrictions in available compound 
material, brabantamides B and C were not re-tested.  
 Results and discussion 93 
 
Table 4.3.17: minimal inhibition concentrations (MICs) of brabantamides (A = 
brabantamide A; B = brabantamide B; C = brabantamide C) 
Organism MIC (µg/ ml) 
 A B C 
Arthrobacter crystallopoietes DSM 20117 12.5 12.5 6.25 
Bacillus subtilis 168 12.5 25 6.25 
Bacillus megaterium n.t. 12.5 6.25 
Corynebacterium xerosis Va 167198 50 n.t. n.t. 
Listeria welchimeri DSM 20650 25 n.t. n.t. 
Micrococcus luteus  n.t. 12.5 6.25 
Mycobacterium smegmatis ATCC 70084 50 n.t. n.t. 
Staphylococcus aureus		SG 511 25 n.t. n.t. 
n.t. = not tested 
 
 Cytotoxicity of brabantamides 4.3.7
 
Cytotoxicity tests were performed by the research group of Prof. 
Dr. H. Brötz–Österhelt (Institute of Pharmaceutical Biology and 
Biotechnology, University of Düsseldorf, Germany) according to 
the method described in chapter 3.1.8. 
Results of the cytotoxicity are shown in table 4.3.18. The 
cytotoxicity of brabantamide A against THP1 and BALB cell lines 
was directly related to the concentration of brabantamide A. 
First cytotoxic effects could be observed at 32 mg/ml (data not 
shown). No difference could be monitored between the values for 
the two different cell lines, even if THP1 represents a more 
sensitive cell line (see values of cycloheximide). 
Table 4.3.18: result of cytotoxicity assay of brabantamide A 
Cell line IC50 [µg/ml] 
 brabantamide A cycloheximide
THP1 (human acute monocytic leukemia cell 
line) 47 0.12 
BALB/3T3 (mouse embryonic fibroblast cell 
line) 47 0.5 
These findings indicate that brabantamide A shows minimal to no 
cytotoxicity at concentrations where it is active towards 
bacteria (12.5 µg/ml).  The cytotoxicity occurs at ranges which 
are around the MIC for C. xerosis and M. smegmatis, about 
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twofold the MIC for S. aureus and L. welshimeri and actually 
fourfold the MIC for A. crystallopoietes and B. subtilis, 
respectively (see table 4.3.17).  
Thus, the cytotoxicity of brabantamide A can be classified as 
uncritical. 
 
 Investigations on the mode of action of brabantamides 4.3.8
 
To gain first insights regarding the target structure of 
brabantamides, a luciferase reporter gene assay was performed by 
the working group of Prof. Dr. H. Brötz–Österhelt (Institute of 
Pharmaceutical Biology and Biotechnology, University of 
Düsseldorf, Germany).  
Five B. subtilis reporter strains were used, carrying different 
antibiotic induced promoters fused to firefly luciferase 
reporter gene (see chapter 3.1.9). This set of promoter-reporter 
fusions enables the diagnosis of antibiotic interference in the 
major biosynthetic pathways of bacteria e.g. in the biosynthesis 
of DNA (yorB-promoter), in protein biosynthesis and by RNA 
inhibition (yheI- and yvgS-promoter), and in cell wall 
biosynthesis and by cell wall stressing agents (ypuA-promoter; 
Urban et al., 2007; Hutter et al., 2004).  
Regarding the latter interferences, a yvqI-(=liaI) promoter 
containing reporter strain indicated more specifically 
inhibition of peptidoglycan biosynthesis (e.g. vancomycin, 
bacitracin and tunicamycin) and membrane damaging agents (e.g. 
ethanol; Mascher et al., 2003; Petersohn et al., 2001). The 
occurrence of an elevated luminescence signal in one of these 
reporter strains by a test compound is indicative of promoter 
induction, thus delivering first starting points for further 
mode of action studies. In the conducted reporter strain assays 
brabantamide A was able to induce the ypuA- and the yvqI-
reporter (see figure 4.3.30 and 4.3.31). These results suggest, 
that brabantamide A causes stress on the cell wall either on the 
membrane or interferes with peptidoglycan.  
The measured effects appeared at a concentration of 8 µg/ml 
which represents two-thirds of the minimal inhibition 
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concentration determined for brabantamide A on B. subtilis. In 
higher concentrations no effect on the promoters could be 
observed what might be caused by a damage of the cells that 
precludes expression of the reporter gene. The remainder of the 
reporter-strains did not show an induction in the presence of 
brabantamide A (for data see appendix figures 8.1.21-8.1.23). 
The influence of DMSO on the results was excluded by repeating 
the assay with different DMSO concentrations (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.3.30: result of brabantamide A (A) on the ypuA promoter
(indicates cell wall synthesis and cell wall envelope stress) in
comparison with the positive control vancomycin (B, inhibitor of cell
wall synthesis); red and blue bars represent the background control and
the tested substance, respectively 
Figure 4.3.31: result of brabantamide A (A) on the yvqI promoter
(indicates cell wall synthesis and cell wall envelope stress) in
comparison with the positive control vancomycin (B, inhibitor of cell wall
synthesis); red and blue bars represent the background control and the
tested substance, respectively  
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 Investigations on Empedopeptin 4.4
 
 Isolation of empedopeptin 4.4.1
 
Empedobacter haloabium nov. spec. (ATCC31962) was cultivated on 
a 3L scale (3.1.3), extracted (3.3.1) and the resulting crude 
extract subjected to RP-VLC. 
Aberrant from the established standard VLC-scheme (3.3.2) used 
in this study, a stepwise gradient of water-methanol (70:30-
0:100) and methanol-dichloromethane was applied to give 10 
fractions. Based on LC-MS profiling, fraction 8 (eluted 100% 
MeOH) was further purified by RP-HPLC, using system 3 and column 
7 (see 3.3.3), employing a linear gradient of 62:38-75:25 MeOH-
H2O (2 mM NH4OAc) over a period of 30 min with a flow rate of 1.8 
ml/min (UV-monitoring at 210 nm). 
Purification of the semi pure empedopeptin was continued by a 
second RP-HPLC on the same system using column 1 (UV-monitoring 
at 210 nm) using two linear gradients of 60:40 MeOH-H2O (2 mM 
NH4OAc) over a period of 15 min, constantly increasing to 90:10 
MeOH-H2O (2mM NH4OAc) in a 5 min period, followed by isocratic 
elution at 90:10 for 10 min. The purification resulted in 6.2 mg 
of pure empedopeptin. The obtained purity of empedopeptin was 
monitored by LC-MS analysis (see chapter 3.3.5). During this 
monitoring, three compounds with similar physicochemical 
properties could be detected and isolated with very small yields 
(compound 1: 3.11 mg, compound 2: 1.22 mg and compound 3: 0.58 
mg). 
 
 Structure elucidation of empedopeptin 4.4.2
 
The structure elucidation of empedopeptin was mainly based on 
NMR experiments (see chapter 3.3.4). Based on the limited amount 
of substance, its poor solubility and the tendency to form 
micelles, only a 1H-spectrum (see figure 4.4.1), a 1H-13C HSQC 
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spectrum, a TOCSY- and a NOESY spectrum could be recorded with 
sufficient quality . 
 
Figure 4.4.1: 1H NMR spectrum of empedopeptin in d6-DMSO (900 MHz) 
The 1H-13C HSQC spectrum correlated all proton resonances to the 
13C-NMR resonances of directly bonded carbon atoms (see figure 
8.1.24, appendix and table 4.4.1). The analysis of the TOCSY 
spectrum revealed the presence of characteristic spin systems 
for two serine moieties, two proline and two 3-hydroxy aspartic 
acid residues as well as a 3-hydroxy proline, arginine and a 3-
hydroxy fatty acid as partial structures (Pretsch et al., 2001).  
Interpretation of the proton-proton through-space interactions 
of empedopeptin, observed in a 2D-NOESY NMR spectrum (see figure 
8.1.25, appendix), enabled the assembly of the partial 
structures to give the suggested peptide sequence of 
empedopeptin (figure 4.4.2). 
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Figure 4.4.2: partial structures deduced from the TOCSY spectrum and complete 
structure of empedopeptin; black lines indicate TOCSY couplings, red arrows 
indicate NOESY correlations 
For the isolated potential congeners of empedopeptin (compound 
1-3) measurements of NMR spectra with sufficient quality were 
not possible due to the small amount of substances. 
Nevertheless, a first structure proposal was done by comparison 
of the determined molecular masses of the structures. Thus, it 
can be suggested, that compound 1 (empedopeptin B) is the ring-
opened congener of empedopeptin (figure 4.4.3 a) showing a 
molecular mass of 1144.5726 g/mol in the LC-MS spectra 
(calculated: 1144.2291 g/mol). Compound 2 (empedopeptin C) with 
a calculated mass of 1158.2127 (measured: ~ 1158) is suggested 
to be a derivative which consists of three instead of one 
hydroxylated proline residue (figure 4.4.3 b). Compound 3 
(empedopeptin D) could possibly be a variety containing lauric 
acid instead of myristic acid as fatty acid component (see 
figure 4.4.3 c) based on the mass difference of 29 to 
empedopeptin (calc. mass of compound 3: 1097.5241; measured: 
~1097).  
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Table 4.4.1: NMR spectral data for empedopeptin in DMSO 
N protons connected to nitrogen atoms 
# weak signal 
  
 position δC [ppm] δH [ppm] NOE 
carbon/ 
nitrogen
no.  
3-hydroxy  
aspartic acid 
(1) 
NH - 7.69 6/7 1N
α 54.8 4.63 1N 2 
β 69.9 4.21  3 
3-hydroxy- 
proline 
α  66.6 4.42 8, 1N 6 
β 69.1 4.42 8, 1N 7 
γ 32.3 1.78; 1.93 6/7 8 
 δ 43.5 3.25; 3.44 6/7, 11, 1N 9 
serine (1) NH - 8.34  2N
 α 51.6 CH 4.57 2N 11 
 β 61.1 CH2 3.51; 3.62  12 
3-hydroxy 
aspartic acid 
(2) 
NH - 8.03  3N
α 58.3 CH2 4.29 3N 14 β 71.2 CH 3.87 1N, 2N  15 
arginine α 52.1 CH 4.24 15, 19 18 
 β 28.9 CH2 1.71 25# 19 
 γ 23.6 CH2 1.31 19 20 
 δ 40.3 CH2 3.04; 3.08 25# 21 
proline (1)  α 59.8 CH 4.85 25, 27, 29 24 
 β 31.4 CH2 2.05; 2.10 24 25 
 γ 22.0 CH2 1.74  26 
 δ 46.2 CH2 3.31; 3.36 24 27 
serine (2)  NH - 8.00 27, 29, 30, 32, 34 4N
 α 53.2 CH 4.11 24, 32, 4N 29 
 β 60.4 CH2 3.43; 3.47  30 
proline (2) α 57.9 CH 4.47 29, 33, 4N 32 
 β 18.6 CH2 1.98  33 
 γ 23.7 CH2 1.81  34 
 δ 46.6 CH2 3.43; 3.61 34 35 
3-hydroxy 
myristic acid 
α  37.2 CH2 2.59; 2.75  2’ β 71.6 CH 4.94 6/7# 3’ 
γ 32.8 CH2 1.62  4’ 
δ 
31.0; 
28.6;  
21.8 CH2 
~1.24         5’-13’ 
-CH3 13.6 CH3 0.86  14’ 
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 Discussion and Outlook 5
 
The study was performed within the frame of the DFG research 
group (FOR 854) “Post-genomic strategies for new antibiotic 
drugs and targets”. In this context, partial project 8 “Genomic 
mining for antimicrobial lipopeptides” aimed to isolate and test 
antibacterial cyclic lipopeptides derived from bacteria.  
To reach this goal, a genome-driven approach was chosen to 
identify alleged candidate biosynthetic pathways encoded in 
genomes of the genus Pseudomonas and related genera.   
Furthermore, the lipodepsipeptide empedopeptin should be 
isolated from the strain Empedobacter haloabium nov. sp. for the 
purpose of structural confirmation and collaborative mode of 
action studies. 
In the following, the employed approaches of the study and the 
achieved objectives will be discussed as well as an insight in 
potential future perspectives, will be given. 
 
 Applied methods of genome mining  5.1
 
As mentioned above, the concept of genome mining was applied 
during this study to identify potential strains of the genus 
Pseudomonas or of related genera for the isolation of new 
antibiotic CLPs. Up to date, genome mining covers four 
methodologies to discover orphan gene clusters and subsequently 
isolate and characterise the corresponding product: the 
´bioinformatic and screening´ approach, the ´genomisotopic 
approach´, ´heterologous expression´ and the method of ´knockout 
and comparative profiling´ (see chapter 1.3; Gross, 2009). 
The first method applied in this study was the ´bioinformatic 
and screening´ approach. Thus, an in silico screening employing 
specific target structures, in this case the sequence of a 
double terminal TE domain of orfamide, was chosen to identify 
several Pseudomonas strains, which contain similar sequences and 
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thus were suggested to produce antimicrobial cyclic 
lipopeptides. 
The resulting eight gene clusters were subsequently subjected to 
a bioinformatical analysis and revealed the potential target 
structures of the corresponding cyclic lipopeptides (see chapter 
4.1). Out of these candidates five were chosen and the 
corresponding strains i.e. Pseudomonas syringae pv. syringae 
B728a and pv. tomato DC3000 as well as P. sp. SH-C52 were 
subjected to a broad screening for the predicted lipopeptides 
(see chapter 4.2).  
This first applied approach of genome mining can be assessed as 
semi-successful. On the one hand, the ´bioinformatic and 
screening´ approach led to the discovery of the abovementioned 
eight gene clusters and up to date most of the corresponding 
cyclic lipopeptides were identified e.g. brabantamides (this 
study), entolysins (Vallet-Gely et al., 2010) and syringafactins 
(Berti et al., 2007). This can be regarded as very successful, 
considering that structure elucidation of the remainder of 
candidate structures is on-going (Watrous et al., 2012).  
On the other hand, this method depends on the expression of the 
orphan pathway. Therefore, the missing expression of a chosen 
gene cluster is an obstacle which has to be overcome (Gross, 
2009). In this study, these problems occurred in case of P. 
syringae pv. syringae B728a and pv. tomato DC3000 as well as P. 
sp. SH-C52 regarding the second predicted CLP.  
In order to overcome this problem, the OSMAC approach was chosen 
which did not lead to success either (see chapter 4.2). 
Contemplating the first two strains and the fact, that some of 
the desired metabolites were already isolated from them, this 
might be due to a loss of metabolite production throughout time. 
In case of P. sp. SH-C52, the lacking production of the second 
CLP, termed thanamycin, could be based on production rates which 
are too low for the applied LC-MS system. This suggestion can be 
supported by the partial structure elucidation of thanamycin of 
a collaborative research group employing nanoDESI technology 
which shows a substantially higher sensitivity (Watrous et al., 
2012).  
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A second method of the ´genome mining concept´, applied during 
this study, was the ´genomisotopic approach´. Hereby, the ´in-
frame´-deletion mutants targeting the glycosyltransferase 
(strain C52Δ26IF) of P. sp SH-C52 was fed with 1-13C–L–serine to 
track down the expected aglycon-congener. This concept cannot be 
rated due to the obvious lack of brabantamide production in the 
knockout strains (see chapter 4.3.5.9).  
The method of ´knockout and comparative profiling´ was applied 
as third genome mining approach in this study. Thereby, both 
gene clusters of interest in P. sp. SH-C52 were disrupted in 
their NRPS moieties to perform knockout studies, followed by 
comparative profiling (see chapter 4.3.2).  
This approach can be regarded as successful in case of the 
knockout mutant strain C52Δ27. Hereby, comparative metabolite 
profiling led both to the desired metabolite and provided proof 
of the cluster (see figure 4.3.5).   
In the case of knockout-strain C52Δ33 no differences in the 
metabolite profile, compared to the one of the wild-type strain 
could be observed. In order to activate the expression of the 
thaABC gene cluster, the strain was included into the 
abovementioned OSMAC strategy.  
In summary, in this study all available genome mining 
techniques, except the ´heterologous expression´ approach, were 
employed., The genome mining approach turned out to be a strong 
concept to identify potential antibiotic producing bacterial 
strains and provided insights into corresponding candidate 
structures as well as proof of gene clusters. In combination 
with ´heterologous expression´ of gene clusters which would 
overcome the observed lack of expression, genome mining can be 
regarded as a straightforward strategy in the search for new 
antibiotic compounds.    
A limitation of genome mining represents the restriction that 
only known biosynthetic machineries can be discovered in silico. 
Up to date, this criterion is met by four important classes of 
secondary metabolites: ribosomal and non-ribosomal peptides, 
polyketides and terpenes (Gross, 2009). Products of specialised 
pathways will currently not be detected. However, the fact that 
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peptides, polyketides and terpenoids make up the majority of 
bioactive compounds relativizes this restriction.  
In exchange, genome mining targets candidate structures, which 
are not captured by traditional bioassay-guided approaches based 
on the lacking possibility to cultivate many of the producers. 
Furthermore, new methods of genome mining like the recently 
published ´mass spectrometry-guided´ approach (Kersten et al., 
2012) indicate that the potential of genome mining is nowhere 
near exhausted.   
 
 Investigations on brabantamides isolated from 5.2
Pseudomonas sp. SH-C52 
 
In this study, chemical and biosynthetic studies were focussed 
on the orphan gene clusters of the strain P. sp. SH-C52 among 
other due to an exclusive access given by collaboration with the 
University of Wageningen which granted investigations without 
competition. 
 
 Investigations on the gene cluster of brabantamides 5.2.1
 
The gene cluster encoding brabantamides comprises five genes 
coding for a glycosyltransferase (braA), a NRPS (braB), a 
monooxygenase (braC), a LuxR-type transcriptional regulator 
(braD) and a RND-type efflux system (braE) (Figure 5.2.1).  
 
 
 
 
 
 
 
braA braB braC
ProSer 
braE braD 
Figure 5.2.1: brabantamide gene cluster comprising braABCDE 
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Since braB was already discussed in chapter 4.3.1, only the 
products of the remaining structural and accessory genes will be 
highlighted in the following. 
 
 BraA – an inverting rhamnosyltransferase 5.2.1.1
 
Glycosyltransferases (GTs) comprise one of the most diverse 
groups of enzymes. They catalyse the attachment of sugars to an 
aglycon wherewith they are able to modify every group of 
biopolymers like proteins and oligosaccharides as well as 
natural products and are present in nearly all investigated 
organisms (Hu & Walker, 2002). In contrast to their huge 
structural and functional variety and the resulting low sequence 
similarities (Hu & Walker, 2002), the majority of 
glycosyltransferases can be subdivided into only two structural 
superfamilies, termed GT-A and GT-B, each consisting of two 
domains (Erb et al., 2009). These superfamilies differ in folds, 
active sites and different mechanisms regarding the 
glycosyltransfer (Hu & Walker, 2002). 
Enzymes belonging to the GT-A class comprise two disparate 
domains. At the N-terminal domain, several Rossmann folds (ß-
sheets flanked by α-helices) recognise the sugar-nucleotide 
donor, while the C-terminal domain contains the acceptor-binding 
site and consists of mixed ß-sheets. Glycosyltransferases of the 
GT-B fold comprise two similar Rosssmann-like folds. Thereby, 
the acceptor and donor sides are contrary to those of the GT-A 
fold, i.e. the N-terminal domain provides the acceptor-binding 
site, while the C-terminal domain binds the donor. In both 
superfamilies the domains comprise a linker region where the 
active site is located (Erb et al., 2009). 
A further class of glycosyltransferases, GT-C, was predicted by 
sequence similarity (Liu & Mushegian, 2003). They consist of a 
large hydrophobic transmembrane protein having between 8 and 13 
transmembrane helices and an active site located on a long-loop 
region (Strahl-Bohlsinger et al., 1993; Takahashi et al., 1996; 
Maeda et al., 2001). This classification is problematic because 
the alignment, which is based on the transmembrane region, does 
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not include the predicted loop bearing the active site (Lairson 
et al., 2008). 
Furthermore, glycosyltransferases are classified into clans 
dependent on the stereochemical outcome of the reaction at the 
anomeric centre, relative to that of the donor sugar as either 
retaining or inverting GTs. Thereby, the overall fold of the 
enzyme does not dictate this outcome as can be seen in examples 
for both types of reactions found in either GT-A and GT-B 
(Coutinho et al., 2003). To date, all enzymes of the predicted 
GT-C fold are inverting GTs (Lairson et al., 2008). 
Investigations on the glycosyltransferase, encoded by braA, 
belonging to the gene cluster of brabantamide by homology search 
(see chapter 4.3.1) revealed the highest sequence similarity to 
a rhamnosyltransferase deriving from Burkholderia thailandensis 
E264 (see table 8.1.1). The relatively low homology of 50% can 
be explained by the aforementioned huge diversity of GTs. 
Interestingly, all glycosyltransferases showing noticeable 
homology to braA belong to the GT-B superfamily of GTs why it is 
likely that BraA comprises a GT-B fold as well.  
This result could be borne out by comparison of the obtained 
similar sequences with the Carbohydrate-Active Enzymes database 
(CAZy, http://www.cazy.org; Cantarel et al., 2009). The CAZy 
database proposes the continuously updated classification of GTs 
into distinct sequence-based families by reference to a 
classification of Campbell et al. (Campbell et al., 1997; 
Campbell et al., 1998) and was later complemented by Coutinho et 
al. (Coutinho et al., 2003). At the moment over 100,000 modules 
of GTs are classified into 94 family numbers. Three of the 
glycosyltransferases obtained from homology blast performed for 
BraA - Bcen2424_5095, Bamb4507 and Bcen_3273 - were available at 
the database, all assigned to the GT1 family.  
Since the GT1 family is corresponding to clan II i.e. an 
inverting enzyme comprising a GT-B fold, it can be assumed that 
BraA shares these features. The mechanistic strategy of 
inverting GTs involves a direct displacement SN2-like reaction 
(see figure 5.2.2). Thereby, the active-site side chain 
deprotonates the incoming nucleophile of the acceptor serving as 
a base catalyst, relieving direct displacement of the activated 
(substituted) phosphate leaving group (Lairson et al., 2008).  
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Figure 5.2.2: usual mechanism of inverting GTs with GT-A fold, following an 
SN2 mechanism adopted from Lairson et al., 2008 
In difference to the mechanism displayed in figure 5.2.2, GTs of 
the GT-B fold often use a metal ion-independent mechanism where 
for example a histidine residue acts as activator (Offen et al., 
2006; Lairson et al., 2008). 
Summarising, the attached L-rhamnose of brabantamide A secures 
that braA codes for a rhamnosyltransferase as assumed based on 
the homology search. Furthermore, it seems likely, that braA 
encodes an inverting GT exhibiting GT-B fold that belongs to the 
GT1 family. The fact that BraA is inverting would lead to the 
expectation that the attached α-L-rhamnose of brabantamide 
initially was in ß-form since there is no evidence for a mixture 
of anomers. Even if inverting GTs are able to invert both 
anomers, it is known, that they are highly specific and therewith 
only pick up the needed anomer (Watkins, 1986).  
 
 BraC – a flavoprotein monooxygenase 5.2.1.2
 
Monooxygenases (MOs) belong to the group of oxidoreductases, 
enzymes which catalyse the electron transfer between molecules, 
and are responsible for the introduction of one atom of molecular 
oxygen into an organic substrate. The numerous sundry types of 
enzymes catalysing monooxygenation reactions include the family 
of cytochrome P450 MOs as well as non-heme, copper-dependent and 
flavin-dependent monooxygenases and some MOs which do not depend 
on any of the abovementioned cofactors (van Berkel et al., 2006).   
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Investigations on the monooxygenase belonging to the gene cluster 
of brabantamide by homology-search (see chapter 4.3.1) revealed 
the highest sequence similarity for BraC to a putative FAD-
dependent monooxygenase from Xenorhabdus bovienii SS-2004 
[YP_003466257.1]. The resulting low homologies, showing a maximum 
identity of 44% to other described monooxygenases, are not 
astonishing taking into account that there are multitudes of 
different MOs (van Berkel et al., 2006). 
Even if the result of the homology blast performed for braC is 
vague, all MOs identified thereby belong to the group of 
flavoprotein monooxygenases (FPMOs; see table 8.1.2). Despite 
other types of MOs which use e.g. transition metals for the 
transfer of oxygen into the organic substrate, FPMOs employ a 
purely organic cofactor, FAD, for the oxygenation which can only 
react with molecular oxygen in its reduced form. FMPOs can be 
divided in internal and external monooxygenases. Internal MOs 
reduce the flavin cofactor by the substrate itself while external 
MOs reduce the cofactor with the help of electrons provided by 
consumption of reduced coenzymes like NADH (van Berkel et al., 
2006).  
Van Berkel et al. classified external FPMOs into six subclasses 
A-F, based on sequence similarity and the presence of specific 
protein sequence motifs (van Berkel et al., 2006).  
Due to the hypothesised biosynthesis of brabantamide, the 
monooxygenase encoded by braC found in the corresponding gene 
cluster was expected to be a Baeyer-Villiger (BV) monooxygenase. 
Thus, it was anticipated that BraC belongs to subclass B or C of 
the FAD-dependent monooxygenases which are known to catalyse BV 
reactions.  
Monooxygenases of the subclasses C-F are encoded by at the 
minimum two genes, which code for one reductase and at least one 
monooxygenase (van Berkel et al., 2006). Due to the absence of a 
reductase in the brabantamide gene cluster or a further 
monooxygenase, these subclasses could be excluded for BraC.   
The remaining FPMOs of the subclasses A and B are encoded by a 
single gene and both contain a tightly bound FAD cofactor. Class 
A and B differentiate in there structural composition of either 
one or two dinucleotide binding domains, respectively (van Berkel 
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et al., 2006). These domains (Rossmann folds) bind the ADP moiety 
of FAD and can be evidenced by the GXGXX(G/A) motif (Wierenga et 
al., 1986). 
Contrary to the expectation, BraC can be assigned to subclass A 
showing only one motif for a Rossmann fold in the sequence (see 
figure 5.2.3). Interestingly, the BVMO-identifying sequence motif 
(FXGXXXHXXXW(P/D)) or the similar motif for FPMOs 
(FXGXXXHXXX(Y/F)) elucidated by Fraaije and co-workers is also 
lacking in the sequence of BraC (Fraaije et al., 2002).  
 
 
 
 
 
 
 
 
 
 
Figure 5.2.3: sequence of BraC with the fingerprint motifs 1-3; the conserved 
sequence motifs for FPMOs shown above the sequence are adopted from Eppink et 
al., 1997; uppercase letters in the profile define amino acid residues, 
lowercase letters are: x = all residues, c = charged residues, h = 
hydrophobic residues, s = small residues; violet indicates the highly 
conserved motifs  
Additional structural features found in exponents of subclass A 
are a second fingerprint motif, GD, whose amino acids are in 
contact with the riboflavin moiety of FAD (Eggink et al., 1990) 
and a third fingerprint sequence (see figure 5.2.3) with the 
highly conserved DG motif (Eppink et al., 1997) which is involved 
in binding the pyrophosphate moieties of both FAD and NADPH (van 
Berkel et al., 2006).  
Monooxygenases like BraC, belonging to subclass A are dependent 
of NADPH or NADH. Typical substrates are aromatic compounds that 
contain an activating hydroxyl or amino group which undergo an 
electrophilic attack by the C(4a)-hydroxyflavin as oxygenating 
flavin species.  
The 4-hydroxybenzoate 3-monooxygenase from Pseudomonas qualifies 
pyrophosphate binding site 
dinucleotide binding domain
riboflavin binding site 
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as prototype enzyme of class A FPMOs which usually catalyse 
ortho- or para- hydroxylations of aromatic rings (van Berkel et 
al., 2006) or modify aromatic polyketides like for example 
griseorhodin (Li & Piel, 2002).  Aside hydroxylation, they are 
known to catalyse epoxidations as seen in squalene monooxygenase.  
Nevertheless, the postulated biosynthesis (see chapter 4.3.4) 
following a Baeyer-Villiger reaction remains likely, supported by 
the recently discovered bacterial enzyme MtmOIV, a class A FPMO, 
which is involved in the biosynthesis of the polyketide 
mithramycin (Gibson et al., 2005; Prado et al., 1999). 
Thus, BraC could be the first flavin-dependent Baeyer-Villiger 
monooxygenase belonging to class A which is involved in the 
biosynthesis of a NRPS-derived product. 
 
 BraD - a LuxR-type transcriptional regulator 5.2.1.3
 
Investigations on braD by comparative alignments revealed 
maximum identities of 69 % and 70 % to SalC and SyrF, 
respectively, both derived from Pseudomonas syringae pv. 
syringae B728a. Both proteins were described to exhibit homology 
to regulatory proteins of the LuxR family (Lu et al., 2002). The 
LuxR superfamily consists of transcriptional regulators 
containing helix-turn-helix DNA-binding motifs at their C-
termini which are also present in the sequence of braD (data not 
shown). The majority of these regulators can be classified into 
two major groups regarding their activation mechanism: (1) 
regulators that belong to a two-component sensory transduction 
system and are activated by phosphorylation and (2) regulators 
activated by binding to an autoinducer like N-acylhomoserine 
lactone (N-AHL; de Bruijn & Raaijmakers, 2009). Furthermore, 
there are numerous LuxR-type regulators which do not belong to 
these subfamilies e.g. regulators that are activated upon ligand 
binding like for example MalT of Escherichia coli, induced by 
maltotriose (Schlegel et al., 2002). Further examples of LuxR-
type regulators which do not belong either to one of the two 
subfamilies are SyrG, SalA and SyrF from P. syringae pv. 
syringae the latter representing the second hit regarding the 
homology blast performed with the sequence of braD. SalA, syrF, 
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and syrG genes were identified within the syr-syp genomic 
island, encoding the cyclic lipopeptide toxins syringomycin and 
syringopeptin, whereby the syrG gene is not essential for toxin 
production but is associated with virulence of P. syringae pv. 
syringae (Lu et al., 2005). 
In contrast, salA and syrF are essential for the production of 
syringomycin, whereby SalA is required for transcription of syrF, 
and a functional SyrF is essential for transcription of syrB1 
and syringomycin i.e. SalA positively regulates the expression 
of SyrF (Lu et al., 2002). Furthermore, both genes are involved 
in the production of syringopeptin production (Wang et al., 
2006; Lu et al., 2002).  
Based on the high similarity of braD to syrF it can be assumed, 
that BraD is a LuxR-type regulator which positively regulates 
the expression of braB and therewith the production of 
brabantamides. 
 
 BraE – an outer membrane protein associated with a RND-5.2.1.4
type efflux system 
 
Investigations on braE by comparative alignments revealed 
maximum identities of 81 % and 80 % to a RND efflux system/NodT 
[EGH5526.1] and a putative outer membrane protein [AAK83331.1], 
respectively, both derived from Pseudomonas syringae. These 
genes encode outer membrane proteins associated to efflux 
transporters, whereby NodT, which also occurred in further 
homology hits (data not shown), was first described in 1990 
contained typical sequences of transit peptides enabling the 
secretion of proteins through the bacterial inner membrane 
(Surin et al., 1990).  
The described outer membrane proteins belong to the group of the 
´outer membrane factor´ (OMF) family which is one of two 
accessory proteins found in conjunction with ´multidrug 
resistance transporters´ (MDRs) from Gram-negative bacteria. The 
second associated protein, the periplasmic protein belongs to 
the group of ´membrane fusion protein´ (MFP) family (Zgurskaya 
et al., 2009). The typical MDR efflux pump consists of three 
genes, and can be classified into families depending on the 
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number of transmembrane-spanning regions of the transporter 
protein, the number of components that the pump has (single or 
multiple), the used energy source and the types of exported 
substrates (Piddock, 2005).  
Regarding the results of the homology blast, it seems likely 
that braE belongs to a MDR system of the ´resistance nodulation 
division´ (RND) superfamily. The putative outer membrane protein 
termed Orf1 [AAK83331.1] found to be similar to BraE is 
described as closely related to OprM of Pseudomonas aeruginosa 
(Lu et al., 2002), which is part of a suchlike three-component 
MDR pump, the  MexAB-OprM pump. This pump consists of the subunit 
protein MexB, an inner membrane-spanning protein, the inner 
membrane-associated periplasmic MexA and the outer membrane 
subunit OprM (Nakajima et al., 2000) and provides a significant 
contribution to the intrinsic resistance of P. aeruginosa e.g. 
towards tetracyclines and chloramphenicol (Poole et al., 1993).  
Whether BraE as outer membrane protein and therewith a suggested 
part of a MDR system possesses a different function if occurring 
alone or is non-functional in the cluster can currently not be 
deduced. Further possibilities are that a homolog of mexAB is 
localized elsewhere in the genome or that BraE represents a new 
class of efflux systems with dual functions. 
 
 Biosynthetic studies on brabantamides 5.2.2
 
Brabantamides are NRPS-derived cyclic lipodipeptides. Usually, 
NRPS either generate a linear peptide by hydrolytic release of 
the compound from the synthetase or a diketopiperazine is formed 
after cleavage from the enzyme by the thioesterase module (see 
chapter 1.1.1). Contrary to the initial bioinformatic 
predictions, brabantamides revealed an unexpected bicyclic 
carbamate core connected to a glycosylated fatty acid side 
chain.  
The unique core structure of brabantamide suggested, that there 
must have taken place a massive rearrangement of carbon atoms 
during the biosynthesis. The hypothetical biosynthesis 
generating the bicyclic carbamate was already introduced in 
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chapter 4.3.4 and had to be verified by means of labelling 
experiments with stable isotopes (see chapter 4.3.5). 
 
 
 
 
 
 
 
 
 
 
The results obtained from the feeding experiments with 1-13C- and 
1,2-13C sodium acetate proofed the biosynthetic origin of the 
fatty acid side chain, revealing the expected labelling pattern 
and approved intact incorporation of acetate units, respectively 
(see figure 5.2.4).  
Furthermore, the incorporation of acetate units in carbons 
number four and five respectively seven and eight can be 
regarded as an indirect proof for the incorporation of proline, 
given that proline can be generated by acetate units introduced 
into the citrate cycle (see figure 4.3.28).  
As one of the predicted substrates for the NRPS of 
brabantamides, the negative results obtained from the 
incorporation studies with 1-13C L-proline keep unresolved. 
Maybe, the expected incorporation of L-proline failed due to 
scale up or the loss of production of the applied cryo-culture. 
However, the uptake of 14C-labelled proline showed that there is 
no general problem with the application and up-take of proline 
in Pseudomonas sp. SH-C52, which excludes also the possibility 
that the applied proline concentrations had a toxic effect on 
the organism.   
Further experiments with single and universally labelled L-
serine precursors confirmed the origin of carbon atoms number 
two, four and nine (see figure 5.2.4). This result is not only 
indicative for the biosynthetic origin of the carbons but also 
supports the proposed rearrangement following a Baeyer-Villiger 
serine-derived carbon 
complete acetate 
unit 
C1 of acetate  
Figure 5.2.4: origin of carbon atoms of brabantamide A which could be 
verified with labelling experiments 
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reaction (see figure 4.3.13) and hence also the investigations 
regarding the classification of the monooxygenase (see chapter 
5.2.1.2). 
 Brabantamides as bioactive compounds 5.2.3
 
Brabantamides A, B and C, formerly known as SB-253514, SB-253517 
and SB-253518, respectively, were up to date only investigated 
regarding their function as selective competitive inhibitors of 
lipoprotein associated phospholipase A2 (LpPLA2; Thirkettle, 
2000a; Thirkettle et al., 2000; Pinto et al., 2000). LpPLA2 is a 
serine dependent lipase which is associated with the presence of 
low-density lipoprotein (LDL) in plasma and converts oxidised 
free fatty acids and phosphatidylcholine to lysophosphatidyl-
choline, two chemo attractants for circulating monocytes. Thus, 
inhibition of LpPLA2 activity hinders the build-up of 
lysophosphatidylcholine and thereby macrophage proliferation and 
endothelial dysfunction, which provides an attractive strategy 
in the treatment of atherosclerosis and related disorders 
(Thirkettle, 2000a). In this context, SB-253514 (brabantamide A) 
showed in vivo activity in Watanabe heritable hyperlipidaemic 
(WHL) rabbits when administered intravenous but not if it was 
orally applied.  
In contrast to this known biological activity, within the frame 
of this PhD project, brabantamides were encountered as 
antibiotically active substances (see chapter 4.3.6).  
Brabantamides showed significant MICs towards several Gram-
positives (see table 4.3.17). Thus, in combination with the low 
cytotoxicity (see chapter 4.3.7) proved them to be potential 
antibiotics. Furthermore, a dependency on calcium could be 
excluded by retesting in the presence of Ca2+ ions (see chapter 
4.3.6). The lacking activity of brabantamide A towards Gram-
negative species is not surprising (see chapter 1.1.4) and is in 
line with previous observations (Nybroe & Sørensen, 2004; 
Sinnaeve et al., 2009a).  
Furthermore, during the study first insights into structure-
activity relationship (see chapter 5.2.3.1) and the potential 
target structure as well as the possible mode of action of 
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brabantamides could be gained (see chapter 5.2.3.2) which will 
be discussed in the following. 
 
 Structure – activity relationship 5.2.3.1
 
Investigating the MICs of brabantamides (see table 4.3.17) 
brabantamide C exhibited considerable lower MICs towards the 
tested strains (A. crystallopoietes DSM 20117, B. subtilis 168, 
B. megaterium and M. luteus). Thus, two-fold higher potencies in 
comparison with brabantamide A and B and regarding the activity 
towards B. subtilis 168 a four-fold higher potency in comparison 
with brabantamide B was observed. 
Based on the fact, that the structures only differ in the nature 
of the lipid portion (see figure 4.3.11), the activity seems to 
increase with increasing chain length. Furthermore, the 
saturation of the fatty acid contributes to bioactivity as can 
be seen in the differing MIC values for brabantamides B and C.  
These observations are coincident with diverse studies on the 
impact of the lipid moiety on the biological properties of 
cyclic lipopeptides which point out that the antimicrobial 
behaviour and toxicity are affected massively by the nature of 
the incorporated fatty acid group (Debono et al., 1988). This 
might be due to the general mode of action of cyclic 
lipopeptides which is commonly ascribed to interactions with 
membranes and an unspecific detergent-like activity (see chapter 
5.2.3.2). Numerous attempts to gain insight into this structure-
activity relation underlined this coherence. For example, 
Youssef et al. investigated eight lipopeptides comprising the 
same amino acid but differing in fatty acid composition produced 
by various Bacillus species and hypothesized that branched even-
numbered fatty acids (in this case, iso-C14 was the only 
branched even-numbered fatty acid) might give the optimum 
hydrophilic lipophilic balance required for optimum surface 
activity (Youssef et al., 2005). Furthermore, investigations on 
surfactin and derivatives and their activity towards three 
enveloped viruses (VSV, SHV-1, SFV) belonging to different virus 
families (rhabdoviridae, herpesviridae and togaviridae) showed, 
that with increasing fatty acid hydrophobicity the virus 
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inactivation capacity of the isoforms increased (Kracht et al., 
1999). 
For the above mentioned CLPs only unspecific detergent-like 
mechanisms are assumed. However, also within the class of 
specifically acting CLPs, variations of the lipid side chain 
influence the antibiotic activity. These could be found in 
investigations on daptomycin and analogues, where an increase up 
to chain length C-12 to C-13 coincided well with increasing in 
vitro and in vivo activities against S. aureus and Streptococcus 
pyogenes (Debono et al., 1988) and investigations on polymyxin B 
and colistin, wherein introduction of fatty acids bearing 
aliphatic or aromatic ring structures greatly increased their 
bactericidal activity (Okimura et al., 2007). 
 
 Mode of action of brabantamides 5.2.3.2
 
The bioactivity of lipopeptides is commonly attributed to 
membrane interactions and the main destructive action on cell 
membranes has been referred to their unspecific detergent like 
activity. This can deduced from their ability to disintegrate 
lipid bilayers (Coraiola et al., 2006; Carillo et al., 2003; 
Sinnaeve et al., 2009b). However, based on recent mode of 
actions studies, a different picture emerged. For an increasing 
number of CLPs specific mechanisms can be demonstrated, like 
e.g. for friulimicin B or the below mentioned empedopeptin 
(Schneider et al., 2009; Müller et al., 2012).  
Therefore, a first attempt to gain insight into the mode of 
action of brabantamide A was to investigate molecular 
interactions between brabantamide A and bacteria-like lipid 
model membranes (Reder-Christ et al., 2012). These were analysed 
in detail via complementary biophysical techniques by the 
research group of Prof. Dr. G. Bendas (Pharmaceutical Institute, 
Pharmaceutical Chemistry II, University of Bonn, Germany).  
For this purpose, three types of experiments were performed 
(Reder-Christ et al., 2012):  
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1. Investigations on the intensity and kinetic of brabantamide 
A binding towards lipid biolayers using the quartz crystal 
microbalance (QCM), 
2. detection of changes in membrane permeability e.g. pore 
formation due to interaction between brabantamide A and the 
membranes via cyclic voltammetry (CV) and 
3. a subphase-assay to investigate surface activity indicating 
the ability of brabantamide A to insert into a phospholipid 
monolayer. 
 
Application of the QCM showed, that SB-253514 (brabantamide A) 
displays a high overall binding affinity to the model membranes 
which was in the low micromolar range (~ 0.55 µM – 1.28 µM) and 
is mainly based on their rapid association rates (Reder-Christ 
et al., 2012). 
The subphase-assay showed a medium incorporation tendency of 
brabantamide A into monolayers comparable to those of 
arthrofactin and massetolide A. However, a direct correlation 
between antibacterial activity and membrane incorporation was 
not observed but a correlation between structural features of 
the CLPs and the incorporation tendency (Reder-Christ et al., 
2012).  
Furthermore, in CV experiments brabantamide A revealed no 
membrane permeabilisation effects neither at inhibitory- nor at 
two-, four- or tenfold MICs. Thus, membrane permeabilisation can 
be excluded as active principle for the antibacterial activity 
of brabantamide A.  
Therefore, it was concluded, that the bioactivity of 
brabantamide A is not based on an unspecific detergent-like 
mechanism but seems to occur via a defined structural target 
(Reder-Christ et al., 2012). 	
 
Referring to this conclusion, a second attempt to investigate 
the target structure of brabantamides was intended by luciferase 
reporter gene assays (see chapter 4.3.8), enabling the diagnosis 
of antibiotic interference in the major biosynthetic pathways of 
bacteria. In these assays, brabantamide A was shown to induce 
only the ypuA- and the yvqI-reporter strains (see figures 4.3.30 
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and 4.3.31). YvqI is strongly induced by cell wall active 
antibiotics like vancomycin and bacitracin as well as by 
membrane damaging agents like ethanol (Petersohn et al., 2001). 
Induction of ypuA is generated by cell wall biosynthesis 
inhibitors and cell envelope stressing agents like vancomycin or 
the cell membrane perturbing agent polymyxin B (Urban et al., 
2007). Thus, the mode of action of brabantamide A points towards 
an interference with peptidoglycan or triggering of stress 
either on the cell wall or on the cell membrane.  
Even if the effect appeared at a concentration of 8 µg/ml which 
represents two-thirds of the minimal inhibition concentration 
determined for brabantamide A on B. subtilis and higher 
concentrations did not reveal any effect what might be due to 
cell damage, the positive result of the reporter-gene assay 
provided first insight into the target area.  
 
 Future perspectives 5.2.4
 
The antibiotically active brabantamides are unique regarding 
their chemical structure and their biosynthesis. Although this 
study already provided significant insights into their extended 
activity and biosynthesis, in turn it represents a starting 
point for further experimental work and scientific questions.  
 
Even if some evidences for the hypothesised biosynthetic 
assembly of brabantamides could be gained, further insights into 
the detailed mechanisms of the glycosyltransferase braA and the 
monooxygenase braC could be achieved by heterologous expression. 
This would enable both, the investigation of the precise 
reaction mechanisms and the investigation of the substrate 
specifity of both enzymes. Regarding the putative BV-mechanism 
of BraC, the methodology used for functional studies on MtmOIV 
from the mithramycin gene cluster could be reproduced. Thereby, 
the mechanism of this first BV-MO belonging to class A was 
secured by studies with isolated and overexpressed enzymes 
complemented by feeding experiments (Gibson et al., 2005).  
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Furthermore, applied systems for heterologous expression would 
allow the generation of new congeners by feeding of diverse 
precursors.  
Another possibility to verify the BV mechanism of the MO would 
be the performance of an additional feeding experiment with 
stable oxygen isotopes. Thereby, the incorporation of a labelled 
oxygen precursor via the flavin- associated monooxygenase would 
provide additional insight (see figure 5.2.5).  
 
 
 
 
 
  
 
Regarding the substrate specifity of the A-domains belonging to 
braB, enzyme assays using the exchange of γ-18O4-ATP 
pyrophosphate could give some indication of the accepted amino 
acids and might unravel the failed proline incorporation (Phelan 
et al., 2009; Felnagle et al., 2010). In order to gain deeper 
insight into the C-domain specifity attempts following the 
example of Mahariel and co-workers are desirable (Kraas et al., 
2010). 
 
The good antimicrobial activities of brabantamides in 
combination with their low cytotoxicity (see chapter 4.3.7) 
demonstrate that brabantamides are interesting antibiotic 
candidates. Especially the potential of brabantamide B which 
displays a twofold higher potency than brabantamides A and C 
indicate the need of further investigations regarding the 
structure-activity relationship.   
The chemical structure of brabantamides consist of a 5,5-
bicyclic cyclocarbamate structure, which is fused to a 
glycosylated 3-hydroxy-fatty acid. With these structural motifs 
brabantamides are unique in two ways: a) the unprecedented 5,5-
bicyclic core structure is unparalleled in nature and b) they 
Figure 5.2.5: expected labelling pattern of brabantamide A if fed with 17O2
following the hypothetical biosynthesis 
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represent the only Pseudomonas CLPs known so far with a 
glycosylated 3-hydroxy fatty acid side chain. Glycosylated side 
chains were so far only observed in Burkholderia CLPs.  
Chemical variations can be envisioned to take place at the 
cyclic peptide core, the fatty acid side chain or the sugar 
moiety. Typical variations of CLPs include the exchange of 
incorporated peptide monomers of the cyclic structure or the 
diversification of the fatty acid moiety. These variations can 
be seen for example in plusbacins which exchange hydroxy proline 
against proline, termed plusbacins A and B, respectively and 
vary in the length of the fatty acid side chain A1-A4 and B1-B4 
(Shoji et al., 1992a&b). Since the influence of the fatty acid 
side chain was already discussed in chapter 5.2.3.1, the other 
possible variations will be highlighted in the following. 
The strong influence of the amino acid monomers on the 
antimicrobial activity of CLPs has been proven in diverse 
studies. Thus, daptomycin was shown to exhibit lowered in vitro 
activities by exchanges of the amino acids at positions twelve 
and thirteen (Strieker & Mahariel, 2009) and for polymyxin B an 
influence of the composition of monomers or even the side chains 
of incorporated amino acids could be approved (Kanazawa et al., 
2009). 
Furthermore, massetolide A and viscosin exhibited twofold 
potency against M. tuberculosis and M. avium by variations of 
the side chains of the component amino acids in position four 
and nine pointing towards a general correlation between greater 
lipophilicity and increase of potency in antimycobacterial 
compounds (Gerard et al., 1997). 
Beyond that, attempts to predict the bioactivity of nonribosomal 
peptides by means of their monomeric composition were recently 
provided by Caboche and co-workers who suggested a direct 
correlation based on their study of nonribosomal peptides in the 
Norine database (Caboche et al., 2010).  
Regarding the monomers in brabantamide A, it seems likely that 
the massive rearrangements during the biosynthesis might hinder 
a high exchangeability of the two peptides. However, three types 
of exchanges are conceivable: 1) exchange of proline against 
hydroxyproline, 2) incorporation of a bioisoster like cysteine 
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instead of serine and 3) a change in the stereochemistry of 
serine and/or proline.  
The latter mentioned was investigated by Pinto et al. who 
reported a twofold higher potency of the R-isomer versus the S-
isomer regarding LpPLA2 inhibition (Pinto et al., 2000). 
Concerning other exchanges and variations of the fatty acid side 
chain (see chapter 5.2.3.1), further insights could be achieved 
by generation of new related compounds and subsequent analysis 
of their activity. These efforts could be achieved using either 
a semi-synthetic approach as seen in investigations regarding 
polymyxins B (Okimura et al., 2007) or by combinatorial 
biosynthesis efforts such as described for mithramycin (Pérez et 
al., 2008). Furthermore, the semi-synthesis of several new 
congeners was described by Pinto and co-workers which were up to 
date not investigated regarding their antibacterial activity and 
could be used in this aspect either (Pinto et al., 2000). 
Regarding the fatty acid side chain, a more accessible approach 
could be the addition of branched-chain amino acids into the 
growth medium which might alter the fatty acid composition of 
the produced brabantamides (Youssef et al., 2005). 
 
It is well established that the attached carbohydrates of many 
types of bioactive natural products like anthracyclines, 
macrolide antibiotics or glycopeptides strongly influence their 
antibiotic activity (Weymouth-Wilson, 1997). Thus, 
investigations on the deglycosylated compounds would be another 
helpful approach but the instability of the carbamate structure 
precludes the application of acidic conditions. Thirkettle and 
co-workers attained deglycosylation across enzymatic hydrolysis 
using naringinase (Thirkettle, 2000b). Thereby, comparison of 
the phospholipid-inhibitory activity of the aglycons and the 
original compounds could show an increase of potency of the 
saturated side chain species (brabantamides A and C) but a 
reduced potency of brabantamide B with the unsaturated side-
chain was observed (Thirkettle, 2000b). 
Since naringinase was not commercially available, a deletion 
mutant targeting the glycosyl-transferase encoding gene braA was 
generated but abolished production. Therefore, the synthesis of 
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the deglycosylated compounds seems advisable to investigate the 
impact of the rhamnose moiety towards antibiotic activity. 
 
 Investigations on empedopeptin  5.3
 
In a side-project of this study, the antimicrobial cyclic 
lipodepsipeptide empedopeptin should be isolated from the strain 
Empedobacter haloabium nov. sp. ATCC31962 with the purpose of 
structural confirmation and collaborative mode of action 
studies. 
Empedopeptin was first isolated in 1984, where two coherent 
publications described its isolation, structure elucidation and 
its antibacterial activity in vitro and in vivo (Konishi et al., 
1984; Sugawara et al., 1984). Thereby, empedopeptin was reported 
as a potent antibiotic compound, whose antibacterial spectrum 
resembles that of amphomycin and vancomycin, inhibiting 
predominantly Gram-positive and anaerobic bacteria, including 
clinical relevant pathogens such as Staphylococcus aureus, 
Streptococcus pneumoniae, and Clostridium difficile (Konishi et 
al., 1984).  
Even if the potency of empedopeptin as antibiotic was 
investigated back then, exhibiting MICs in the low micro molar 
range also against antibiotic-resistant strains accompanied by 
low acute toxicity and promising therapeutic in vivo efficacy in 
lethal bloodstream infections, the mode of action remained 
unresolved. Furthermore, the structure elucidation was based 
solely on partial hydrolysis and mass spectral analysis 
(Sugawara et al., 1984). No direct evidence was provided in this 
report about the cyclization scheme which is why it was decided 
to confirm the structure of empedopeptin by NMR.  
During the study a sufficient amount of empedopeptin could be 
isolated to enable the collaborative group to elucidate the mode 
of action of empedopeptin. It could be demonstrated that 
empedopeptin interferes with late stages of cell wall 
biosynthesis in bacterial cells by inhibition of N-acetyl 
glucosamine incorporation into the cell wall and thus blocking 
peptidoglycan biosynthesis (Müller et al., 2012). Furthermore, 
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empedopeptin was shown to target primarily lipid II at the 
outside of the cell wall forming a complex in 1:2 molar 
stoichiometry and to depend strongly on the presence of Ca2+-ions 
at concentrations similar of those occurring in human serum 
presumably due to the induced stronger interaction with its 
targets and with negatively charged phospholipids in the 
membrane (Müller et al., 2012).  
Using NMR spectroscopy, the peptide sequence published in 1984 
(Sugawara et al., 1984) could be confirmed. Furthermore, three 
new congeners (empedopeptin B-D) of empedopeptin were isolated, 
which are suggested to represent a linear variety, a metabolite 
with three hydroxylated proline moieties and an alternative with 
3-hydroxy lauric acid as fatty acid component, respectively (see 
figure 4.4.3).  
The suggested structure for empedopeptin B deviates from the co-
isolated cyclised congeners. The occurrence of the linear form 
might be due to the separation and purification of the 
metabolite including numerous solvents at different pH which 
possibly resulted in the cleavage of the ring system of 
empdeopeptin A and yielded congener B. Another option could be a 
hydrolytic cleavage from the NRPS by the thioesterase as 
described in chapter 1.1.1 without an optional cyclisation like 
in the proposed biosynthesis of syringafactins (Berti et al., 
2007).  
The suggested structure of empedopeptin C seems likely based on 
the fact, that there is a certain promiscuity of non-ribosomal 
peptide synthetases,  especially regarding their A-domains, 
which are responsible for the recognition and activation the 
amino acid precursors. Thus, it is conceivable, that proline 
might be exchanged by 3-hydroxyproline. Such variations in 
substrate usage of synthetases were proven for siderophores 
generated by the same assembly lines which could use similar 
precursors like 2,3-dihydroxybenzoate (DHB) in place of 2-
hydroxybenzoate (salicylate) at one NRPS leading to different 
products (Wuest et al., 2009). This promiscuity also appeared in 
the biosynthesis of anabaenopeptins whose A-domain in the first 
module activates Arg as well as Tyr (Christiansen et al., 2011). 
The authors suggest that this promiscuity has evolved through 
point mutations. Further examples for the exchange of 3-hydroxy 
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proline and proline can be found in the plusbacins A1-A4 and B1-B4 
(Shoji et al., 1992a&b).  
The generation of congeners with the same amino acid composition 
which only differ in the fatty acid side chains as proposed for 
empedopeptin D is a common variation in the biosynthesis of 
Pseudomonas CLPs (Gross & Loper, 2009). The variability of the 
fatty acid moieties can be attributed to their origin in the 
primary metabolism. This could be shown in a study of Youssef 
and co-workers who altered the fatty acid composition of the 
produced bio surfactant by the addition of branched-chain amino 
acids into the growth medium (Youssef et al., 2005).   
 
 Future perspectives 5.3.1
 
Within this study, the structure elucidation as well as the 
illumination of the mode of action represents a significant 
progress. Nevertheless, a re-isolation of empedopeptin seems 
indispensable, because so far only the peptide sequence could be 
confirmed. Still pending is the proof for the cyclisation 
scheme.  
Taking into account, that the majority of cyclic lipopeptides 
cyclise within the peptide moiety, it seems questionable, that 
empedopeptin cyclises into the fatty acid side chain. 
Unfortunately, the recorded spectra could not yet clarify 
whether the published cyclisation is correct, because no 
couplings confirming or refuting this theory could be detected 
in the corresponding HMBC or NOESY spectra.  
Upon structure elucidation, the additional obtained material 
could also serve for the determination of the absolute 
configuration of the 3-hydroxy group of the lipid side chain.  
Another purpose for the re-cultivation is the isolation of the 
abovementioned novel congeners of empedopeptin which should be 
investigated in-depth to elucidate their structures and 
potential bioactivity. 
Considering the enormous effort to isolate and purify 
empedopeptin from E. haloabium, which is complicated by the 
handling as a biosafety level 2 strain, the required complex 
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medium and the low production rate, it would be worth working on 
systems for heterologous expression of the corresponding gene 
cluster.  
Besides overcoming the above mentioned difficulties, 
heterologous expression would be an adequate technique to 
investigate the biosynthesis of empedopeptin and possibly lead 
to the opportunity to create new congeners with similar or 
increased bioactivity. 
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  Summary 6
 
The study was aimed to find new antibacterial cyclic 
lipopeptides in Pseudomonas bacteria using genome mining 
techniques. Application of this genome-driven approach led to 
the in-silico identification of several orphan biosynthetic gene 
clusters in plant- and insect-associated Pseudomonas strains. 
The strain Pseudomonas sp. SH-C52 was chosen for an in-depth 
analysis due to the presence of a unique gene cluster coding for 
an unprecedented lipo-dipeptide, a glycosyltransferase and a 
novel class of FAD-dependent monooxygenase.  
In a first step, using gene knockout experiments and comparative 
metabolite profiling, it could be demonstrated that the gene 
cluster is responsible for the production of the known compound 
SB-253514 (brabantamide A), and its minor congeners SB-253517 
(brabantamide B) and SB-253518 (brabantamide C).  
The obtained brabantamides were subsequently subjected to a 
broad antimicrobial screening which revealed significant 
calcium-independent activities towards selected clinical 
relevant Gram-positives, e.g. Bacillus subtilis 168 and 
Arthrobacter crystallopoietes. The minor metabolites 
brabantamides B and C exhibited a broader antibiotic spectrum 
including activity towards B. megaterium and Micrococcus luteus. 
Thereby, especially brabantamide B, which contains an 
unsaturated fatty acid side chain, exhibited a twofold higher 
antibacterial potency in comparison with brabantamide A. Thus, a 
correlation between the side chain and the observed activity 
became apparent and provided first insights into structure-
activity relationships. 
First preliminary mode of action studies with brabantamide A 
involving model membrane studies could show that this compound 
class acts via a defined target and that the antibiotic effects 
are not mediated by unspecific detergent-like membrane 
permeabilisation. Complementary luciferase reporter gene assays 
indicated that brabantamides interfere with peptidoglycan or 
trigger stress on the cell wall. Furthermore, in cytotoxicity 
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assays brabantamide A was proven to be not toxic to eukaryotic 
cell lines at antibiotically active concentrations. 
 
Due to the uniqueness of the 5,5-bicyclic carbamate structure of 
brabantamides, whose assembly require a massive rearrangement of 
the carbon skeleton of a linear dilipopeptide precursor, the 
second part of the study was focussed on their intriguing 
biosynthesis. Thus, a biosynthesis hypothesis was developed 
involving a Baeyer-Villiger reaction mechanism, mediated by the 
novel monooxygenase BraC. In a series of extensive feeding 
experiments employing 13C-labelled precursors the hypothesis was 
tested and finally confirmed.  
 
The third part of this study dealt with the potent antimicrobial 
lipodepsipeptide empedopeptin A. This lipopeptide was isolated 
along with two new minor congeners, empedopeptin B and C. The 
peptide sequence of empedopeptin A but not its cyclisation 
scheme could be confirmed by NMR and MS experiments. In a 
collaborative effort, also the specific mode of action of 
empedopeptin A was examined. It could be demonstrated that 
empedopeptin A inhibits cell wall biosynthesis through Ca2+-
dependent complex formation, predominantly with peptidoglycan 
precursor lipid II, and with lower affinity also with 
undecaprenyl pyrophosphate and teichoic acid.   
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Table 8.1.1: sequences producing significant alignments with the GT from the 
lipodipeptide cluster of P. sp. SH-C52 (see figure 4.2.1). 
score: value calculated from the number of gaps and substitutions associated 
with each aligned sequence (higher scores indicate significant alignments) 
Q. coverage = query coverage: percent of match 
E-value: describes possibility of false-positive match    
 
 
 
 
 
 
 
  
Description of the sequence 
(strain), [accession no.] score Q. cov. E-value
Max 
ident. Pos. Gaps 
rhamnosyltransferase I, 
subunit B (B. thailandensis 
E264), [ZP_05590657.1]  
395 96 % 8e-131 211/423 
50% 
270/423 
64% 
3/423
1% 
GT family 28 (B. ambifaria 
IOP40-10), [ZP_02891477.1] 
394 94% 1e-130 205/414 
50% 
259/414 
63% 
5/414
1% 
GT family protein (B. 
cenocepacia MC0-3) 
[YP_001778806] 
391 93% 2e-129 208/411
51% 
265/411 
64% 
 
5/4111%
GT family 28 (B. cenocepacia 
HI2424), [YP_838721.1] 
390 93% 4e-129 209/411 
51% 
264/411 
64% 
5/411
1% 
GT family 28 (B. ambifaria 
MEX-5), [ZP_02907619.1] 
390 94% 5e-129 204/414 
49% 
259/414 
63% 
5/414
1% 
GT family 28 (B. cenocepacia 
AU 1054), [YP_623141.1] 
390 93% 7e-129 209/411 
51% 
264/411 
64% 
5/411
1% 
GT family protein (B. 
ambifaria AMMD), [YP_776391.1]
387 94% 7e-128 203/414 
49% 
258/414 
62% 
5/414
1% 
GT family 28 (B. cenocepacia 
PC184), [ZP_04943307.1] 
387 93% 8e-128 208/411 
51% 
263/411 
64% 
5/411
1% 
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Table 8.1.2: sequences producing significant alignments with the MO from the 
lipodipeptide cluster of P. sp. SH-C52 (see figure 4.2.1) 
 
score: value calculated from the number of gaps and substitutions associated 
with each aligned sequence (higher scores indicate significant alignments) 
Q. coverage = query coverage: percent of match 
E-value: describes possibility of false-positive match 
 
 
  
Description of the sequence 
(strain), [accession no.] score Q. cov. E-value 
Max 
ident. Pos. Gaps 
putative FAD-dependent MO 
(Xenorhabdus bovienii SS-
2004), [YP_003466257.1] 
321 96% 3e-103 161/383
42% 
226/383 
59% 
1/383 
0% 
FAD-binding MO (Nocardia 
brasiliensis ATCC 700358), 
[ZP_09844437.1] 
316 97% 3e-101 171/385
44% 
227/385 
59% 
5/385 
1% 
putative FAD-dependent MO (S. 
bingchenggensis BCW-1), 
[YP_004959073.1] 
311 95% 2e-99 169/380
44% 
231/380 
61% 
2/380 
1% 
protein VMA_001458 (Vibrio 
mimicus VM223) [ZP_06032750.1] 
306 95% 2e-97 159/380
42% 
222/380 
58% 
1/380 
0% 
putative FAD-dependent MO (S. 
clavuligerus ATCC 27064), 
[ZP_06771754.1] 
303 96% 3e-96 172/382
45% 
228/382 
60% 
 
2/381 
1% 
putative aromatic-ring 
hydroxylase (Vibrio mimicus 
VM603),  [ZP_05721943.1] 
295 95% 3e-93 155/380 
41% 
218/380 
57% 
1/380 
0% 
putative FAD- dependent MO (S. 
cattleya NRRL 8057), 
[YP_004912775.1] 
294 97% 1e-92 170/387 
44% 
225/387 
58% 
3/387 
1% 
conserved hypoth. protein (S. 
clavuligerus ATCC 27064), 
[ZP_05004048.1] 
285 93% 4e-89 162/370 
44% 
217/370 
59% 
 
2/370 
1% 
 
hypoth. protein (P. aeruginosa 
PACS2),  [ZP_01366778.1] 
279 91% 8e-87 162/365 
44% 
214/365 
59% 
 
8/365 
2% 
putative FAD-dependent MO (P. 
aeruginosa 39016),  
[NP_252018.1] 
279 91% 9e-87 162/365 
44% 
214/365 
59% 
 
8/365 
2% 
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Figure 8.1.1: CD spectrum of brabantamide A measured in methanol 
102030405060708090100110120130140150160170180190
f1 (ppm)  
Figure 8.1.2: 13C-NMR spectrum of compound 1 (SB-253514/ brabantamide A) in 
d4-methanol (75 MHz) 
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Figure 8.1.3: DEPT135 spectrum of compound 1 (SB-253514/ brabantamide A) in 
d4-methanol (300 MHz) 
 
Figure 8.1.4 HSQC spectrum of compound 1 (SB-253514/ brabantamide A) in d4-
methanol (300 MHz) 
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Figure 8.1.5: 1H-1H COSY spectrum of compound 1 (SB-253514/ brabantamide A) in 
d4-methanol (300 MHz) 
 
Figure 8.1.6: 1H-13C HMBC spectrum of compound 1 (SB-253514/ brabantamide A) 
in d4-methanol at 300 MHz 
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Figure 8.1.7: 1H-1H COSY spectrum of compound 2 (SB-253517/ brabantamide B) in 
d4-methanol (300 MHz) 
 
 
Figure 8.1.8: DEPT135 spectrum of compound 2 (SB-253517/ brabantamide B) in 
d4-methanol (300 MHz, 20400 scans) 
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Figure 8.1.9: 1H-NMR spectrum of compound 3 (SB-253518/ brabantamide C) in d4-
methanol (500 MHz) 
 
Figure 8.1.10: 13C-NMR of compound 3 (SB-253518/ brabantamide C) in d4-
methanol (125 MHz, 20000 scans) 
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Figure 8.1.11: calibration line for the determination of production rate of 
brabantamide A 
 
 
Figure 8.1.12: 1H-NMR of brabantamide A in d4-methanol after labelling with 1-
13C sodium acetate (300 MHz)  
standard 
no. 
brabantamide 
A [µg/ml] peak area 
1 0.25 - 
2 0.5 8,49E+05 
3 2.5 4.67E+06 
4 5 6.93E+06 
5 125 1.64E+08 
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Figure 8.1.13: 13C-NMR of brabantamide A in d4-methanol after labelling with 
1-13C – sodium acetate, 60000 scans (300 MHz) 
 
Figure 8.1.14: 1H-NMR of brabantamide A after labelling with U-13C sodium 
acetate in d4-methanol (300 MHz) 
158  Appendix 
 
Figure 8.1.15: 1H-NMR of brabantamide A in d4-methanol after labelling with 1-
13C- L-serine (300 MHz) 
 
Figure 8.1.16: 1H-NMR spectrum of brabantamide A after labelling with 1,2-13C 
L-serine in d4-methanol (300 MHz) 
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Figure 8.1.17: proposed pathway of the label at C4’ in brabantamide A after 
labelling with 1,2-13C L-serine (pathway is based on KEGG; Madduri et al., 
2001; Thibodeaux et al., 2008) – part one 
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Figure 8.1.18: proposed pathway of the label at C-4’ in brabantamide A after 
labelling with 1,2-13C L-serine (pathway is based on KEGG; Madduri et al., 
2001; Thibodeaux et al., 2008) – part two 
 
Figure 8.1.19: 1H NMR spectrum of brabantamide A after labelling with 1-13C 
hydrogen carbonate in d4-methanol (300 MHz) 
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Figure 8.1.20: 13C-NMR of brabantamide A in d4-methanol after labelling with 
1-13C - hydrogen carbonate, 26000 scans (300 MHz) 
Table 8.1.3: determination of proline-uptake in Pseudomonas sp. SH-C52; CPM = 
counts per minute; OD = optical density 
 
   1. determination 2. determination 
time [min] CPM OD CPM OD
0 342 0.57 489 0.95 
5 839
15 1004
30 1407 0.71 6484 0.98 
45 2290
60 3164 0.81 10368 1.10 
75 3470
90 4350 1.03 13290 1.52 
120 5211 1.08 17085 1.67 
150  20787 1.65 
180 6277
210  1.22 1.90 
240  1.40 2.16 
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Table 8.1.4: antimicrobial disk diffusion inhibitory activities of 
brabantamides (A = brabantamide A; B = brabantamide B; C = brabantamide C) 
Organism Zone of inhibition [mm] 
 A B C 
Gram-positive bacteria 
Arthrobacter crystallopoietes DSM 20117 13 14 14 
Bacillus cereus   n.t. 8d 8b 
Bacillus subtilis 168 4 11a 10a 
Bacillus megaterium 0 11c 10c 
Corynebacterium pseudodiphtheriticum 3 n.t. n.t. 
Corynebacterium diphtheriae 3 n.t. n.t. 
Corynebacterium xerosis Va 167198 3 12b 12b 
Enterococcus faecium I-11305b 0 0 0 
Enterococcus faecium I-11054 n.t. 0 0 
Listeria welchimeri DSM 20650 3 0 0 
Micrococcus luteus ATCC 1856 0 n.t. n.t. 
Micrococcus luteus ATCC 4698 n.t. 10a 10a 
Mycobacterium smegmatis ATCC 70084 3 0 0 
Staphylococcus aureus SG 511 3 0 0 
Staphylococcus aureus 133 n.t. 0 0 
Staphylococcus aureus 5185 (MS) 3 4a 0 
Staphylococcus aureus I-11574 (MS)  n.t. 6a 0 
Staphylococcus aureus LT-1334 (MR)  0 6a 0 
Staphylococcus aureus LT-1338 (MR) 0 0 0 
Staphylococcus epidermidis LT-1324 (MR) 0 0 0 
Staphylococcus epidermidis ATCC 12228 0 0 0 
Staphylococcus epidermidis LT-1324 (MR) n.t. 0 0 
Staphylococcus simulans 22 0 0 0 
Gram-negative bacteria 
Citrobacter freundii I-11090 0 0 0 
Escherichia coli DH5 alpha 0 n.t. n.t. 
Escherichia coli O-19592 0 0 0 
Escherichia coli I-11276b n.t. 0 0 
Klebsiella pneumonia I-10910 0 n.t. n.t. 
K. pneumoniae subsp. ozeanaeI-10910 n.t. 0 0 
Pseudomonas aeruginosa I-10968 0 0 0 
Pseudomonas aeruginosa 4991 n.t. 0 0 
Serratia marcescens 0 n.t. n.t. 
Stenotrophomonas maltophilia O-16451 n.t. 0 0 
Stenotrophomonas maltophilia I-10717 n.t. 0 0 
Fungi 
Candida albicans I-11301 n.t. 0 0 
Candida albicans I-11301 n.t. 0 0 
a turbid; b very turbid; c clear with resistances; d bright with turbid court 
MS = methicillin-susceptible; MR = methicillin-resistant; n.t. = not tested 
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Figure 8.1.21: result of brabantamide A on the yorB promoter
(indicates inhibition of DNA-synthesis) in comparison with the 
positive control ciprofloxacin (inhibits gyrase); red and blue bars 
represent the background control and the tested substance,
respectively; A: brabantamide A, B: ciprofloxacin 
Figure 8.1.22: result of brabantamide A on the yvgS promoter
(indicates inhibition of RNA biosynthesis) in comparison with the
positive control rifampicin (inhibits RNA polymerase); red and blue 
bars represent the background control and the tested substance,
respectively; A: brabantamide A, B: rifampicin 
Figure 8.1.23: result of brabantamide A on the yheI promoter
(indicates inhibition of protein biosynthesis) in comparison with the
positive control chloramphenicol (inhibits protein synthesis); red
and blue bars represent the background control and the tested
substance, respectively; A: brabantamide A, B: chloramphenicol 
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Figure 8.1.24: 1H-13C HSQC spectrum of empedopeptin in d6-DMSO (900 MHz) 
 
Figure 8.1.25: NOESY spectrum of empedopeptin in d6-DMSO (900 MHz) 
 
